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Zusammenfassung 
 
Primäre Immun-Thrombozytopenie (ITP) ist eine verbreitete und benigne 
Autoimmunkrankheit, welche die Thrombozyten betrifft. Pädiatrische ITP kommt häufig nach 
viralen Infekten vor und wird vermutlich durch eine Produktion von Autoantikörpern gegen 
Glykoproteine der Thrombozytenoberfläche verursacht. Vieles weist darauf hin, dass diese 
Autoantikörper am beschleunigten Abbau der Thrombozyten beteiligt sein könnten, welcher 
in ITP Patienten festgestellt wird und zu einer tiefen Thrombozytenzahl führt. 
Charakteristisch für die ITP sind Spontanblutungen, wobei es sich meistens um Petechien 
handelt; punktförmige Haut- und Schleimhautblutungen. Pro Jahr treten etwa 100 
Neuerkrankungen in einer Million Menschen auf, wobei die Hälfte der betroffenen Patienten 
Kinder sind. Die meisten Fälle der akuten ITP heilen spontan oder nach Therapie innerhalb 
von 3 Monaten aus. Jedoch besteht das Risiko für möglicherweise fatale Hirnblutungen, die 
bei etwa 0.1 – 0.2% der Patienten auftreten. Zudem manifestiert sich die Krankheit in 
ungefähr 10% der Patienten länger als 1 Jahr und entwickelt sich zu einer chronischen ITP. 
ITP Patienten werden mit intravenösen Immunglobulinen (IVIg) behandelt, welche einen 
Anstieg in der Thrombozytenzahl bewirken. Die derzeitige Hypothese zum 
Wirkmechanismus der IVIg nimmt an, dass IVIg die Fc Rezeptoren der Makrophagen 
blockiert und dadurch den erhöhten Abbau der Thrombozyten verhindert. Dieser Hypothese 
entsprechend führte die Verabreichung von anti-Thrombozyten Antikörpern in Mäusen zu 
einer schweren Thrombozytopenie. Jedoch wurden in diesen Thrombozyten apoptotische 
Vorgänge beobachtet. Sowohl Thrombozytopenie wie auch die apoptotischen Vorgänge in 
den Thrombozyten wurden im Mausmodell durch IVIg verbessert. Bis jetzt war nicht bekannt, 
ob diese apoptotischen Vorgänge auch in der pädiatrischen ITP vorkommen.  
Programmierter Zelltod, auch Apoptose genannt, ist der Hauptmechanismus, der die 
zelluläre Lebensspanne reguliert, aber auch zur Eliminierung von beschädigten nukleären 
Zellen beiträgt. Entscheidend in der apoptotischen Signalkaskade sind Caspasen, welche 
eine proteolytische Funktion haben. Caspase-8 ist Teil der extrinsischen, Caspase-9 Teil der 
intrinsischen apoptotischen Signalkaskade. Aktivierung von Caspase-8 oder -9 führt zu 
aktiver Caspase-3 und -7. Diese Effektor-Caspasen schneiden spezifische Substrate, was 
zum Tod der Zelle führt. Aktive Caspase-9, -3 und -7 werden durch XIAP, ein X-
chromosomales anti-apoptotisches Protein, inhibiert. XIAP wiederum wird von der pro-
apoptotischen Protease Omi/HtrA2 inaktiviert. Omi/HtrA2 ist eine Komponente der 
intrinsischen Signalkaskade und wird nach Permeabilisierung der äusseren mitochondrialen 
Membran von Mitochondrien freigesetzt. Auch in den anukleären Thrombozyten wurden 
apoptotische Vorgänge festgestellt, unter anderem die mitochondriale Freisetzung von 
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Cytochrom c, eine Aktivierung von Caspase-3 oder ein Anstieg von Mikropartikel. Das 
Vorkommen von XIAP wie auch Omi/HtrA2 in Thrombozyten wurde jedoch noch nicht 
beschrieben. Auch in anderen Erkrankungen wie zum Beispiel beim Bernhard Soulier 
Syndrom oder beim Diabetes Mellitus Typ 2 wurden apoptotische Vorgänge im 
Thrombozyten beobachtet. Gleichzeitig kommen in diesen Krankheiten oft auch 
Thrombozytendefekte vor. Thrombozytenapoptose und Thrombozytenfunktion wurden noch 
nicht in einer pädiatrischen ITP Population vor und nach IVIg Behandlung untersucht. 
Ausserdem wurden in Thrombozyten noch nicht alle pro- und anti-apoptotische Proteine 
identifiziert, welche auch in ITP eine Rolle spielen könnten. Auch ist es nicht bekannt, was 
Apoptose in den Thrombozyten der ITP auslöst.  
In Mäusen wurde gezeigt, dass TNF-apoptotische Vorgänge wie auch eine 
Thromobzytopenie induziert. Diese Beobachtung deutet darauf hin, dass Zytokine einen 
Einfluss haben könnten auf das Einsetzten der Apoptose. Die Ziele meiner Dissertation 
waren (I) zu untersuchen, ob ITP Patienten bei Diagnose erhöhte apoptotische Vorgänge in 
ihren Thrombozyten aufweisen, (II) zu prüfen ob Thrombozyten von ITP Patienten eine 
beeinträchtigte Funktion haben, (III) die apoptotische Signalkaskade in gesunden 
Thrombozyten zu charakterisieren, und (IV) zu analysieren ob die Plasma Zytokinlevel von 
ITP Patienten mit der Caspase-Aktivierung, die in ITP Thrombozyten beobachtet wurde, 
korrelieren.  
 ITP Patienten wiesen bei Diagnose einen erhöhten Anteil von Thrombozyten mit 
aktiver Caspase-3, -8 und -9 wie auch von Mikropartikel auf. All diese apoptotischen Zeichen 
waren nach IVIg Behandlung normalisiert. Ausserdem hatten Thrombozyten von ITP 
Patienten bei Diagnose eine erhöhte Oberflächenexpression von CD63 und CD62P, eine 
verringerte Thrombozyten-Aktivierbarkeit und ein reduziertes Thrombingenerationspotenzial. 
Wir haben herausgefunden, dass in Thrombozyten nach Beginn der Apoptose, Omi/HtrA2 
von Mitochondrien ins Zytosol freigesetzt wird. Zudem haben wir bestätigt, dass 
Mitochondrien von Thrombozyten Cytochrom c und Smac/Diablo freisetzen. In gesunden 
Thrombozyten konnte die Aktivierung von Caspase-3 und -9 durch eine Inhibition von 
Omi/HtrA2 mittels Ucf-101, einem pharmakologischen Inhibitor, reduziert werden. Wir 
konnten XIAP mit Embelin inhibieren und dabei apoptotische Vorgänge in Thrombozyten 
induzieren. Zudem fanden wir in Thrombozyten auch FADD, eine Komponente der 
extrinsischen apoptotischen Signalkaskade. Ausserdem stellten wir in ITP Patienten bei 
Diagnose nicht nur Thromozytenapoptose und eine reduzierte Thrombozytenaktivität fest, 
sondern auch ein erhöhtes Plasmalevel von Zytokinen der Th1 und Th2 Familie.  
 Zusammenfassend sehen wir, dass akute ITP Patienten erhöhte apoptotische 
Vorgänge in Thrombozyten aufweisen, wie auch eine reduzierte 
Thrombozytenaktivierbarkeit. Diese Ereignisse wurden nach einem Anstieg der 
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Thrombozytenzahl, verursacht durch die IVIg Behandlung, normalisiert. Ebenfalls haben 
akute ITP Patienten erhöhte Plasma Zytokinlevel. Wir konnten keine Korrelationen aufzeigen 
zwischen den analysierten Zytokinen und der Caspase Aktivierung. Deshalb ist es 
unwahrscheinlich, dass die von uns untersuchten Zyokine in Thrombozyten von ITP 
Patienten Apoptose induzieren. Eine Inhibierung von Omi/HtrA2 durch Ucf-101 in gesunden 
Thrombozyten bewies die anti-apoptotische Funktion von Omi/HtrA2. Eine Inhibierung von 
XIAP durch Embelin deutete an, dass in Thrombozyten aktive Caspase-3 und Caspase-9 
durch XIAP inhibiert wurden. Diese Resultate unterlegen, dass Thrombozyten eine 
funktionelle apoptotische Signalkaskade haben in Gesunden wie auch in Kranken.  
 Indem wir die Mechanismen, welche zum programmierten Zelltod im Thrombozyten 
führen analysieren, könnten wir neue Einblicke in die Pathophysiologie der ITP gewinnen 
und neue mögliche Therapieansätze entwickeln. Eine Ausweitung der Studie könnte 
eventuell dazu beitragen einen Laborparameter zu identifizieren, welcher mit dem 
Schweregrad der Blutungen korreliert um somit besser vorauszusagen, welche ITP 
Patienten ein Risiko für eine Hirnblutung, bzw. eine chronische ITP zu entwickeln aufweisen. 
   
VI 
 
Summary 
 
Primary pediatric immune thrombocytopenia is a common and benign platelet autoimmune 
disorder. Pediatric ITP usually occurs after viral infections and is characterized by a 
production of autoantibodies against platelet glycoproteins. There is evidence that these 
autoantibodies are involved in the enhanced clearance of platelets that is observed in ITP 
patients. Due to the low platelet count, a typical feature of ITP is a sudden onset of petechiae 
in formerly healthy children. The yearly incidence of ITP is 100 cases per 1 million people 
whereas half of the affected patients are children. In most cases, acute ITP resolves 
spontaneously or after treatment within three months. However, 0.1 – 0.2% of the patients 
are at high risk for fatal cerebral bleeding. In around 10% the disease lasts longer than 1 
year and progresses into a chronic ITP. Treatment of ITP patients with intravenous 
immunoglobulins (IVIg) causes an increase in platelet count. The current working model of 
ITP suggests that IVIg prevents the enhanced platelet clearance by blocking the Fc receptors 
of macrophages. In a murine model of ITP, administration of anti-platelet antibodies 
developed a severe thrombocytopenia. Additionally, also apoptotic events were observed in 
these platelets. Both thrombocytopenia and platelet apoptotic events were ameliorated by 
IVIg in the murine ITP model. So far it was not known whether these apoptotic events occur 
also in pediatric ITP. 
Apoptosis is the main mechanism that regulates cellular life span but also leads to the 
elimination of damaged nucleated cells. Crucial mediators of the apoptotic signaling are 
caspases that have a proteolytic function. Caspase-8 is involved in the extrinsic and 
caspase-9 in the intrinsic apoptotic pathway. Activation of caspase-8 or -9 results in active 
caspase-3 and -7 that are effector caspases that cleave target substrates causing cell death. 
Active caspase-9, -3 and -7 are inhibited by XIAP, an X-linked inhibitor of apoptosis proteins. 
In contrast, XIAP is inactivated by the pro-apoptotic protease Omi/HtrA2, a component of the 
intrinsic pathway that is released from mitochondria after mitochondrial outer membrane 
permeabilization. Also in anuclear platelets, apoptotic manifestations such as a release of 
cytochrome c, an activation of caspase-3 or an increase in platelet-derived microparticles 
were identified. However, the presence of XIAP and Omi/HtrA2 has not been described yet in 
platelets. Platelet apoptosis was shown to occur also in diseases such as Bernard-Soulier 
syndrome or diabetes mellitus type 2. Apoptotic events seen in these diseases are often 
accompanied by defects in platelet function. Until now, platelet apoptosis and platelet 
function have not been analyzed in a well-defined pediatric ITP cohort before and after IVIg 
therapy. Besides, in platelets, not all pro- and anti-apoptotic proteins were identified that 
might as well be involved the disease of ITP. Additionally, it is not clear what the initial 
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apoptotic trigger in platelets of ITP patients is. In mice, TNF- was shown to induce apoptotic 
events and thrombocytopenia. This observation indicated that cytokines might be involved in 
the onset of apoptosis. Therefore, the aims of my PhD thesis were (I) to investigate whether 
ITP patients at diagnosis have increased apoptotic events in platelets, (II) to study whether 
platelets of ITP patients show an impaired function, (III) to characterize the apoptotic 
signaling in healthy platelets, and (IV) to analyze if levels of cytokines in plasma of ITP 
patients correlate to caspase activation seen in ITP platelets.  
ITP patients at diagnosis presented increased proportions of platelets with activated 
caspase-3, -8 and -9 as well as elevated platelet-derived microparticles. All these apoptotic 
manifestations were ameliorated after an increase in platelet count by IVIg treatment. 
Furthermore, platelets of ITP patients at diagnosis had enhanced surface expression of 
CD63 and CD62P compared to healthy individuals, a decreased activability of platelets and a 
reduced endogenous thrombin potential. In healthy platelets, apoptotic events as activation 
of caspase-3 and caspase-9 were decreased by inhibiting Omi/HtrA2 with its 
pharmacological inhibitor Ucf-101. We demonstrated that Omi/HtrA2 is released from 
mitochondria into the cytosol upon induction of apoptosis. We also confirmed that platelet-
mitochondria release the mitochondrial proteins cytochrome c and Smac/Diablo into the 
cytosol. By antagonizing XIAP with its inhibitor embelin we were able to induce apoptotic 
events in platelets. Additionally, we found that FADD, a component of the extrinsic apoptotic 
signaling pathway, is expressed in platelets. Besides, ITP patients at diagnosis presented not 
only increased platelet apoptosis and reduced platelet activability but also elevated plasma 
levels of cytokines of the Th1 and Th2 family.  
To conclude, acute ITP patients had increased platelet apoptotic events and reduced 
platelet activability that were ameliorated after an increase in platelet count caused by IVIg 
treatment. Furthermore, ITP patients presented elevated plasma cytokine levels. We could 
not show a correlation of analyzed cytokines to caspase activation thus it is unlikely that 
these cytokines function as an extrinsic apoptotic trigger in platelets of ITP. In healthy 
platelets, inhibition of Omi/HtrA2 by Ucf-101 proved the pro-apoptotic function of Omi/HtrA2 
and inhibition of XIAP by embelin demonstrated that active caspase-3 and caspase-9 were 
inhibited. Concluding, these results highlight that platelets have a functional intrinsic 
apoptotic signaling pathway in health as well as in disease.  
By analyzing the programmed cell death in platelets, especially its onset, we might 
gain new insights into the pathophysiology of ITP and reveal possible targets for additional 
therapeutic approaches. By including more subjects in our study, we may be able to find a 
laboratory parameter such as thrombin generation that correlates to the bleeding signs or the 
patient’s history and thereby better predict which ITP patients are potentially prone for 
cerebral bleeding or chronic ITP; this is our future clinical research intention.
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General introduction 
 
Platelet apoptosis in health and disease 
 
 
Platelet physiology 
 
Platelets are important players in hemostasis and blood coagulation; additionally they 
are involved in inflammation, thrombosis and wound healing. Hemostasis is the process that 
terminates bleeding, primarily mediated by the formation of blood clots characterized as 
blood coagulation [1]. Thrombosis is defined by a newly generated blood clot in an injured 
blood vessel and not only occurs in injured platelets but also in physiologically altered 
arteries during diseases such as heart attacks. Platelets are produced by megakaryocytes in 
the bone marrow [2]. Megakaryocytes arise from CD34 expressing pluripotent bone marrow 
stem cells [3]. Chemokines and cytokines contribute essentially for their differentiation into 
megakaryocytes: the granulocyte-macrophage colony-stimulating factor GM-CSF as well as 
interleukin IL-3 are important for the formation of megakaryocyte colonies while IL-6 is a late 
factor in megakaryocytes differentiation [4]. During maturation, megakaryocytes enlarge to a 
diameter of 100 m and become polyploid as they lose their capacity to divide but retain their 
ability to replicate DNA [5]. During this process, the c-Mpl ligand thrombopoetin (TPO) 
stimulates megakaryoctes to increase in cell-size and ploidy. Platelets are generated by 
cytoplasmic extensions of megakaryocytes. These so called proplatelets contain granules 
and organelles and are released into the bloodstream [2]. During proplatelet formation, 
changes in the organization of the cytoskeleton occur caused by activation of microtubules, 
actin depolymerization and phosphorylation of myosin [6]. One megakaryocyte generates 
around 2000-3000 platelets. Following platelet release, the remaining megakaryocytes, 
consisting of some residual cytoplasm surrounding the nucleus, undergo apoptotic cell death 
[2]. A healthy platelet production results in around 1 x1011 platelets per day and a normal 
platelet count varies around 150-400 x109/L. Megakarocytes regulate the number of 
circulating platelets via the hormone TPO that binds to the TPO receptor c-Mpl [7]. Platelets 
are discoid and have a diameter of 2-3 m. They possess mRNA from megakaryocytes and 
they are capable of protein synthesis.  
 
Platelets contribute to hemostasis by their adhesive functions and by activating 
coagulation mechanisms (Figure 1). Hemostasis can be stuctured into primary and 
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secondary hemostasis. Primary hemostasis includes the formation of a primary platelet plug 
at the injured vessel wall site and involves platelets, the blood vessel wall and von Willebrand 
Factor (vWF) [8]. The secondary hemostasis occurs simultaneously and results in the 
formation of a stable platelet plug by the formation of fibrin through a coagulation cascade, a 
process where coagulation and clotting factors play an important role as well as Ca2+. A 
crucial step in the primary hemostasis is the activation of platelets that comprises platelet 
adhesion, secretion and aggregation [9] [10]. Upon vessel injury, the thrombin producing 
tissue factor (TF) that is present in endothelial cells, platelets and leukocytes is exposed to 
the bloodstream as well as collagen and vWF. The coagulation cascade is initiated by the 
TF. The expression of TF was shown to be upregulated in endothelial cells and monocytes 
by the tumor necrosis factor TNF- or by IL-6 [11]. Platelets adhere to the subendothelial 
matrix via interaction of their gylcoproteins (GP) with collagen and vWF and become 
activated after their exposure to collagen, thrombin and other agonists. During this process 
collagen binds to GPVI and GPIa/IIa, vWF to GPIb and to activated GPIIb/IIIa (also known as 
IIb3), and thrombin to the receptors PAR-1 and PAR-4. During platelet activation, Ca
2+ is 
mobilized from the dense tubular system, an analog to the endoplasmatic reticulum in 
nucleated cells (Figure 2), into the cytoplasm. This mobilized Ca2+ activates scramblase that 
transports phospholipids between membrane leaflets in a bidirectional way [12]. The 
transmembrane protein 16F (TMEM16F) was identified as an essential component of the 
scramblase activity [12]. In activated platelets, TMEM16F mediates the Ca2+-dependent 
externalization of phosphatidylserine (PS) from the inner to the outer plasma membrane 
leaflet [12]. This externalization of PS generates a negatively charged platelet surface that 
presents a suitable surface for the assembly of coagulation proteins via binding to the 
prothrombinase complex (Xa/Va) as well as tenase complex (IXa/VIIIa) and enhancing the 
activation of prothrombin [13]. Therefore, exposed PS contributes to the coagulation cascade 
and finally is involved in the generation of thrombin. In response to the elevated intracellular 
Ca2+ level or the thrombin signaling, platelets change their shape and form pseudopodia. 
Another consequence of the Ca2+ influx is the secretion of their granule or lysosomal 
contents as ADP, vWF and serotonin as well as P-selectin (CD62P) and CD63 that both 
become subsequently expressed at the platelet surface. Moreover, there is a conformational 
change of the fibrinogen receptor GPIIb/IIIa into the active form capable of binding 
fibrinogen. The continuous platelet adhesion to the endothelial wall leads to a constriction of 
the damaged vessels and to the formation of a plug. Following adhesion, platelets aggregate 
through the released agonists ADP and thromboxane A2 building stable fibrin clots finally 
resulting in blood coagulation. The tissue factor (TF) initiates a signaling cascade where 
coagulation factors, predominantly serine proteases, play a crucial role. The platelet surface 
factor Xa/Va complex cleaves prothrombin to thrombin that generates a thrombin burst while 
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thrombin, a serine protease, cleaves fibrinogen into fibrin [14]. Fibrinogen binds to activated 
GPIIb/IIIa, an important step in platelet aggregation. This activated fibrinogen receptor can 
be detected by PAC-1, a murine monoclonal antibody that recognizes an epitope on the 
GPIIb/IIIa complex of activated platelets only [15]. Soluble fragments of adhesion molecules 
such as the - or dense- granule protein CD62P, the lysosomal protein CD63 or the cytosolic 
protein sCD40L are further released and get into circulation [16] [17]. This is an important 
step as sCD40L and CD62P participate in immune responses via an interaction of platelets 
with leukocytes or monocytes. CD40L binding to CD40 receptor is involved in the interaction 
of platelets with leukocytes as well as of endothelial cells with T cells [17]. CD62P on the 
other hand mediates adhesion of activated platelets to monocytes and neutrophils. CD63 
plays an important role in complexing with integrins; a deficiency in CD63 presents as a 
storage pool defect as described in the Hermansky-Pudlak Syndrome [18]. Additionally, 
activated platelets shed plasma membrane vesicles also known as platelet-derived 
microparticles that have a pro-inflammatory effect and promote coagulation [19]. Strong 
physiological platelet agonists are collagen and thrombin. Processes occurring during 
platelet activation such as platelet secretion, aggregation and microparticle formation are 
thought to be regulated by calpains [20]. Calpain is a Ca2+-dependent cysteine protease that 
upon platelet activation and Ca2+ increase cleaves cytoskeletal proteins including actin and 
undergoes autoproteolysis. The implication of calpains in platelet activation is considered to 
be initiated by integrin (GPIIb/IIIa) signaling [20]. 
Platelets circulate for around 10 days in the blood stream where they are cleared by 
the reticuloendothelial system (RES) [21] [22]. Apart from platelet clearance by the RES, 
platelet aging was also associated with apoptotic-like events [23] [24] [25]. Concretely, 
Mason et al. reported a connection between senescence of platelets and the intrinsic 
apoptotic signaling pathway and showed that platelet life span is determined by the balance 
of the anti-apoptotic factor Bcl-XL and the pro-apoptotic factor Bak [25].  
 - 7 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Platelet hemostasis 
1) Adhesion of platelets (Plt) to the damaged subendothelial wall via collagen and vWF, molecules 
released from endothelial cells (EC), to their GP receptors. 2) Activation of platelets (aPlt) leads to 
shape change, secretion of ADP, expression of proteins such as CD62P as well as to an activation of 
the fibrinogen receptor GPIIb/IIIa. Aggregation occurs via binding of activated GPIIb/IIIa to fibrinogen, 
while more activated platelets are recruited. 3) Formation of a stable platelet aggregate and 
generation of a thrombin burst. Activated platelets fragment microparticles (MP) as well as soluble 
CD62P and sCD40L. Figure adapted from Jurk et al. [26]. 
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The apoptotic signaling pathway of nucleated cells 
 
Apoptosis in nucleated cells is a well-known process controlling the numbers of cells 
and their life-span. There are different apoptotic signaling pathways, here the extrinsic and 
the intrinsic pathway will be described in more detail. Cysteine-dependent ASPartyl-specific 
proteases, known as caspases, are the key mediators of apoptosis. They are inactive 
zymogens called pro-caspases that become activated upon induction of apoptosis, resulting 
in cleaved active fragments. The effector caspases, caspase-3 and caspase-7, act at the 
very end of the apoptotic signaling cascade. Caspases trigger cell destruction by cleavage of 
specific substrates e.g. the cytoskeletal proteins gelsolin or fodrin. The extrinsic pathway 
occurs via death receptors on the cell surface; for instance Fas or TNF-receptor. After 
activation by a ligand these death receptors recruit the cytoplasmic protein FADD leading to 
an activation of the initiator caspase-8 and subsequently to an activation of caspase-3 or 
caspase-7. The intrinsic apoptotic pathway is initiated by a depolarization of the 
mitochondrial membrane potential (m) often caused by DNA damage or endoplasmatic 
reticulum stress. Depolarization of the mitochondria can be initiated by two different 
mechanisms, either by opening of the mitochondrial permeability transition pore (MPTP) in 
the inner mitochondrial membrane, a non-selective multiprotein pore spanning the two 
membrane leaflets, or directly by apoptotic proteins of the Bcl-2 family members. The 
formation of the MPTP occurs in response to a disruption in the Ca2+ homeostasis upon 
apoptotic stimuli and is followed by mitochondrial outer membrane permeabilization (MOMP) 
[27]. Bcl-2 family members such as Bad, Bid or Bax act on the outer membrane forming 
pores by oligomerization of Bak and Bax thus inducing MOMP [28] [29]. The extrinsic 
pathway is connected to the intrinsic pathway via Bid signaling: activated caspase-8 cleaves 
Bid and truncated Bid gets localized to the mitochondria. [30] Loss of MOMP is the onset for 
the release of pro-apoptotic proteins from the mitochondrial intermembrane space (IMS) as 
cytochrome c, Smac/Diablo or the protease Omi/HtrA2 into the cytosol. In response to a 
decrease in ATP levels due to cytochrome c depletion or to a free diffusion of ions between 
cytosol and matrix, mitochondria lose their inner mitochondrial membrane potential m [29] 
[27]. Other proteins released from IMS are the apoptosis inducing factor AIF or the 
endonuclease G [29]. Those proteins contribute to nuclear apoptosis by degrading and 
fragmenting DNA and also to chromatin condensation, a process where chromatin changes 
from a heterogeneous, genetically active network to an inert highly condensed form. At least 
two different pathways lead to nuclear apoptosis, a caspase-independent pathway including 
AIF or endonuclease G, and a caspase-dependent pathway via a caspase-activated DNase 
(CAD) [31]. Translocation of AIF from mitochondria to nuclei causes initial (peripheral) 
chromatin condensation and large-scale DNA fragmentation into around 50 kb fragments 
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whereas CAD induces advanced chromatin condensation and oligonucleosomal DNA 
fragmentation [31].  
Following MOMP and cytochrome c release, caspase-9 is activated through the 
interaction of cytochrome c with Apaf-1, a process that eventually results in an activation of 
effector caspase-3 and -7 [32]. XIAP, an X-linked inhibitor of apoptotic proteins (IAPs), as 
well as the anti-apoptotic proteins of the Bcl-2 family members (Bcl-2 and Bcl-XL) are 
important players preventing apoptosis. Bcl-XL prevents the pro-apoptotic protein Bax from 
oligomerization and translocation to the mitochondria, a crucial step for MOMP. XIAP inhibits 
the catalytic activity of caspase-3, -7 and -9 while the pro-apoptotic proteins Omi/HtrA2 as 
well as Smac/Diablo are caspase activators that antagonize the inhibitory effect of XIAP [33] 
[34] [35]. cIAP-1 and cIAP-2 are other IAPs, binding to active caspase-3 and -7 [36]. The 
proteins of the IAP family are highly conserved and contain one to three baculovirus inhibitor 
of apoptosis protein repeats (BIR motif). These BIR motifs bind to caspases and inhibit their 
activity; BIR-3 was identified to specific inhibit caspase-9 while the linker region of BIR1-2 is 
important for caspase-3 and -7 inhibition [37]. The inhibition of caspases by IAPs is 
negatively regulated by the second-derived activator of caspases, Smac/Diablo, as well as 
the serine protease Omi/HtrA2, both proteins are released from IMS upon MOMP. 
Smac/Diablo competes with XIAP by binding of its BIR3 domain to the N-terminal BIR3 
recognition motif of caspase-9 [38] as well as of its BIR1-2 domain to the N-terminal region of 
caspase-3 and -7 [39]. Omi belongs to the heat shock response serine proteases (HtrA2), is 
highly conserved and is sequestered in the mitochondria, protecting healthy cells from its 
proteolytic activity as long as mitochondria are intact. In mammalian cells, Omi/HtrA is also 
involved in the degradation of aberrantly folded proteins during cellular or endoplasmatic 
reticulum stress as well as heat shock. The BIR3 domain of Omi/HtrA2 interacts with XIAP, 
the same region to which also Smac/Diablo binds, and XIAP is degraded by the protease 
activity of Omi/HtrA2 [35]. Omi/HtrA2 was shown to induce apoptosis in human cells in a 
caspase-independent manner through its protease activity, and in a caspase-dependent 
manner via its ability to disrupt caspase-IAP interaction [40] 
Apoptosis can be initiated or prevented by certain drugs, natural or artificial 
compounds. The anti-apoptotic effect of Bcl-XL is antagonized directly by the 
pharmacological inhibitor BH3 mimetic ABT-737 [41]. ABT-737 is a small-molecule inhibitor 
of Bcl-2, Bcl-XL and Bcl-w. ABT-737 was first analyzed in cancer cell lines and shown to 
improve survival and to cause regression of established tumors [41]. The inner mitochondrial 
matrix protein cyclophilin D (CypD) was identified as an essential regulator of the MPTP; the 
immunosuppressive drug cyclosporin A (CsA) interacts with CypD inhibiting formation of 
MPTP [28]. However, in CypD deficient mice, apoptosis was normal [42]. CypD has also 
been described to have a role in platelet activation and thrombosis [43]. CypD deficient 
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platelets present defects in PS exposure, microparticle formation and procoagulant activity 
upon physiological activation such as the combination of thrombin plus convulxin or thrombin 
plus H2O2 [43]. The pharmacological compound Ucf-101 inhibits the proteolytic activity of the 
pro-apoptotic protein Omi/HtrA2. It was demonstrated that in caspase-9 deficient mouse 
embryonic fibroblasts, Ucf-101 blocks the Omi/HtrA2 induced cell death [44]. Additionally, 
Ucf-101 was shown to have a therapeutic neuroprotective effect as in rats suffering from 
focal cerebral ischemia Ucf-101 reduced neurological deficits and infarct volume [45]. 
Embelin, an extract from the Japanese Ardisia herb, is an apoptosis activator. Embelin binds 
to the BIR3 domain of XIAP as does Smac/Diablo or Omi/HtrA2 thus preventing XIAP from 
binding to active caspase-9. In prostate cancer cells that contain high levels of XIAP, embelin 
selectively induced caspase-9 mediated apoptosis and inhibited cell growth [46]. 
Other hallmarks for apoptosis in nucleated cells include phosphatidylserine (PS) 
exposure that is the reorganization and loss of the asymmetry of phospholipids at the plasma 
membrane as well as membrane blebbing, a process that generates microparticles. Although 
platelets are anucleate they possess apoptotic proteins. In platelets, apoptosis was first 
described by Vanags in 1997 indicating the existence of an apoptotic signaling pathway [47].  
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Platelets have an intrinsic apoptotic signaling pathway 
 
Since 1997 various apoptotic factors were identified in platelets on the mRNA level: 
caspase-1, -2, -3, -4, -6, -8, -9, p53, the death receptors DR3, DR5, DR4, TRAIL, TNF 
receptor p55 and RIP as well as the Bcl-2 family proteins Bcl-X, Bcl-2, Bfl-1, Bad, Bak, Bax 
and Mcl-1 [47] [48]. On the protein level caspase-2, -3, -7, -8 and -9 were verified in platelets 
[49] [50]. As activated platelets present similar events as nucleated apoptotic cells for 
instance PS exposure, formation of microparticles or activation of caspases, the events 
leading to active caspases in platelets were studied in comparison to platelet activation: The 
artificial agonist Ca2+ ionophore A23187 as well as the combination of the physiological 
agonists collagen and thrombin were shown to induce caspase-3 activation and PS exposure 
[51]; even thrombin alone triggered apoptotic events as caspase-3 and caspase-9 activation 
[52] [53]. However, only a high thrombin concentration (10-100 nmol/L), as eventually 
generated locally during coagulation, mediated platelet apoptosis [54]. In addition, thrombin 
was found to depolarize m and to generate reactive oxygen as H2O2, also an inducer of 
cytochrome c release, and lead to caspase-3 and caspase-9 activation [55]. Moreover, 
thrombin induced the translocation of caspase-3 and -9 from the cytosol to the actin 
cytoskeleton, a process that is dependent of the protein kinase C (PKC) [55]. Similar to 
activated platelets, platelets undergoing apoptosis shed increased microparticles, possibly an 
analogous event as membrane blebbing [19]. An increased production of platelet derived-
microparticles was observed in response to strong activation by A23187 as well as by 
thrombin plus collagen [51]. It is known that in human platelets physiological agonists induce 
Ca2+ release from the dense tubular system (DTS) through the activation of PAR-1 and PAR-
4 and that activation of the GPIb complex (GPIb-IX-V) results in Ca2+ release from the acidic 
stores, a Ca2+ pool in lysosome-related acidic organelles [56]. Lopez et al. demonstrated that 
DTS stress-mediated platelet apoptosis leads to activation of caspase-3, -8 and -9 [57]. In 
brief, Ca2+ mobilization is one of the first steps in platelet activation as well as in platelet 
apoptosis initiated by physiological agonists. Although similar events occur during platelet 
activation and platelet apoptosis, they are different phenomena occurring sequentially in 
platelet aging evidenced by platelet storage experiments [58]. It was demonstrated that PS 
exposure not only occurs in platelet activation but also in apoptotic platelets independently of 
platelet activation [59]. Two distinct pathways were shown to regulate PS exposure and 
therefore the pro-coagulant activity, a Ca2+-dependent pathway which is caspase-
independent and a caspase-dependent pathway which is Bak/Bax-dependent and is 
triggered for instance by ABT-737 [59].  
Platelets contain mitochondria that are important for their energy metabolism and 
protein synthesis. An early sign of apoptosis is the collapse of m due to a Ca2+ overload in 
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the mitochondria via elevated intracellular Ca2+ levels in response to a disrupture in the Ca2+ 
homeostasis e.g. induced by agonists or drugs. Thrombin as well as the under physiological 
stimuli generated reactive oxygen species (ROS) H2O2 induce a m depolarization [52] [55] 
[60]. A total breakdown of m was observed upon stimulation of platelets with thrombin plus 
collagen [51], with the Ca2+ ionophores ionomycin or A23187 [61] as well as with thrombin 
plus convulxin, a GPVI agonist [43]. Activation of caspase-3 and PS exposure are dependent 
on the level of m. The inhibitor of caspase-3, zVAD, only inhibited activation of caspase-3 
while CsA inhibited both depolarization of m as well as PS exposure. PS exposure 
therefore was considered to be independent or an upstream manifestation of caspase-3 
activation whereas m depolarization was thought to be an upstream event of caspase-9 
and caspase-3 activation as well as of PS exposure [62] consistent with apoptosis in 
nucleated cells. PS exposure was shown to occur independently of m indicating that 
platelet apoptosis is a different mechanism than platelet stimulation [61]. To summarize, 
physiological as well as artificial agonists lead to m loss, a hallmark for the initiation of 
apoptosis.   
 Platelets contain the Bcl-2 family proteins Bcl-XL, Bax, Bak, Bad and Bid; among 
those Bcl-XL, Bax and Bak were studied extensively. It was shown that in resting platelets 
Bak was sequestered by the anti apoptotic protein Bcl-XL [63]. Stimulation of platelets with 
A23187 increased the expression of Bax and Bak but not of the anti-apoptotic factor Bcl-2 
[64]. Thrombin was shown to induce a rapid activation of Bid and Bax followed by their 
translocation to the mitochondria [60]. Likewise, also the ROS H2O2 triggered an activation 
and translocation of Bid and Bax [60]. It was evidenced that platelet life span is determined 
predominantly by degradation of Bcl-XL during platelet aging leading to Bak triggered 
apoptosis followed by platelet clearance. Moreover, antagonizing the pro-survival Bcl-XL by 
ABT-737 resulted in thrombocytopenia, activation of caspase-3 as well as cleavage of 
gelsolin [25] [63]. Loss of Bak ameliorated thrombocytopenia caused by ABT-737 abolishing 
the effect of ABT-737 [25]. In contrast to the inhibition of an anti-apoptotic protein, activation 
of platelets by the collagen or thrombin mimetics CRP-XL (collagen-related peptide) or TRAP 
(thrombin receptor activated peptide) did not induce apoptotic signaling [63]. ABT-737-
induced apoptosis promoted the generation of thrombin due to the increased PS exposure 
[25] [63]. Furthermore, ABT-737 interference showed defects in platelet adhesion as 
shedding of the platelet adhesion receptors GPIb and GPVI occurred [65]. Additionally, it was 
demonstrated that ABT-737 induces Bax activation and translocation [66]. In contrast to the 
regulation of platelet life span by Bcl-2 family proteins, the BH3-only activator proteins Bid 
and Bim were not required for Bax activation and mitochondrial apoptosis [66], the severe 
thrombocytopenia induced by loss of Bcl-XL was only dependent on Bak/Bax. In contrast, 
loss of either Bcl-XL, Bid or Bim did not alleviate thrombocytopenia [66]. Therefore, Bax 
 - 13 - 
activation and apoptotic cell death can occur in the absence of Bid and Bim [66]. To 
summarize, inhibition of the anti-apoptotic protein Bcl-XL leads to platelet apoptosis observed 
by platelet clearance, thrombocytopenia and induction of apoptotic events.   
Platelets also possess the important players of the intrinsic apoptotic pathway 
cytochrome c and Apaf-1 [49]. Cytochrome c and dATP-dependent caspase activation were 
shown to result in proteolysis of gelsolin and fodrin, proteins cleaved during apoptosis [49]. A 
release of cytochrome c that indicates permeabilization of the outer mitochondrial membrane 
was first observed in platelets aging in culture [23]. Consistent with this finding, Vogler et al. 
showed that apoptosis induced by ABT-737 not only mediates loss of m and caspases 
cleavage but also release of cytochrome c [63]. 
However, other apoptotic factors of the intrinsic pathway have not been investigated 
well before as Omi/HtrA2 or XIAP. It was shown that Smac/Diablo is expressed in platelets 
and that during storage of platelet concentrates it is released from mitochondria [67]. The 
interplay of the intrinsic apoptotic proteins has not been depicted precisely. Neither is it 
entirely elucidated whether platelets have an extrinsic signaling apoptotic pathway, as there 
is no evidence for the presence of death receptors or death ligands as DR3, DR5, TRAIL or 
TNF. Platelets express the mRNA for the death ligand TRAIL and the death receptors 
TNFR1, DR3, DR4, DR5 and TRADD but not for the Fas receptor nor Fas ligand [48]. All 
these proteins have not been detected in platelets on the protein expression level. 
Exclusively the decoy receptor DcR2 was found to be slightly expressed in platelets, while its 
expression increased during platelet storage [67]. Besides, it was reported that the death 
ligand TNF induced apoptotic events as thrombocytopenia, an increased production of 
microparticles and an activation of caspase-3, -8 and -9 [68]. By flow cytometry, the TNFR1 
receptor was confirmed to be involved in the TNF signaling suggesting that death receptors 
and ligands have a role in platelet apoptosis [68]. However, those results where only seen in 
a Ca2+ -free, thus a non-physiological, condition.  
 
To conclude, it is assumed that platelets have an intrinsic apoptotic signaling pathway 
that is initiated by a disruption in the Ca2+ homeostasis or the activation and translocation of 
pro-apoptotic proteins as Bax or by Bid signaling. Apoptosis is also triggered by physiological 
agonists such as thrombin or collagen leading to MOMP that causes a release of 
mitochondrial proteins as cytochrome c, Omi/HtrA2 and Smac/Diablo, a m depolarization 
and finally to an activation of caspase-3/7 (Figure 2). Platelet apoptosis is further induced by 
artificial agonists, in a Ca2+-dependent manner by A23187 or Ca2+-independently by ABT-
737, both ways lead to m collapse and the release of mitochondrial proteins (Figure 3). In 
short, once platelets have lost their inner m, they are determined for destruction by 
apoptosis. In nucleated cells, apoptosis can be diminished by the Omi/HtrA2 inhibitor Ucf-
 - 14 - 
101 and initiated by the XIAP inhibitor embelin. It remains to be elucidated whether Ucf-101 
and embelin also impair platelet apoptosis (Figure 3).  
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Figure 2.  Model for apoptosis in platelets. Once platelets are determined for apoptosis, apoptotic 
stimuli or a Ca
2+
overload lead to a depolarization of the m and Bax forms pores into the outer 
mitochondrial membrane releasing cytochrome c, Omi/HtrA2 and Smac/Diablo from the IMS. The 
apoptosome assembling from released cytochrome c, dATP and Apaf-1 activates caspase-9 leading 
to an activation of caspase-3 or -7. The X-linked inhibitor of apoptosis (XIAP) inhibits active caspase-
3, -7 and -9 and itself is inhibited by Omi/HtrA2 and Smac/Diablo. The protein Fas-associated-death-
domain (FADD) is necessary for Caspase-8 activation. However, death receptors that initiate this 
extrinsic pathway were not discovered yet in platelets. Caspase-8 is not exclusively involved in the 
extrinsic pathway as it can link the extrinsic to the intrinsic pathway via truncated Bid. Physiological 
agonists as thrombin or collagen lead to a release of Ca
2+
 from the dense tubular system (DTS), 
depolarizing the m and releasing cytochrome c, Omi/HtrA2 and Smac/Diablo. In this step collagen 
(GPVI) and thrombin (PAR-1 or PAR-4) receptors are involved. PS exposure which is the translocation 
from PS from the inner to the outer plasma membrane occurs shortly after platelet activation as well 
as in platelet apoptosis upstream of caspase activation.  
 
 In addition, apoptotic events in platelets can be induced by drugs or mechanical 
forces. Local anesthetics as dibucaine and tetracaine promote an increase of cytosolic and 
mitochondrial Ca2+ levels inducing PS exposure, m dissipation, cytochrome c release, and 
finally an activation of caspase-9 and -3 [69]. Here, PS exposure was associated with 
mitochondrial apoptotic events independently of Ca2+ as experiments were performed in the 
absence of extracellular Ca2+ [69]. As a control for these experiments, stimulation of platelets 
with A23187 were also performed in the absence of Ca2+ that did not induce PS exposure 
[69]. Calmodulin (CaM) is a Ca2+-sensing protein, responsible for the changes in cytoplasmic 
Ca2+ concentration, that interacts with the platelet membrane GPIb-IX-V complex and that is 
also considered to be involved in the regulation of apoptosis [70]. Agonists of CaM as 
tamoxifen or trifluoperazine have been shown to induce apoptosis in tumor cells and inhibit 
cell invasion and metastasis. Furthermore, it was demonstrated that CaM agonists increase 
the intracellular Ca2+ level, a depolarization of m, caspase-3 activation and PS exposure in 
platelets but do not induce platelet activation [71] [72]. Furthermore, platelet adhesion and 
aggregation were impaired as CaM agonists interfere with the CaM binding to platelet 
receptors as GPVI or GPIb-IX-V [72]. In contrast, other drugs inhibit apoptosis as the 
immunosuppressive drug cyclosporine (CsA) that binds to the MPTP regulator cyclophilin D 
[72]. CsA ablolished loss of m, activated caspase-3 as well as the formation of 
microparticles in A23187-stimulated platelets [72]. As for mechanical forces, apoptosis in 
platelets is also induced by pathologic high shear stress that are present for instance in 
stenotic vessels [62]. Pathologic high shear stress but not physiological shear stress induced 
loss of m, caspase-3 activation, PS exposure, microparticle formation in addition to 
platelet activation [62]. 
 - 17 - 
 
 
 
Figure 3.  Model for targets of artificial agonists in the intrinsic apoptotic signaling pathway. 1) 
ABT-737 inhibits the anti-apoptotic protein Bcl-XL inducing depolarization of m releasing 
cytochrome c that forms the apoptosome together with Apaf-1 and activates caspase-9. Caspase-9 
activates caspase-3 or -7. 2) The Ca
2+
 ionophore A23187 forms pores in the plasmamembrane 
releasing Ca
2+ 
that again induces loss of m and activates caspases. 3) Ucf-101 inhibits Omi/HtrA2 
in nucleated cells, preventing its inhibitory effect of XIAP 4) Embelin inhibits XIAP in nucleated cells, 
preventing XIAP from inhibiting active caspase-3, -7 and -9.  
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Apoptotic events in platelet storage and senescence 
 
It is well known that upon storage platelets lose their discoid morphology and have 
decreased aggregation and changes in the cell surface proteins, the so called platelet 
storage lesions. Loss of the intact platelet function however is a critical event in the 
transfusion medicine where patients suffering from a low platelet count such as leukemic 
patients are treated with a platelet concentrate transfusion. So far the maximum storage time 
of platelet concentrates has been defined to 5-7 days.  
Apoptotic-like events had been associated with platelet aging; however, observations 
are not entirely consistent, apparently depending on the storage condition. Platelets stored in 
plasma-deprived medium for 18-24 hr presented apoptotic events. Specifically an increase in 
PS exposure, Bax and Bak expression as well as diminished m and a release of 
cytochrome c were reported [23]. Importantly, no cleaved fragments of caspase-3 could be 
detected suggesting that platelet death occurs in a caspase-independent way [23]. Platelets 
underwent a morphological condensation and monocyte-derived macrophages are supposed 
to be responsible for the uptake of platelets via class A scavenger receptors [23]. In contrast, 
a recent study of human PRP stored ex-vivo up to 5 days demonstrated a gradual increase 
in activated caspase-3 during platelet aging [66]. Furthermore apoptotic cell death was 
observed with a decline of Bcl-XL. Also expression of Bid, Bim, Bax and Bak decreased 
probably as no new proteins are synthesized; however, the decrease of Bak occurred later at 
day 5. Consistent with the finding that platelet life span is determined by the balance of the 
anti-apoptotic factor Bcl-XL and the pro-apoptotic factor Bak [25], Kodama et al. concluded 
that apoptosis is regulated by a fine balance between anti- and pro-apoptotic multidomain 
Bcl-2 family proteins and that spontaneous apoptosis in stored platelets occurs in a Bax/Bak-
dependent way [66]. Platelet life span has also been associated with anti-platelet antibodies 
that promoted or inhibited activation of caspases and production of microparticles thus 
prolonging or shortening platelet life span [73]. 
An in vivo dog model with senescent circulating platelets due to the suppressed 
thrombopoiesis, showed evidence of a decreased m and increased PS exposure [24]. 
Platelets with shortened survival as well as senescent platelets in vivo presented increased 
PS exposure that was considered to be the responsible signal for platelet clearance [61]. In 
vivo senescent platelets further presented loss of m but no increased CD62P [61]. 
Platelets stored in buffer in vitro maintained the procoagulant surface for at least 4 hr 
suggesting that PS exposure may be responsible for thrombosis [74]. However, PS-exposing 
platelets were not cleared immediately from the circulation [75] [61] but increasing amounts 
of PS exposure due to stimulation with A23187 had shortened survival when injected into 
animals [61]. PS exposure can occur independently of m loss; interestingly, a 
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subpopulation of platelets showed loss of m but no PS-exposure indicating that platelet 
aging is a different mechanism than platelet stimulation [61].  
Apoptotic events were analyzed also in human platelet concentrates (PCs), stored 
under standard blood bank conditions. 7 days after storage of human PCs, platelets had 
increased PS exposure as well as CD62P [67]. The active fragment of caspase-3 was 
present but m was still intact [67]. Others reported that platelet activation as CD62P 
occurred gradually during storage of PCs and that a decreased m was observed only 
upon prolonged storage [76]. In another study of stored PCs a slight increased activation of 
caspase-3 was detected besides an increased expression of Bim as well as Smac/Diablo 
[50]. Moreover, stored PCs showed increased expression of the decoy receptor DcR2 that is 
an early apoptotic event [50]. Bcl-XL remained unchanged during storage as well as the pro-
apoptotic proteins Bax and Bid while Bim partly translocated from the cytosol at day 11 of 
storage. Smac/Diablo release occurred at day 11 but no significant release of cytochrome c 
was observed [50]. Microparticles were shown to accumulate during 5 days of PCs storage, 
an apoptosis induced process without platelet activation [77] [78]. These apoptosis-induced 
platelet microparticles have activated GPIIb/IIIa, increased PAC-1, CD62P and PS exposure 
and form microparticle aggregates [77]. Therefore it was suggested that apoptosis-induced 
platelet microparticles promote cell macrophage differentiation and are thought to have an 
effect on the immune system by interacting with monocytes. Adhesion of microparticles to 
monocytic cells was observed, as well as the differentiation of monocytes to resident M2 
monocytes and phagocytes [77]. Phagocytes are responsible for the clearance of apoptotic 
platelets and apoptosis-induced microparticles [77]. In an in vivo rabbit model it was shown 
that platelet-derived microparticles are cleared rapidly from the circulation [79]. PCs used for 
transfusions need to follow exact storage conditions. Only a change of temperature, 
especially a cold-storage followed by rewarming induced platelet apoptosis [80]. Cold 
storage induced a change in GPIb distribution by clustering and an association of GPIb with 
14-3-3 scaffold proteins [80]. 14-3-3 proteins bind to Bad and upon association with GPIb 
dissociate from Bad inducing its dephosphorylation and activation, liberating Bax from Bcl-XL 
[81]. This GPIb-14-3-3 mediated signaling leads to translocation of Bax, depolarization of 
m, release of cytochrome c and an activation of caspase-9 [80]. Rewarming reduced a 
second wave of apoptosis with production of thromboxane that leads to more Bax activation 
and depolarization of m [80]. New approaches to reduce the risk of an infection during 
platelet transfusions include a pathogen reduction technology (PRT). PRT uses riboflavin or 
UV-light to inactivate pathogens. However, PRT treatment, affected both platelet viability and 
function [82]. After 5-7 days of storage of PRT treated PCs, PS exposure was increased and 
the pro-apoptotic proteins Bak and Bax as well as released cytochorme c and activated of 
caspase-3 were present [82]. Only expression of Bcl-XL was not affected by PRT [82]. 
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Furthermore, in an earlier study it was demonstrated that UV-light induces loss of m [76]. 
So far storage of PCs has been limited to 5 days as platelet lesions occur upon longer 
storage. The late event of Smac/Diablo release may be associated with the observed platelet 
storage lesion [50]. 
 
 
The relation of megakaryocytes death to the generation of platelets 
 
During a long time it was accepted that the generation of platelets is regulated by a 
caspase-dependent mechanism [83] [84]. Specifically the intrinsic apoptotic pathway was 
considered to be involved, as activation of caspases and release of cytochrome c were 
observed during in vitro maturation of megakaryocytes, shortly before proplatelet formation 
[83]. This observation was strengthened by the fact that the caspase inhibitor zVAD or an 
over-expression of Bcl-2 inhibited proplatelet formation [83]. However, interestingly, 
proplatelet formation was not induced by the apoptotic inducer staurosporine and 
cytoplasmic distribution of activated caspase-3 in proplatelets differed from that in senescent 
platelets where it is observed as DNA fragmentation and a diffuse staining pattern [83]. An 
increase in proplatelet production has also been observed upon induction of the extrinsic 
apoptotic pathway by Fas ligation [84]. In contrast to De Botton et al., Clarke et al. did not 
find an implication of the intrinsic pathway in proplatelet formation as neither m 
depolarization nor cytochrome c release occurred in megakaryocytes extensions and as 
these events only were observed in senescent platelets [84]. Furthermore, in recent in vivo 
studies of mice deficient for either Bak/Bax, Bcl-XL or caspase-9 as well as in vitro studies of 
megakaryocytes it has been demonstrated, that apoptosis is not required for platelet 
production, or even counterproductive [85] [86]. Activation of caspases by deleting Bcl-XL in 
megakaryocytes resulted in megakaryocyte apoptosis and a failure of platelet shedding [85]. 
In contrast, platelet production was undisturbed when Bak and Bax were deleted in 
megakaryocytes indicating that for platelet production a Bak/Bax-mediated apoptosis is not 
required [85]. It was shown that the caspase-inhibitor Q-VD-OPh did not impair proplatelet 
formation in contrast to zVAD, indicating that high doses of zVAD might trigger caspase-
independent toxicity in megakaryocytes [85]. Besides, data showing that platelets are 
regulated by apoptosis was based on cell culture as well as on over-expression experiments 
only, but any over-expressed protein may have an impact on cellular processes and in vitro 
culture studies may cause errors. To conclude, Joseffson et al. evidenced that caspase 
activation has a negative impact on proplatelet formation and that Bak/Bax-deficient mice 
have an increased platelet number and life span [85]. Consistent with these findings, 
experiments with caspase-9-deficient mice demonstrated that caspase-9 is not essential for 
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the generation of megakaryocytes and platelets nor for their hemostatic functions [86]. 
Megakaryocytes of caspsase-9-deficient mice remained the ability to form proplatelets upon 
4 days in culture assuming that caspase-9 is only required for the promotion of apoptotic 
death in megakaryocytes and platelets [86]. To conclude, megakaryocytes must restrain the 
intrinsic apoptotic signaling pathway to successively form proplatelets and shed platelets 
[85], while activation of the intrinsic apoptotic pathway is only mandatory for the death of 
megakaryocytes and platelets [85] [86]. In favor of the initial assumption of proplatelet 
formation is that late stage megakaryocytes produce platelets suggesting that platelet 
formation occurs concurrently with megakaryocytes death.  
 
 
Platelet activation and apoptosis in human pathophysiology 
 
Various diseases have been associated with platelet dysfunction, activation or 
apoptosis. Scott syndrome is a rare inherited bleeding disorder presenting defective platelet 
procoagulancy. Scott patients have a normal platelet count and structure, but their platelets 
fail to promote PS exposure as well as fibrin formation upon platelet activation causing 
bleeding events. Scott syndrome patients have deficient scramblase activity [87]; TMEM16F 
contributes to the scramblase complex and is essential for the Ca2+-dependent PS exposure 
[12]. A mutation at a splice-acceptor site of the gene encoding the protein TMEM16F has 
been found to be responsible for its premature termination. In contrast to Scott syndrome, 
Bernard-Soulier syndrome (BSS) presents increased PS exposure of non activated platelets. 
BSS is an inherited platelet function disorder resulting in macro thrombocytopenia and 
bleeding. Patients with BSS present abnormality in the GPIb-IX-V receptor and a decreased 
interaction of both vWF and thrombin to GPIb. The low thrombin concentrations cause 
impaired adhesion to vessel wall and aggregation, thus bleeding. BSS was also associated 
with increased CD62P and apoptotic events as microparticle formation and dissipation of 
m [88]. Furthermore, abnormal platelets were discovered in patients with diabetes mellitus 
type 2. Those patients presented more thrombotic events probably due to hypercoagulation 
[89]. Diabetic rats showed a 30x increase in thrombin activity and an increased proportion of 
platelets with activated caspase-3, -6, -8 and -9 as well as microparticles [89]. These 
observed elevated microparticles are supposed to contribute to coagulation. Another disease 
where apoptotic events and platelet activation play a role is chronic uremia, a disease that is 
accompanied by kidney failure. Uremic platelets have a procoagulant activity shown by an 
increased thrombin generation caused by increased PS exposure [90]. Uremic platelets also 
presented apoptotic events as increased activated caspase-3 [90]. Furthermore, the severe 
form of malaria also known as cerebral malaria due to the breakdown of blood brain barrier 
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presented thrombocytopenia due to a reduced platelet life span. In a mouse model, cerebral 
malaria was associated with increased platelet-derived microparticles as well as increased 
proportion of platelets with activated caspases (-1, -3, -6, -8, -9) [91]. Another well-known 
platelet disease is immune thrombocytopenia (ITP) usually occurring upon viral infections. 
ITP results in a low platelet count probably due to autoantibodies generated by viruses. 
Infection with helicobacter pylori has been shown to be associated with ITP. The 
thrombocytopenia generated during H. pylori infection is due to a CD62P-dependent platelet 
aggregation; PS expression as well as increased microparticles were observed [92]. In a 
murine model it was shown that ITP is associated with apoptotic events, specifically PS-
exposure, m loss and activation of caspase-3 [93]. 
 
 
Immune thrombocytopenia 
 
Immune thrombocytopenia (ITP) is a platelet autoimmune disorder leading to a 
reduced circulating platelet count. At diagnosis, most ITP cases have a platelet count below 
100 x109/L. ITP patients often have a preceding viral infection of approximately two weeks. 
The incidence of ITP is around 100 cases in 1 million people per year, half of them are 
children with a peak incidence of 5 years. ITP patients have mucocutaneous bleeding 
characterized by bruises, petechiae or purpura. Complications of ITP are chronic ITP if the 
disease lasts over 1 year in around 10% of the patients and cerebral hemorrhage in around 
0.1 – 0.2%. ITP patients are diagnosed by a high amount of newly produced circulating 
platelets referred to as reticulated platelets containing a high mRNA content. [94] [95] 
It is supposed that autoantibodies against platelet glycoproteins produced by viruses 
are responsible for the enhanced clearance of platelets in ITP. These autoantibodies of the 
IgG class, in particular with specificity to GPIIb/IIIa and GPIb/IX, lead to the enhanced 
platelet clearance (Figure 4) [95]. Subsequently, the antibody-coated platelets bind to 
macrophages or dendritic cells through Fc receptors and are then internalized and degraded 
in the spleen and liver. These antigen presenting cells additionally generate epitopes from 
platelet glycoproteins and express the novel peptides on their cell surface along with 
costimulatory help and cytokines that facilitate the proliferation of T cell clones. T cells on the 
other hand stimulate B cells whose immunoglobulin receptors proliferate and synthesize 
anti–glycoproteins too. Unfortunately, it is very difficult to diagnose ITP patients by measuring 
platelet autoantibodies. Cytokines were also considered to be involved in the history of ITP 
patients, while they were mainly measured in chronic ITP. It was shown that chronic ITP 
patients have increased plasma levels of the Th1 cytokines IFN- [96] [97], TNF- and IL-2 
[96]. Th1 cytokines are involved in inflammatory reactions and in the activation of 
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macrophages. Furthermore, increased levels of the Th17 cytokine IL-17 as well as IL-6 and 
IL-23 that are involved in the activation of Th17 cells were observed [97]. Th17 cells have 
been associated with inflammatory diseases and especially with autoimmune diseases. 
Acute ITP patients presented increased levels of GM-CSF [98], that is important in the 
generation of megakaryocytes. 
ITP patients often recover spontaneously; however, due to the risk of fatal intracranial 
hemorrhage, in Switzerland most pediatric ITP patients are treated with intravenous 
immunoglobulins (IVIg), in other countries patients are more treated with corticosteroids or 
anti D-antibodies [94]. IVIg is an antibody preparation from blood donors that blocks the Fc 
receptors of macrophages so that platelets are not degraded anymore; anti-D antibodies also 
prevent platelet clearance by blocking the reticuloendothelial system (RES) and 
corticosteroids as oral prednisone suppress the action of the immune system. In the majority 
of ITP patients, platelet count increases 24 - 48 hr after administration of IVIg. ITP patients 
not responding to the above mentioned therapies, mainly chronic patients, are treated with 
splenectomy removing the primary site of platelet clearance. A further therapy is the 
administration of anti-CD20 antibodies as Rituximab that interfere with platelet autoantibody 
production eliminating the B cells by lysis. A new treatment for chronic ITP includes 
thrombopoietin (TPO) mimetics as Eltrompopag that increase the production of platelets by 
enhancing thrombopoiesis [99] [100]. Despite the low platelet count, circulating 
thrombopoietin (TPO) levels are mostly normal in ITP patients. It was reported that impaired 
platelet production is involved in some ITP cases as platelet autoantibodies may also inhibit 
megakaryopoiesis [101]. As TPO not only is involved in the regulation of the circulating 
platelets but also stimulates the differentiation of megakaryocytes, TPO mimetics leading to 
an increase in TPO levels may counteract this deficit of impaired megakayorcytosis. In a 
murine model of ITP it was shown that when anti-GPIIb antibodies are injected into mice it 
leads to thrombocytopenia which is ameliorated by IVIg [93] [102]. Further it was shown that 
murine ITP is associated with apoptotic like events as caspase-3 activation and PS exposure 
which are ameliorated by IVIg [93]. Administration of anti-GPIIb antibodies further induced a 
depolarization of the mitochondrial membrane potential (m); however, this early sign of 
apoptosis was not ameliorated by IVIg suggesting that IVIg only targets downstream 
apoptotic effects [93].  
As anti-platelet antibodies lead to thrombocytopenia and apoptotic events in mice, we 
wanted to investigate whether platelet apoptosis is involved in the enhanced platelet 
clearance that occurs in childhood ITP. The aims of this thesis were to investigate whether 
markers for apoptosis as well as for activation are altered in platelets from acute pediatric 
ITP patients. Especially we examined if an increase in platelet count in response to IVIg is 
associated with a decrease of markers for platelet apoptosis and activation. Besides, we 
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aimed to find out whether an extrinsic signal is responsible for the induction of apoptosis in 
acute ITP, by analyzing plasma levels of 42 different cytokines in ITP patients before and 
after IVIg treatment. We also studied the platelet function in ITP patients in regard to 
thrombin generation. To refer our findings to the autoimmune disease of ITP patients and not 
to the thrombocytopenia itself, we included patients with a chemotherapy-related 
thrombocytopenia. Furthermore, we aimed to understand the potential apoptotic signaling 
pathway(s) in healthy platelets. Therefore we identified apoptotic factors in platelets and 
inhibited or induced apoptosis in platelets by specific pharmacological compounds.   
 
In this study, we show that ITP patients at diagnosis have increased platelet 
apoptosis, increased platelet activation and a reduced endogenous thrombin potential. All 
these manifestations were ameliorated by IVIg treatment. As well, ITP patients at diagnosis 
had elevated levels of cytokines of the Th1 family or Th2 family involved in B cell 
differentiation. We further demonstrate that platelets have a complete intrinsic apoptotic 
signaling pathway including the pro-apoptotic protein Omi/HtrA2 and its target inhibitor XIAP.  
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Figure 4.  ITP pathophysiology and targets of therapies [103] 
1) T cells lose tolerance to platelet glycoproteins, presenting platelet antigens to B cells. 2) Stimulated 
B cells then produce platelet antibodies, anti-CD20 antibodies as Rituximab treatment intererferes with 
this step. 3) Platelet autoantibodies bind to platelets through their fab fragment. 4) Macrophages 
recognize the platelet bound autoantibodies degrading them in the spleen; this primary target for 
platelet clearance is removed by splenectomy. 5) Platelet autoantibodies may also lead to a 
destruction of megakarycytes. 6) TPO is constantly secreted by the liver, as well as by the kidneys 
and bone marrow. TPO levels vary in ITP patients; they can be similar to controls but also lower. TPO 
mimetics increase the platelet production.  
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Outline of the thesis 
 
In order to better understand the apoptotic signaling in platelets, we analyzed platelet 
apoptosis in disease and health and characterized the intrinsic apoptotic signaling pathway in 
human platelets. We investigated not only platelet apoptosis but also the platelet function in 
patients with pediatric immune thrombocytopenia (ITP), before and after treatment with 
intravenous immunoglobulins (IVIg). 
 
ln Chapter two we describe apoptotic events in children with acute ITP before and after 
treatment with IVIg. This study demonstrates that ITP patients at diagnosis have increased 
proportion of platelets with activated caspase-3, -8 and -9 as well as enhanced formation of 
microparticles. These apoptotic events were normalized after treatment with IVIg. 
 
To assess if ITP patients have an impaired platelet function, we analyzed bleeding signs, 
platelet activability and the generation of thrombin before and after treatment of ITP patients. 
In Chapter three we present that ITP patients at diagnosis have elevated CD62P and CD63 
expression, as well as a reduced thrombin potential. Further we show that IVIg reduces 
thrombin activation and increases the endogenous thrombin potential. 
 
To determine further proteins of the apoptotic signaling pathway in healthy platelets, we first 
identified and then specifically inhibited components of the intrinsic apoptotic pathway by 
pharmacological compounds. In Chapter four we describe that platelets contain the pro-
apoptotic protein Omi/HtrA2 and its target anti-apoptotic protein XIAP. Ucf-101, a specific 
inhibitor of the protease Omi/HtrA2 diminishes apoptotic events, while embelin, a XIAP 
inhibitor, induces apoptosis. 
 
To investigate whether cytokines are involved in the apoptotic signaling of ITP as an extrinsic 
trigger, we describe in Chapter five 42 cytokines in ITP patients’ plasma before and after 
treatment. ITP patients at diagnosis present increased plasma levels of cytokines such as 
TNF-, IFN-, IL-2, IL-6, IL-10, IL-13 and GM-SCF.  
 
Chapter six provides a general discussion of the work described in this thesis.  
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Summary 
 
To evaluate the role of intravenous immunoglobulin (IVIg) in platelet apoptosis in pediatric 
immune thrombocytopenia, we investigated platelets of 20 pediatric patients with acute 
immune thrombocytopenia (ITP), before and after IVIg treatment. Healthy children with 
platelet counts in the normal range and children with thrombocytopenia due to chemotherapy 
were enrolled as controls. All ITP patients presented with platelet counts < 20 x 109/L and 
bleeding symptoms. Markers of apoptosis, including activated caspase-3, -8 and -9, 
phosphatidylserine (PS) exposure, mitochondrial inner membrane potential ∆m, as well as 
platelet-derived microparticle formation, were analyzed by flow cytometry. After IVIg 
treatment, platelet counts increased to > 20 x 109/L in all patients. ITP patients had 
significantly increased proportions of platelets with activated caspase-3, -8 and -9, with PS 
exposure, and with decreased mitochondrial inner membrane potential, and demonstrated 
increased microparticle formation. Except for ∆m, these markers for apoptosis were 
reduced by IVIg treatment. Platelets of children with thrombocytopenia after chemotherapy 
also demonstrated increased microparticle formation and decreased ∆Ψm, but no activation 
of caspases 3, 8 and 9 or PS exposure. In conclusion, in acute pediatric ITP, enhanced 
platelet apoptosis is seen at diagnosis that normalizes after IVIg treatment.  
 
 
Keywords: childhood ITP, IVIg, platelet apoptosis, caspase-3, phosphatidylserine 
exposure 
 
 
 - 38 - 
Introduction 
 
 Primary immune thrombocytopenia (ITP) is a common and mostly benign illness; 
children with ITP often have a history of a viral infection (Walker and Walker, 1984, Wright et 
al., 1996). In rare occasions, severe and even life-threatening hemorrhage can occur and 
currently, the majority of patients with acute primary ITP receive treatment with 
corticosteroids, anti-D antibody or intravenous immunoglobulin (IVIg) (Blanchette and Bolton-
Maggs, 2008; Neunert et al., 2008). IVIg, an antibody preparation collected from a large 
number of blood donors, increases the platelet count in most patients with primary ITP. 
 Apoptosis is the main mechanism that regulates cell life span and the elimination of 
damaged or infected nucleated cells. Although platelets are anucleate, they have been 
observed to undergo apoptotic-like events such as collapse of the mitochondrial inner 
membrane potential (∆m), activation of caspases-3, -8 and -9, phosphatidylserine (PS) 
externalization and shedding of microparticles (Leytin et al., 2009; Leytin et al., 2008; Leytin 
et al., 2006a; Leytin et al., 2006b; Lopez et al., 2009; Mason et al., 2007; Rand et al., 2004; 
Schoenwaelder et al., 2009; Vogler et al., 2011). Recently, in a murine model of ITP, it has 
been shown that the profound thrombocytopenia that results from the injection of anti-
glycoprotein (GP)IIb antibodies is accompanied by apoptotic-like events in the platelets; 
administration of IVIg was demonstrated to ameliorate the thrombocytopenia, and to inhibit 
late mechanisms of platelet apoptosis (Crow et al., 2003; Leytin et al., 2006b; Piguet and 
Vesin, 2002; Siragam et al., 2005; Song et al., 2003). 
 To extend these previous observations of others in an animal model of ITP to studies 
in ITP patients, we investigated whether enhanced apoptotic processes occur in platelets of 
pediatric patients with primary ITP, and whether treatment with IVIg ameliorates the 
enhanced apoptosis.  
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Materials and methods 
 
Patients 
 In this prospective study, approved by the local ethics committee, 20 children (11 
females and 9 males) with newly diagnosed ITP were investigated after obtaining written 
informed parental consent (Table 1). All patients fulfilled the criteria for primary ITP (Provan 
et al., 2010). The median age at diagnosis was 4.8 years (range: 2.1 – 14.4 years). The 
median platelet count at diagnosis was 4 x 109/L (range: <1 – 17 x 109/L). 
 In 13 patients, ITP was preceded by 1–3 weeks by an infectious disease: 5 children 
suffered from an upper respiratory tract infection; 4 had a gastrointestinal infection, including 
one due to Campylobacter; 1 child suffered from respiratory tract infection and Norovirus 
infection; 1 had a Varicella Zoster virus infection; and 2 patients had a febrile illness of 
unclear etiology. In 7 patients, there was no history of infection. The severity of bleeding 
symptoms at diagnosis was graded with a standardized bleeding score according to 
Buchanan and Adix (Buchanan and Adix, 2002) and Bolton-Maggs and Moon (Bolton-Maggs 
and Moon, 1997) with minor changes. 
 All patients were treated with an IVIg dose of 0.8 g/kg. Platelet counts were re-
evaluated 12 to 24 hours after IVIg therapy. If they remained below 20 x 109/L, patients 
received an additional dose of IVIg (0.8 g/kg). Platelet counts were then re-evaluated again 
12 to 24 hours later. If they remained below 20 x 109/L, another dose of IVIg was given. 
Maximally, three IVIg doses were administered. 
 Nineteen healthy control children, 10 females and 9 males, median age of 6.9 years 
(range: 0.8 – 19 years), with no history of autoimmune disease, coagulopathy, transfusion of 
blood products, or of ongoing medication, were recruited from the outpatient clinic after 
obtaining written informed parental consent. To control effects due to thrombocytopenia 
itself, in addition, 10 children, 4 females and 6 males, median age 10 years (range: 3.7 – 
15.4 years), with chemotherapy-related thrombocytopenia (cTP), were recruited after 
obtaining written informed parental consent. Their median platelet count was 14 x 109/L 
(range: 3 – 50 x 109/L). 
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 Table 1  
Clinical and laboratory characteristics of children with primary ITP: bleeding scores and platelet count 
results before and after IVIg treatment are presented for each individual patient 
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Materials 
 For flow cytometric analyses, PE-conjugated monoclonal antibodies (MAbs) to 
CD41a (GPIIb, clone HIP8), CD42a (GPIX, clone BEB1) and CD42b (GPIb, clone HIP1) 
were used, as well as APC-labeled annexin A5 (that binds to cell-surface exposed 
phosphatidylserine). Labelled MAbs, annexin A5, and thiazole orange were purchased from 
Becton Dickinson (Rotkreuz, Switzerland); fluorochrome inhibitors of caspases (FLICA) FAM-
DEVD-FMK specific to active caspase-3, FAM-LETD-FMK specific to active caspase-8 and  
FAM-LEHD-FMK specific to active caspase-9 were from Millipore (Zug, Switzerland); the 
voltage-dependent, membrane intercalating dye tetramethylrhodamine-ethyl-ester (TMRE) 
used to analyze ∆Ψm was purchased from Invitrogen (Basel, Switzerland). The 0.9 m 
polystyrene latex marker beads used to discriminate platelets from platelet-derived 
microparticles were purchased from BioCytex (Marseille, France). 
 
Blood sampling and routine testing  
 Venous blood samples for flow cytometric analyses were taken from ITP patients at 
the time of diagnosis prior to treatment, and 12 to 24 hours after the last treatment with IVIg 
(prior to discharge from hospital). Blood samples were taken from healthy controls when 
inserting a venous line and from children with cTP prior to transfusion of a platelet 
concentrate. Samples were collected into citrate anticoagulant (final concentration, 10.5 
mM). The total volumes of the blood samples taken did not exceed 1% of the total blood 
volume of the patients or the controls. Blood indices including platelet counts were measured 
using an automated blood counter, Sysmex XE-2100 (Sysmex Digitana, Horgen, 
Switzerland).   
 
Flow cytometry  
 Flow cytometric analyses were done using platelet-rich plasma (PRP) obtained from 
citrated whole blood by centrifugation at 140 g at 22 °C for 10 min. To analyze markers of 
platelet apoptosis, PRP was diluted 10-fold with isotonic Hepes-buffered saline with Ca2+ 
(HBS-Ca2+; 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 2 mM GPRP, 2 mM Hepes, pH 7.4), 
containing the PE-labeled MAb to CD42b, annexin A5-APC and either FAM-DEVD-FMK, 
FAM-LETD-FMK, or FAM-LEHD-FMK, for analysis of active caspase-3, -8 or -9, respectively. 
For analysis of ∆Ψm, PRP was diluted 10-fold with HBS-Ca2+ containing PerCP-labeled MAb 
to CD42a and 100 nM TMRE. After 1 hour incubation at 22°C, samples were diluted further 
10-fold with HBS-Ca2+ and acquired. To quantify the fraction of reticulated platelets (RP), 
PRP was diluted 100-fold in PBS, pH 7.4, containing 2 mM thiazole orange and the PE-
labeled MAb to CD41a, incubated for 1 hour at 22°C, and acquired. For each sample, 10’000 
platelets, identified as CD42a-, CD42b or CD41a-positive events, were acquired using a 
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FACSCalibur flow cytometer (Becton Dickinson, Rotkreuz, Switzerland). Platelet 
microparticles (MPs) were distinguished from intact platelets on the basis of the profile of 
forward light scatter vs. fluorescence, as described (Schmugge et al., 2003). The percentage 
of MPs was defined as the proportion of all CD42a-positive events smaller than 0.9 m, 
determined using calibrated beads. Results are expressed as the percentage of platelets 
binding FAM-DEVD-FMK, FAM-LETD-FMK, FAM-LEHD-FMK, annexin A5, or thiazole 
orange. For ∆Ψm analysis, the geometric mean fluorescence intensity (MFI) for TMRE of 
CD41a positive events was quantified. Data were analyzed with FCS Express (De Novo 
Software, Los Angeles, CA, USA). 
 
Western blotting  
 Platelet proteins were separated on 12% BisTris NuPage gels (Invitrogen, Basel, 
Switzerland) and transferred to nitrocellulose membranes (Bio-Rad Laboratories AG, 
Reinach, Switzerland). Caspase-3 was detected with a monoclonal mouse IgG anti-human 
caspase-3 antibody (Cell Signaling Technology, Boston, MA, USA) recognizing the proform 
of caspase-3 (~30 kDa), and the large (~14-21 kDa) subunit of activated caspase-3, and an 
anti-mouse IgG coupled to horse radish peroxidase (Jackson ImmunoResearch, Newmarket, 
UK). Immunoreactive bands were visualized using ECL reagents (GE Healthcare, 
Glattbrugg, Switzerland) and autoradiography. 
 
Statistical analyses  
 Statistical analysis between the 4 groups (ITP, ITP after IVIg, healthy controls, cTP) 
was done using Kruskal-Wallis one-way ANOVA, followed by Wilcoxon signed-rank test 
between pairs of medians. Correlation was assessed by the Spearman correlation 
coefficient. Medians were considered statistically significantly different for p<0.05. Analysis 
was done using SPSS (SPSS, Zurich, Switzerland). 
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Results   
 
 At diagnosis, 17 children had platelet counts below 10 x 109/L, and three between 10 
and 20 x 109/L. All patients presented with bleeding symptoms, seven patients having a 
bleeding score of 3, twelve of 2 or 2.5 and one of 1 (Table 1).  
 After IVIg therapy (0.8 g/kg), platelet counts in 14 children increased to ≥20 x 109/L 
after one dose, in 4 patients after a second, and in 2 patients only after a third dose of IVIg. 
After the last IVIg treatment, all patients showed more than a two-fold increase in their 
platelet count (Table 1). Bleeding symptoms resolved in all patients; new bleeding symptoms 
did not occur once IVIg was given. 
 In a murine ITP model, platelet apoptosis was shown to be enhanced; caspase-3 was 
activated, surface PS exposure was increased and the mitochondrial inner membrane 
potential (∆Ψm) was depolarized (Leytin et al., 2006b). To determine whether these 
observations could be extended to patients with ITP, we investigated apoptosis markers such 
as caspase-3, -8 and -9, as well as PS exposure, platelet-derived microparticles (MPs) and 
∆Ψm in platelets by flow cytometry. At diagnosis, a significantly higher proportion of platelets 
from the ITP patients contained activated caspase-3 (median 20.4%; range 1.4–64; n = 20) 
compared with controls (0.95%, range 0 – 5.9; n = 18) as well as with chemotherapy-related 
thrombocytopenic patients (cTP; 1.3%, range 0.1 – 4.6; n = 10; Figure 1A). Although in ITP 
the median proportion of platelets with increased caspase-3 activation was higher, not all ITP 
patients had platelets with activated caspase-3 even when their platelet counts were greatly 
decreased (Figure 1A). After IVIg therapy, the median proportion of platelets with activated 
caspase-3 in the patients decreased significantly to 8.7% (range 0.2 – 33; n = 19) (Figure 
1A). Western blot analysis confirmed the presence of activated caspase-3 in platelets from 
patients before and after IVIg therapy. Activated caspase-3 was detected by Western blot 
only, when the proportion of platelets with activated caspase-3 as measured by flow 
cytometry was markedly elevated (Figure 1D). Both caspase-8 and -9 were also activated in 
a significantly higher proportion of ITP platelets (median 16.7 %; range 1.0 – 42.7; and 
13.1%; range 1.5 – 59.6 respectively; n = 12) at diagnosis compared with healthy children 
(0.7%; range 0.04 – 2.3 and 0.4; range 0.03 – 2.16; n = 11) and cTP patients (1.8%; range 
0.9 – 3.8; and 1.8%; range 0.6 – 2.9; n = 11; Figure 1B & C). As with caspase-3, proportions 
of platelets with activated caspase-8 and -9 also decreased significantly after IVIg therapy to 
a median of 2.5% (range 0.1 – 10.0; n = 8) and 7.1% (range 0.7 – 15; n = 8), respectively. 
 The proportion of platelets with surface-exposed PS at ITP diagnosis (median 15.3%; 
range 0.9 – 38.5; n = 20), was significantly higher than in controls (1.5%; range 0.6 – 5.5; n = 
19) and in children with cTP (1.7%; range 0.6 – 4.9; n = 10). After IVIg therapy, the 
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proportion of platelets with surface-exposed PS decreased non-significantly to a median of 
7.2% (range 1.3 – 20.3; n = 19; Figure 2A.) 
 In a group of children with ITP (n = 12) platelets double stained for both surface 
exposed PS and activated caspase-3 were studied simultaneously (see material and 
methods). Only a median of 35% (range 3 – 95) of platelets with increased PS exposure also 
had activated caspase-3, and a median of 3.2% (range 0.5 – 46) of platelets had activated 
caspase-3 without PS exposure. Furthermore the proportion of platelets showing PS 
exposure only (median 9.4%; range 0.5 – 28), as well as the proportion of platelets showing 
activated caspase-3 only (median 3.2%; range 0.5 – 46), were both elevated at diagnosis 
and decreased after IVIg (3.8%; range 1.4 – 14.8; and 0.85%; range 0 - 36.8, respectively). 
These findings indicate that surface PS exposure is not necessarily associated with activated 
caspase-3 in platelets from ITP patients.  
 Additionally, the mitochondrial inner membrane potential (∆Ψm) of platelets as 
analyzed by TMRE fluorescence tended to be lower at diagnosis of ITP compared to healthy 
controls. ∆Ψm did not recover after IVIg therapy. Although not significantly different, ∆Ψm in 
platelets from healthy children was higher compared to all other patient groups (Figure 2B). 
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Figure 1. Platelet caspase activation is increased in children with primary ITP and decreased 
after IVIg therapy. (A-C) Percentages of platelets with activated caspase-3, as determined by FAM-
DEVD-FMK fluorescence (A), with activated caspase-8 as determined by FAM- LETD -FMK 
fluorescence (B) and percentages of platelets with activated caspase-9, as determined by FAM- LEHD 
-FMK fluorescence (C). The proportion of platelets with activated caspases for each child is shown 
and the median for each group is indicated by a horizontal line. (D) Western blotting of pro-caspase 
and activated caspase-3 levels from individual patients (patient 13 and 14) and control. Below the 
blots, flow cytometry results of platelets with activated caspase-3 (% FAM-DEVD-FMK
+
 platelets), and 
the respective platelet counts are indicated as well. An overall comparison indicated significant 
differences between groups (caspase-3 p < 0.001; caspase-8 p < 0.01; caspase-9 p < 0.001).  
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Figure 2.  Loss of both platelet membrane phospholipid asymmetry (PS exposure) and 
mitochondrial inner membrane potential in ITP is not significantly ameliorated after IVIg. 
Percentage of platelets exposing PS, as determined by annexin A5 binding (A). Mean fluorescence 
intensity (MFI) of TMRE determining the mitochondrial inner membrane potential (m) in platelets 
(B). Analyzed parameters for each child are shown and the median for each group is indicated by a 
horizontal line. An overall comparison indicated significant differences between groups for PS 
exposure (p < 0.05) but not for ∆m (p = 0.4). 
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 Finally, at diagnosis, platelet-derived MPs were significantly elevated compared with 
controls (median 9.0%; range 3.3 – 23.1; n = 20 vs. 5.6%; range 0.8 – 13.2; n = 19), and 
decreased to normal values after IVIg treatment (5.5%; range 1.5 – 13; n = 18). Interestingly, 
platelet-derived MPs in cTP patients were as high as in ITP at diagnosis (Figure 3).  
 In keeping with previous observations (Kokawa et al., 1991; Saxon et al., 1998; 
Strauss et al., 2010; Thomas-Kaskel et al., 2007), the median proportion of young, 
reticulated platelets as well as median platelet size was significantly elevated (median 
14.9%; range 2.4 – 27.8; and median 32.8 FSC; range 13 – 109; n = 20) in our ITP study 
cohort, compared to that in healthy children (1.1%; range 0.6 – 3.0; and 19.0 FSC; range 
13.6 – 24.1; n = 19) as well as cTP (1.8%; range 1.1 – 4.2; and 21.4 FSC; range 14.0 – 33.1; 
n = 8). There was no correlation between reticulated platelets and caspase-3 activity (r = 
0.21, p = 0.4).  
 After IVIg therapy, the proportion of reticulated platelets as well as platelet volume in 
the patients decreased significantly to 2.9% (range 0.7 – 16; n = 18) and to 25.9 FSC (range 
12.0 – 42.2; n=18), respectively (Figure 4). However, the absolute amount of reticulated 
platelets in ITP (median 0.6 x109/L; range 0.002 – 3.6; n = 19) doubled after IVIg (1.2 x109/L; 
range 0.3 – 9.8, n = 18), recovering towards control levels (2.1 x109/L; range 0.8 – 6.7; n = 
15). The observed increase in the absolute number of reticulated platelets suggests that IVIg 
therapy might also enhance thrombopoiesis, in keeping with recent observations by others 
(Barsam et al., 2011). 
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Figure 3.  The proportion of platelet-derived microparticles is increased in ITP and normalizes 
after IVIg therapy. Percentage of platelet-derived microparticles were defined as the proportion of 
CD42a-positive events <0.9 μm. The proportion of microparticles for each child is shown and the 
median for each group is indicated by a horizontal line. An overall comparison indicated significant 
differences between groups (p < 0.01). 
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Figure 4.  Reticulated platelet count and platelet size in childen with primary ITP pre- and post-
IVIg therapy. Percentages of reticulated platelets, as determined by thiazole orange staining (A). 
Platelet size, as determined by forward scatter (B). The proportion of reticulated platelets and the 
platelet size for each child are shown and the median for each group is indicated by a horizontal line. 
An overall comparison indicated significant differences between groups (reticulated platelets p < 
0.001; platelet volume p < 0.001). 
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Discussion 
 
 In this study, we investigated apoptotic markers in a clinically well-defined group of 
children with very low platelet counts, increased proportions of reticulated platelets and 
increased platelet size that presented with bleeding symptoms including petechiae, large 
hematomas, mucosal bleeding and epistaxis - all typical signs of primary ITP. Further, we 
compared these results in ITP to those from healthy children and children with cTP. 
 In platelets from primary ITP patients we demonstrated the presence of elevated 
apoptosis markers – activated caspase-3, caspase-9, and caspase-8; PS exposure; and 
microparticle formation; as well as decreased ∆Ψm. After IVIg therapy, the clinical symptoms 
of ITP subsided with the increase in platelet counts, whereas the proportions of platelets with 
activated caspase-3, -8 and -9  as well as the propotions of platelet-derived microparticles, 
decreased. PS exposure decreased, but the decrease was not statistically significantly. In 
contrast, ∆Ψm did not recover after IVIg therapy. Children with cTP also demonstrated 
increased microparticle formation and decreased ∆Ψm, but activation of caspases-3, -8 and -
9 and enhanced PS exposure were not found in this group. 
 In nucleated cells, hallmarks of apoptosis are morphological changes such as 
membrane blebbing and chromatin condensation. Additional well-established signs of 
apoptosis are activation of caspase-3, -8 and-9, dissipation of ∆Ψm and release of factors 
from the mitochondrial inner membrane space, such as cytochrome c (Galluzzi et al., 2009). 
In the anucleate platelets, we detected caspase-3, -8 and -9 activation, dissipation of ∆Ψm 
and platelet-derived MPs originating from membrane blebbing; all of these parameters are 
easily measured by flow cytometry. However cytochrome c release, which can only be 
analyzed by Western blot after sub-cellular fractionation or by confocal microscopy, was not 
considered for investigation because the small volumes of pediatric blood samples, 
especially samples from thrombocytopenic patients, contained too few platelets for these 
analyses. 
 It should be noted that there were some patients that had low proportions of platelets 
with activated caspase-3 or PS exposure, or low proportions of platelet-derived 
microparticles before IVIg treatment, comparable with control levels, while their platelet 
counts were low and their proportion of reticulated platelets was increased, indicating a 
heterogeneity in the apoptotic phenotype in ITP. Interestingly, the patients with low 
proportions of platelets with activated caspase-3 were not necessarily those with low 
proportions of PS-exposing platelets or with low proportions of microparticles, indicating a 
further heterogeneity in the apoptotic phenotype.  
 The apoptotic events described in platelets in the murine model of ITP occurred as a 
result of injection of anti-GPIIb antibodies (Leytin et al., 2006b), thus, in this model, the 
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antibody type and titre were both well controlled. In our patients, it is likely that the anti-
platelet antibodies were either anti-GPIIb, -GPIb or –GPIIb/IIIa antibodies (Aref et al., 2009), 
and the titres would have been different among patients. This may contribute to the 
heterogeneity seen in the various apoptotic markers in the platelets from our pediatric ITP 
patients. 
 The observed apoptotic events in platelets from ITP patients might contribute to the 
thrombocytopenia. The increased PS exposure on ITP platelets could lead to their clearance 
from the circulation. In addition the increased activation of caspase-3 might lead to the 
disintegration of platelets and microparticle formation after cleavage of caspase-3 target 
proteins. However, cTP patients also showed elevated microparticle formation but without 
increased proportions of platelets with activated caspases and PS exposure. We speculate 
that in cTP, elevated microparticles originate from endothelial activation, chemotherapy 
related toxicity or previous platelet transfusions (Cauwenberghs et al., 2006; Morel et al., 
2008). Also ∆Ψm seemed to be dissipated in ITP as well as in cTP. Previous studies have 
demonstrated that exogenous thrombin is also able to induce apoptotic events; however this 
always seem to be accompanied by a strong mitochondrial membrane depolarization (Lopez 
et al., 2007). 
 In this prospective study of children with primary ITP, we observed elevated signs of 
platelet apoptosis, specifically caspase-3 activation, PS exposure and microparticle 
formation, which were ameliorated by IVIg administration as the thrombocytopenia improved, 
similar to findings in a murine ITP model (Leytin et al., 2006b).  
 In further support of Leytin et al, also in pediatric ITP IVIg did not inhibit platelet ∆Ψm 
dissipation. With these findings Leytin et al concluded that IVIg does not affect upstream 
breakdown of ∆m in platelets, but does inhibit downstream apoptotic events, caspase-3 
activation and PS exposure (Leytin et al., 2006b). In our study additionally platelet caspase-8 
and caspase-9 activation were investigated: not only activation of caspase-3, but also of 
caspase-8 and -9 were ameliorated by IVIg. Therefore we conclude that in platelets IVIg not 
only inhibits executioner caspase-3 and PS exposure, both downstream of the extrinsic 
death signaling and intrinsic mitochondrial disintegration pathways, but in addition the data 
presented in our study indicate that IVIg also inhibits caspase-8 activation, downstream of 
the cell-surface death receptors, and caspase-9, that is at the crossroad of extrinsic and 
intrinsic apoptosis signaling pathways (Hengartner, 2000).  
 Currently, the pathway that initiates the apoptotic events in ITP platelets and which 
results in its amelioration after IVIg administration is unknown; it appears to be distinct from 
that of platelet activation, confirming the finding of an apoptosis-dependent pathway leading 
to activation of caspase-3, -8 and -9 or PS exposure, independent of P-selectin exposure 
(Leytin et al., 2008; Schoenwaelder et al., 2009; Vogler et al., 2011). In addition, it remains 
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unclear if our findings are specific for acute ITP where they could result from an increased 
pro-platelet formation in response to the peripheral platelet destruction (De Botton et al., 
2002). In contrast, in chronic ITP, resistance to platelet apoptosis has been observed with 
less pronounced caspase activation; this could be a consequence of the abnormal 
megakaryocyte development that has been described (Nugent et al., 2009; Wang et al., 
2010). Further studies are necessary to investigate these mechanisms. 
 
 
Acknowledgement 
 
 The authors would like to thank Karin Zurbriggen, Marlis Schmid and Alexandra 
Förderer for excellent technical support, and Dr. Daniel Garcia together with the Division of 
Emergency Medicine for assistance with patient recruitment. This work was supported by the 
Theodor und Ida Herzog-Egli Stiftung Zurich (to MS), a donation made by UBS AG by order 
of a client (to MS), the EMDO Foundation Zurich (to OS) and the Children’s Research Center 
Zurich (to OS). 
 
 
Authorship and Disclosures 
 
 OS, SK, JW, MS: designed the study; JW, OS, IA: performed the experiments, JW 
performed the experiments of Figure 1B, 1C, 1D and 2B and parts of Figure 1A, 2A, 3 and 4; 
OS, JW, SK: analyzed data; SK, MS: attended and enrolled the patients and collected clinical 
data; KWAB, MLR: provided essential advice and expertise with platelet testing and flow 
cytometry; and OS, MLR, SK, MS, JW: wrote the manuscript. The authors have no conflicts 
of interest to declare. 
 - 54 - 
References 
 
Aref, S., Sleem, T., El Menshawy, N., Ebrahiem, L., Abdella, D., Fouda, M., Samara, N.A., 
 Menessy, A., Abdel-Ghaffar, H., Bassam, A., et al. (2009). Antiplatelet antibodies 
 contribute to thrombocytopenia associated with chronic hepatitis C virus infection. 
 Hematology 14, 277-281. 
Barsam, S.J., Psaila, B., Forestier, M., Page, L.K., Sloane, P.A., Geyer, J.T., Villarica, G.O., Ruisi, 
M.M., Gernsheimer, T.B., Beer, J.H., et al. (2011). Platelet production and platelet destruction: 
assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 117, 5723-
5732. 
Blanchette, V., and Bolton-Maggs, P. (2008). Childhood immune thrombocytopenic purpura: 
 diagnosis and management. Pediatr Clin North Am 55, 393-420, ix. 
Bolton-Maggs, P.H., and Moon, I. (1997). Assessment of UK practice for management of acute 
childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 350, 620-
623. 
Buchanan, G.R., and Adix, L. (2002). Grading of hemorrhage in children with idiopathic 
 thrombocytopenic purpura. J Pediatr 141, 683-688. 
Cauwenberghs, S., Feijge, M.A., Harper, A.G., Sage, S.O., Curvers, J., and Heemskerk, J.W. 
 (2006). Shedding of procoagulant microparticles from unstimulated platelets by  integrin- 
mediated destabilization of actin cytoskeleton. FEBS Lett 580, 5313-5320. 
Crow, A.R., Song, S., Semple, J.W., Freedman, J., and Lazarus, A.H. (2003). IVIG induces dose-
dependent amelioration of ITP in rodent models. Blood 101, 1658-1659; author reply 1659. 
De Botton, S., Sabri, S., Daugas, E., Zermati, Y., Guidotti, J.E., Hermine, O., Kroemer, G., 
 Vainchenker, W., and Debili, N. (2002). Platelet formation is the consequence of 
 caspase activation within megakaryocytes. Blood 100, 1310-1317. 
Galluzzi, L., Aaronson, S.A., Abrams, J., Alnemri, E.S., Andrews, D.W., Baehrecke, E.H., 
 Bazan, N.G., Blagosklonny, M.V., Blomgren, K., Borner, C., et al. (2009). Guidelines for the 
use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death 
Differ 16, 1093-1107. 
Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770-776. 
 Kokawa, T., Nomura, S., and Yasunaga, K. (1991). Relationship between platelet 
 volume and anti-platelet autoantibodies in idiopathic thrombocytopenic purpura. Eur J 
 Haematol 47, 104-108. 
Leytin, V., Allen, D.J., Mutlu, A., Gyulkhandanyan, A.V., Mykhaylov, S., and Freedman, J. 
 (2009). Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an  inhibitor of the 
mitochondrial permeability transition pore. Lab Invest 89, 374-384. 
Leytin, V., Allen, D.J., Mutlu, A., Mykhaylov, S., Lyubimov, E., and Freedman, J. (2008). 
 Platelet activation and apoptosis are different phenomena: evidence from the  sequential 
dynamics and the magnitude of responses during platelet storage. Br J  Haematol 142, 494-
497. 
 - 55 - 
Leytin, V., Allen, D.J., Mykhaylov, S., Lyubimov, E., and Freedman, J. (2006a). Thrombin-
 triggered platelet apoptosis. J Thromb Haemost 4, 2656-2663. 
Leytin, V., Mykhaylov, S., Starkey, A.F., Allen, D.J., Lau, H., Ni, H., Semple, J.W., Lazarus, A.H., and 
Freedman, J. (2006b). Intravenous immunoglobulin inhibits anti- glycoprotein IIb-induced 
platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 133, 78-82. 
Lopez, J.J., Redondo, P.C., Salido, G.M., Pariente, J.A., and Rosado, J.A. (2009). N,N,N',N'-
 tetrakis(2-pyridylmethyl)ethylenediamine induces apoptosis through the activation of 
 caspases-3 and -8 in human platelets. A role for endoplasmic reticulum stress. J 
 Thromb Haemost 7, 992-999. 
Lopez, J.J., Salido, G.M., Gomez-Arteta, E., Rosado, J.A., and Pariente, J.A. (2007). Thrombin 
induces apoptotic events through the generation of reactive oxygen species  in human 
platelets. J Thromb Haemost 5, 1283-1291. 
Mason, K.D., Carpinelli, M.R., Fletcher, J.I., Collinge, J.E., Hilton, A.A., Ellis, S., Kelly, P.N., Ekert, 
P.G., Metcalf, D., Roberts, A.W., et al. (2007). Programmed anuclear cell death delimits 
platelet life span. Cell 128, 1173-1186. 
 Morel, O., Morel, N., Freyssinet, J.M., and Toti, F. (2008). Platelet microparticles and 
 vascular cells interactions: a checkpoint between the haemostatic and thrombotic 
 responses. Platelets 19, 9-23. 
Neunert, C.E., Buchanan, G.R., Imbach, P., Bolton-Maggs, P.H., Bennett, C.M., Neufeld, E.J., Vesely, 
S.K., Adix, L., Blanchette, V.S., and Kuhne, T. (2008). Severe  hemorrhage in children with 
newly diagnosed immune thrombocytopenic purpura.  Blood 112, 4003-4008. 
Nugent, D., McMillan, R., Nichol, J.L., and Slichter, S.J. (2009). Pathogenesis of chronic 
 immune thrombocytopenia: increased platelet destruction and/or decreased platelet 
 production. Br J Haematol 146, 585-596. 
Piguet, P.F., and Vesin, C. (2002). Modulation of platelet caspases and life-span by anti-
 platelet antibodies in mice. Eur J Haematol 68, 253-261. 
Provan, D., Stasi, R., Newland, A.C., Blanchette, V.S., Bolton-Maggs, P., Bussel, J.B.,  Chong, B.H.,  
 Cines, D.B., Gernsheimer, T.B., Godeau, B., et al. (2010). International  consensus report on 
the investigation and management of primary immune thrombocytopenia. Blood 115, 168-186. 
Rand, M.L., Wang, H., Bang, K.W., Poon, K.S., Packham, M.A., and Freedman, J. (2004). 
 Procoagulant surface exposure and apoptosis in rabbit platelets: association with 
 shortened survival and steady-state senescence. J Thromb Haemost 2, 651-659. 
Saxon, B.R., Blanchette, V.S., Butchart, S., Lim-Yin, J., and Poon, A.O. (1998). Reticulated 
 platelet counts in the diagnosis of acute immune thrombocytopenic purpura. J Pediatr 
 Hematol Oncol 20, 44-48. 
Schmugge, M., Rand, M.L., Bang, K.W., Mody, M., Dunn, M.S., Amankwah, K.S., Blanchette, V.S., 
and Freedman, J. (2003). The relationship of von Willebrand factor binding to activated 
platelets from healthy neonates and adults. Pediatr Res 54, 474-479. 
 - 56 - 
 
Schoenwaelder, S.M., Yuan, Y., Josefsson, E.C., White, M.J., Yao, Y., Mason, K.D.,  O'Reilly, L.A.,  
Henley, K.J., Ono, A., Hsiao, S., et al. (2009). Two distinct pathways regulate platelet       
 phosphatidylserine exposure and procoagulant function. Blood 114, 663-666. 
Siragam, V., Brinc, D., Crow, A.R., Song, S., Freedman, J., and Lazarus, A.H. (2005). Can 
 antibodies with specificity for soluble antigens mimic the therapeutic effects of  intravenous 
IgG in the treatment of autoimmune disease? J Clin Invest 115, 155-160. 
Song, S., Crow, A.R., Freedman, J., and Lazarus, A.H. (2003). Monoclonal IgG can ameliorate 
immune thrombocytopenia in a murine model of ITP: an alternative to  IVIG. Blood 101, 
3708-3713. 
Strauss, G., Vollert, C., von Stackelberg, A., Weimann, A., Gaedicke, G., and Schulze, H. 
 (2010). Immature platelet count: A simple parameter for distinguishing  thrombocytopenia in 
pediatric acute lymphocytic leukemia from immunethrombocytopenia. Pediatr Blood Cancer. 
Thomas-Kaskel, A.K., Mattern, D., Kohler, G., Finke, J., and Behringer, D. (2007). Reticulated platelet 
counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura 
and help identify the complex causes of thrombocytopenia in patients after allogeneic 
hematopoietic stem cell transplantation. Cytometry B Clin Cytom 72, 241-248. 
Vogler, M., Hamali, H.A., Sun, X.M., Bampton, E.T., Dinsdale, D., Snowden, R.T., Dyer, M.J., Goodall, 
A.H., and Cohen, G.M. (2011). BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular 
calcium homeostasis, and prevents platelet activation.  Blood 117, 7145-7154. 
Walker, R.W., and Walker, W. (1984). Idiopathic thrombocytopenia, initial illness and long term follow  
up. Arch Dis Child 59, 316-322. 
Wang,  J.D., Ou, T.T., Wang, C.J., Chang, T.K., and Lee, H.J. (2010). Platelet apoptosis 
 resistance and increased CXCR4 expression in pediatric patients with chronic immune 
 thrombocytopenic purpura. Thromb Res 126, 311-318. 
Wright, J.F., Blanchette, V.S., Wang, H., Arya, N., Petric, M., Semple, J.W., Chia, W.K., and 
 Freedman, J. (1996). Characterization of platelet-reactive antibodies in children with 
 varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol 95, 145- 
 152. 
 
 
 
 
 
 - 57 - 
 - 58 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 59 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 60 - 
Original Article 
 
 
Improved thrombin activation of platelets and endogenous 
thrombin potential in pediatric patients with immune 
thrombocytopenia after IVIg treatment 
 
 
Jeannine Winkler*1,2, Sabine Kroiss*1, Oliver Speer1,2, Markus Schmugge1 
* authors contributed equally to the work 
 
 
1
Division of Hematology and Children’s Research Center, University Children’s Hospital Zurich, 
Steinwiesstrasse 75, 8032 Zurich, Switzerland 
2
Zurich Center for Integrated Human Physiology, University of Zurich, Switzerland, University of 
Zurich, Switzerland 
 
 
Running heads: J. Winkler et al. Improved thrombin activation of platelets and ETP in 
pediatric patients with ITP after IVIg treatment 
 
Word count (abstract): 225 
Word count (text): 4806 
Tables and figures: 5 
References: 24 
 
 
 
Written as manuscript for publication 
 
 
Correspondence: Dr. Markus Schmugge, Division of Hematology, University Children’s 
Hospital Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland 
E.Mail: markus.schmugge@kispi.uzh.ch
 - 61 - 
Summary 
 
To assess which ITP patients are prone for high bleeding risk and in which patients treatment 
is dispensable due to low bleeding risk, we investigated platelet function in acute pediatric 
immune thrombocytopenia (ITP) before and after intravenous immunoglobulin (IVIg) 
treatment. We analyzed platelets and plasma of 23 ITP patients for platelet activation, 
response to thrombin stimulation as well as thrombin generation. Healthy children with 
platelet counts in the normal range and children with thrombocytopenia due to chemotherapy 
were enrolled as controls. All ITP patients presented with platelet counts < 20 x 109/L and 
bleeding symptoms. Platelet surface expression of the activation markers CD62P and CD63 
as well as the conformational change in the glycoprotein GPIIb/IIIa were analyzed by flow 
cytometry. Furthermore, the endogenous thrombin potential was measured by a thrombin 
generation assay. ITP patients at diagnosis presented increased proportions of platelets with 
CD62P and CD63 and a decreased endogenous thrombin potential. Additionally, thrombin-
induced activation of platelets was reduced in acute ITP shown by decreased expression of 
CD62P, CD63 and activated GPIIb/IIIa. After IVIg treatment, platelet counts increased to > 
20 x 109/L in all patients. Thrombin-induced activation as well as the low endogenous 
thrombin potential were ameliorated by IVIg in ITP patients. To conclude, after IVIg treatment 
of pediatric ITP patients we observe an improved thrombin activation of platelets and an 
increased endogenous thrombin potential. 
  
 
Keywords: pediatric ITP, IVIg, platelet activation, endogenous thrombin generation 
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Introduction 
 
Primary pediatric immune thrombocytopenia (ITP) is a common and mostly benign 
illness; children with ITP often have a preceding viral infection [1] [2]. ITP is a platelet 
autoimmune disorder leading to a reduced circulating platelet count. ITP patients mostly 
recover spontaneously but in rare occasions fatal intracranial hemorrhage occurs. Also 
around 10% of the patients develop into a chronic ITP when the disease last longer than 12 
months after diagnosis. Treatment of ITP patients includes intravenous immunoglobulins 
(IVIg), anti D-antibodies or corticosteroids [3] [4]. IVIg, an antibody preparation collected from 
a large number of blood donors, increases the platelet count and reduces bleeding 
symptoms in most ITP patients.  
It is suggested that ITP is caused by autoantibodies binding to glycoprotein (GP) 
complex GPIIb/IIIa or GPIb/IX [5] resulting in an enhanced platelet clearance. There is 
evidence that these anti-platelet antibodies can either inhibit or activate platelets and alter 
platelet function [6]. Platelet activation leads to a change in the platelet morphology and to 
the conversion of the fibrinogen receptor GPIIb/IIIa into a functional fibrinogen receptor that 
binds fibrinogen, a process required for normal platelet aggregation [7]. This activated and 
exposed GPIIb/IIIa can be detected by the monoclonal antibody PAC-1 [8]. During platelet 
activation, fusion of granule or lysosomal membranes occurs exposing and expressing P-
selectin (CD62P) [9] as well as CD63 [10] on the platelet surface. A first step upon damage 
of blood vessels is the expression of the tissue factor (TF) into the bloodstream that initiates 
a coagulation signaling cascade. Two different pathways are involved, the extrinsic pathway 
including TF, factor VII and V and the intrinsic pathway that among others consists of factor 
VIII and factor X. The platelet surface factor Xa/Va complex cleaves prothrombin to thrombin 
that generates a thrombin burst while thrombin cleaves fibrinogen into fibrin [11]. This 
generation of thrombin can be measured by a thrombin generation assay that determines the 
endogenous thrombin potential (ETP). ETP determines the time that thrombin has been 
active in a plasma sample and also the generated amount of thrombin [12]. 
We wanted to investigate whether by analyses of the ETP in plasma of ITP patients 
we will be able to better define the bleeding risks. To assess whether ITP patients have an 
impaired ETP, we measured the ETP in ITP patients before and after IVIg treatment as well 
as in chronic ITP patients. Recently we showed that at initial presentation pediatric ITP 
patients present enhanced phosphatidylserine (PS) exposure as well as platelet apoptotic 
events e.g. activated caspases and increased formation of microparticles [13]. PS exposure 
is a sign of platelet apoptosis as well as activation and it is well accepted that two distinct 
pathways regulate procoagulant activity [14]. All these apoptotic manifestations were 
ameliorated by an increase in platelet count after IVIg treatment. Earlier studies 
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demonstrated that platelets are activated in chronic ITP shown by increased CD62P 
expression [15] [16]. 
 
To extend these previous observations we wanted to analyze whether platelet 
function such as platelet activability is impaired in acute ITP patients. To determine whether 
platelet activation or thrombin generation is altered in pediatric ITP and ameliorated by IVIg 
we investigated markers for platelet activation as well as the endogenous generation of 
thrombin before after IVIg treatment. To further study platelet activability of ITP platelets we 
analyzed apoptotic markers as activated caspase-3, -8, and -9 in platelets stimulated by 
thrombin or the Ca2+ ionophore A23187. In this study we demonstrated that ITP patients at 
diagnosis have increased platelet activation, reduced thrombin-induced platelet stimulation 
as well as a reduced ETP. 
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Materials and methods 
 
Patients 
 In this prospective study, approved by the local ethics committee, 23 children (13 
females and 10 males) with newly diagnosed ITP were investigated after obtaining written 
informed parental consent (Table 1). All patients fulfilled the criteria for primary ITP [17]. The 
median age at diagnosis was 4.2 years (range: 1.6 – 14.4 years). The median platelet count 
at diagnosis was 6 x 109/L (range: <1 – 17 x 109/L) and after treatment with IVIg 41 x 109/L 
(range 20 – 123 x 109/L). 3 patients had signs of a respiratory tract infection without fever at 
the time of diagnosis, one of them presented with urtikaria. Two patients had a 1-2 weeks 
preceding respiratory tract infection with fever and one without fever. Two patients were still 
under antibiotic treatment because of streptococcal angina. In 3 patients, ITP was preceded 
by 2–4 weeks by a viral gastroenteritis. One patient presented with diarrhea and fever two 
months ago and one patient had diarrhea 2 weeks ago. One patient had a febrile infection 
and presented vomiting and one patient had fever 5 days before diagnosis. One patient had 
an influenzal infection two weeks before diagnosis and one patient presented with a 4 weeks 
preceding varicella. In 8 patients, there was no history of infection. All patients had a very low 
platelet count median 6 x 109/L (range <1 – 17 x 109/L) at diagnosis. The severity of bleeding 
symptoms at diagnosis was graded with a standardized bleeding score according to 
Buchanan and Adix [18] and Bolton-Maggs and Moon [19] which was modestly adapted. 
Bleeding scores were 2 to 3 with most patients suffering from large hematoma and multiple 
petechiae. 6 patients presented with mucosal bleeding, 2 of them with severe epistaxis and 
hematemesis.  
All acute ITP patients were treated with IVIg at a dose of 0.8 g/kg body weight and 
showed a rise in platelet count above 20 x 109/L in the next 24 to 48 hr, accompanied by 
declining bleeding symptoms. From these patients blood was investigated at this diagnosis 
and after 24-48 hr. Patients were followed during one year. After 6 months 15 patients were 
in remission with stable normalized platelet counts without further treatment. One patient had 
persistent ITP, two a relapsing ITP and 5 patients developed into a chronic ITP. 
We included 13 patients who suffered from a chronic ITP (Table 2) after obtaining 
written informed parental consent. These chronic ITP patients had a median platelet count of 
51 x 109/L (range <1 – 195 x 109/L) (Table 2). The median age was 10.4 years (range 2.6 - 
16.4). Two patients were under treatment at the time of blood collection, one under rituximab 
and one under prednisone treatment. 
22 healthy control children, 11 females and 11 males, median age of 7.6 years 
(range: 0.8 – 19 years), with no history of autoimmune disease, coagulopathy, transfusion of 
blood products, or of ongoing medication, were recruited from the outpatient clinic after 
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obtaining written informed parental consent. To control effects due to the thrombocytopenia 
itself, in addition, 13 children (7 females and 6 males) with a median age of 10.3 years 
(range: 3.8 – 15.4 years), 12 patients with a chemotherapy-related thrombocytopenia and 
one with an aplastic anemia (cTP), were recruited after obtaining written informed parental 
consent. Their median platelet count was 16 x 109/L (range: 3 – 53 x 109/L). 
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 Table 1.  
Clinical and laboratory characteristics of children with primary ITP: bleeding scores and platelet count 
results before and after IVIg treatment are presented for each individual patient. BS indicates blood 
sampling. 
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 Table 2.  
Clinical and laboratory characteristics of children with chronic ITP: Bleeding scores, platelet counts 
and proportion of platelets with activated caspase-3, caspase-9 and caspase-8 are presented for each 
individual patient. BS indicates blood sampling. 
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Materials 
For flow cytometry PerCP-conjugated anti CD42a (glycoprotein (GP) IX, clone BEB1), 
APC-conjugated anti CD62P (clone AK-4), PE-conjugated CD63 (clone H5C6), as well as 
FITC-conjugated PAC-1 (clone PAC-1) were used. Fluorochrome inhibitors of caspases 
(FLICA) FAM-DEVD-FMK specific to active caspase-3, FAM-LETD-FMK specific to active 
caspase-8 and FAM-LEHD-FMK specific to active caspase-9 were from Millipore (Zug, 
Switzerland). Labeled mAbs were purchased from Becton and Dickinson (Rotkreuz, 
Switzerland). 
 
Blood sampling and routine testing  
 Venous blood samples for flow cytometric analyses were taken from ITP patients at 
the time of diagnosis prior to treatment, and 12 to 24 hours after the last treatment with IVIg 
(prior to discharge from hospital). Blood samples were taken from healthy controls when 
inserting a venous line and from children with cTP prior to transfusion of a platelet 
concentrate. Samples were collected into citrate anticoagulant (final concentration, 10.5 
mM). Blood indices including platelet counts were measured using an automated blood 
counter, Sysmex XE-2100 (Sysmex Digitana, Horgen, Switzerland).   
 
Flow cytometry  
 Flow cytometric analyses were done using platelet-rich plasma (PRP) obtained from 
citrated whole blood by centrifugation at 140 g at 22°C for 10 minutes. To analyze markers of 
platelet activation, PRP was diluted 10-fold with isotonic Hepes-buffered saline with Ca2+ 
(HBS-Ca2+; 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 2 mM GPRP, 2 mM Hepes, pH 7.4), 
containing PAC1-FITC, CD42a-PerCP, CD63-PE and CD62P-APC. For analysis of active 
caspase-3, -8 or -9, FAM-DEVD-FMK, FAM-LETD-FMK or FAM-LEHD-FMK were used 
respectively in combination with CD42b-PE. Measurements were done before and after 
thrombin stimulation of platelets with 1 U/ml thrombin as well as by 3 M calcium ionophore 
A23187 in PRP for 1 hr. For each sample, 10’000 platelets, identified as CD42a-positive 
events, were acquired using a FACSCalibur flow cytometer (Becton Dickinson, Rotkreuz, 
Switzerland). Data were analyzed with FCS Express (De Novo Software, Los Angeles, CA, 
USA). 
 
Thrombin generation 
Thrombin generation (ETP) was measured with Technothrombin TGA kit 
(Technothrombin TGA kit, Techonoclone, Vienna, Austria) on an Infinite M200 microplate 
fluorescence reader (Tecan, Männerdorf, Switzerland) with a specially adapted software 
(Technoclone, Vienna, Austria), according to the manufacturer's instructions and as 
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previously reported [20]. The concentration of generated thrombin was registered over time, 
resulting in a thrombin generation curve. From this curve total amount of thrombin generated 
(area under the thrombin generation curve (AUC)) was determined. 
 
Statistical analyses  
Statistical analysis between the 4 groups (ITP, ITP after IVIg, healthy controls, cTP) 
was done using Kruskal-Wallis one-way ANOVA, followed by Wilcoxon signed-rank test 
between pairs of medians. Correlation was assessed by the Spearman correlation 
coefficient. Medians were considered statistically significantly different for p<0.05. Analysis 
was done using SPSS (SPSS, Zurich, Switzerland). 
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Results   
  
At diagnosis, 20 children with acute ITP had platelet counts below 10 x 109/L, and 3 
between 10 and 20 x 109/L. All patients presented with bleeding symptoms, 8 patients having 
a bleeding score of 3, 7 of 2.5, 7 of 2 and 1 of 1 (Table 1). After IVIg therapy (0.8 g/kg), 
platelet counts in 17 children increased to ≥20 x 109/L after one dose, in 4 patients after a 
second, and in 2 patients only after a third dose of IVIg. After the last IVIg treatment, all 
patients showed more than a two-fold increase in their platelet count (Table 1). Bleeding 
symptoms resolved in all patients; new bleeding symptoms did not occur once IVIg was 
given. We included 13 patients with chronic ITP (Table 2) that had a platelet count of 51 x 
109/L, 3 of them presented almost a normal platelet count of above 100 x 109/L One patient 
had no bleeding symptoms while 8 patients having a bleeding score of 1, 3 of 2 and 1 of 2.5 
(Table 2). 
Recently we showed that at initial presentation pediatric ITP patients have enhanced 
platelet apoptotic events such as activation of caspases, PS exposure and formation of 
microparticles [13]. Those apoptotic manifestations were ameliorated after treatment with 
IVIg. In the present study we examined whether the same ITP patients also present impaired 
platelet activation or thrombin generation. To analyze whether platelet activation is impaired 
in pediatric ITP we investigated platelet activation markers such as P-selectin (CD62P), 
CD63 and PAC-1 by flow cytometry with and without stimulation by thrombin before and after 
treatment with IVIg. To determine the amount of generated thrombin in ITP plasma we 
analyzed the endogenous thrombin generation potential in acute ITP patients at diagnosis 
before and after treatment as well as in chronic ITP patients.   
Platelets of childhood ITP patients at diagnosis presented an increased surface 
expression of CD62P (20.09 ± 4.3%) and CD63 (34.4 ± 5.5%) compared to cTP patients 
(CD62P: 4.7 ± 1.3%; CD63: 8.8 ± 2.1%) and healthy children (CD62P: 3.8 ± 0.8%; CD63: 
10.6 ± 2.1%) (Figure 1A & B). Thrombin stimulation significantly enhanced the surface 
expression of CD62P as well as of CD63 in ITP patient’s platelets (CD62P: 63.8 ± 6.2%; 
CD63: 64.0 ± 6.5%) as well as in cTP platelets (CD62P: 54.2 ± 9.6%; CD63: 51.2 ± 6.8%), 
however, values were lower compared to healthy children (CD62P: 91.6 ± 1.6%; CD63: 85.2 
± 3.8%). After IVIg treatment expression levels of CD62P as well as of CD63 were reduced 
in ITP patients, similar to the values of healthy children meaning normalized. The expression 
of CD62P in ITP patient’s platelets after therapy was 18.0 ± 4.9% and increased to 86.9± 
5.1% after thrombin treatment; of CD63 24.4 ± 5.1% that increased to 86.3 ± 4.6%.  
Thrombin-induced PAC-1 binding, thus activation of GPIIb/IIIa, increased after 
stimulation of platelets with thrombin, in patients with ITP or cTP and controls. However, 
PAC-1 binding was reduced in ITP patients (33.5 ± 6.3%) as well as in cTP patients (16.6 ± 
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4.9%) compared to healthy controls (67.3 ± 6.5%) (Figure 1C). After treatment of ITP 
patients with IVIg, thrombin-stimulated platelets showed an increased binding of PAC-1 
(53.9± 7.3%), similar to control levels. PAC-1 levels of resting platelets in ITP (2.6 ± 0.9%) 
and after IVIg therapy (3.5± 2.8%) were neither significantly different from control levels (1.0 
± 0.4%) nor from cTP patients (0.5 ± 0.1%).  
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Figure 1.  ITP patients at diagnosis have impaired platelet activation. P-selectin (CD62P), CD63 
and PAC-1 expression in platelets from ITP patients at diagnosis and after IVIg treatment compared to 
healthy children and children with cTP. Measurements were performed in the absence and presence 
of platelet stimulation by thrombin. Platelet activation markers were measured by flow cytometry. 
Patients with acute ITP present increased surface expression CD62P that is ameliorated by IVIg (A). 
Patients with acute ITP have increased expression of the lysosomal protein CD63 that is ameliorated 
by IVIg (B). Thrombin-induced PAC-1 binding is reduced in ITP and cTP and increases after IVIg 
treatment (C). Data are presented as mean ± SEM. Black symbols: without thrombin, white symbols: 
after thrombin stimulation. Circles indicate ITP patients at diagnosis, squares ITP patients after IVIg 
treatment, triangles healthy children and rectangle children with a chemotherapy-related 
thrombocytopenia. p < 0.05 was considered statistically significant. 
 
 
 
Acute ITP patients showed significantly lower ETP compared to healthy children 
(Figure 2A). The median amount of the generated thrombin at diagnosis of ITP was 152 nM 
(range: 18 - 401 nM). After IVIg treatment, although platelet count did not completely 
normalize, ETP increased to 267 nM (range: 120 – 415 nM) comparable to values seen in 
healthy children (370 nM, range: 85 – 673 nM). One month after IVIg treatment, patients 
presented again a decreased thrombin generation as values were at 194 nM (range: 97 – 
295 nM) (data not shown, n = 14). These patients also presented a low platelet count of 9 x 
109/L (range: 3 – 274). Furthermore, 3 patients developed into a chronic ITP. There was a 
significant correlation observed (p < 0.001) between ETP and platelet count (all study 
subjects included: r = 0.45). For platelet activation markers, no correlation was seen between 
ETP and CD62P or CD63 expression with and without thrombin stimulation. Interestingly, 
cTP patients had not a reduced thrombin generation: 242 nM (range; 185 – 786 nM). We 
also analyzed the ETP in platelets of 13 chronic ITP patients. These patients presented a 
reduced platelet count of 51 x 109/L while 3 patients had nearly a normal platelet count 
between 100 and 200 x 109/L (Table 2). Chronic ITP patients had a significantly reduced ETP 
(143 nM, range: 31 – 477) compared to controls that was similar to acute ITP patients at 
diagnosis (Figure 2B).  
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To determine if chronic ITP patients also have increased proportion of platelets with 
activated caspases as we have detected in acute ITP patients in a recent study [13] (Chapter 
2), we analyzed active caspase-3, caspase-8 and caspase-9 by flow cytometry in platelets of 
chronic ITP patients (Table 2). We found that chronic ITP patients present a less pronounced 
activation of caspase-3 at the time of blood collection (median 2.1 %; range 0.2 – 11.8, n = 
10) (Table 2); compared to control (0.95 %, range 0 –  5.9; n = 18) and acute ITP (median 
20.4 %; range 1.4 – 64; n = 20) as was determined before (Chapter 2). Both caspase-8 and -
9 were also increased in chronic ITP patients, while capase-9 was statistically significant (p < 
0.05) (median 4.0%; range 0.2 – 12.3, n = 10 and 3.8%; range 0.3 – 15.6, n = 10) (Table 2); 
compared to control (0.95%, range 0 – 5.9; n = 18) and acute ITP (median 20.4%; range 1.4 
– 64; n = 20) as determined in the study of Chapter 2. Two chronic ITP patients that both had 
a very low platelet count presented increased activated caspases, while one patient was 
under treatment at the time of blood collection and the other was not (Patient Nr 1 and 2). 
In Figure 1 we showed that ITP patients at diagnosis have reduced thrombin-induced 
platelet activation observed by a decreased expression of platelet markers. To determine 
whether thrombin also negatively influences activation of caspases in acute ITP, we 
investigated active caspase-3, -8 and -9 in thrombin-stimulated ITP platelets. Additionally, we 
also analyzed A23187-stimulated platelets, as the Ca2+ ionophore A23187 is more potent to 
induce apoptotic events in healthy platelets than thrombin. In Table 3 we show that caspase 
activation by thrombin or by A23187 in platelets of ITP patients is not impaired in most 
patients (apart from patient Nr 5) compared to the reduced activation of CD63, CD62P and 
PAC-1 by thrombin shown in Figure 1. In Table 3A & B we describe the proportion of 
platelets in acute ITP patients as well as in controls. In contrast to controls, ITP patients at 
diagnosis have already increased proportions of platelets with activated caspase-3, -8 and -9 
in resting platelets. To better depict the data of Table 3A & B, we determined the fold 
increase in ITP and control (% thrombin-stimulated platelets divided by % resting platelets; % 
A23187-stimulated platelets divided by % resting platelets) of activated caspases in Table 3C 
& D. We have not evaluated yet the data for ITP patients after IVIg treatment. The fold 
increase in ITP patient’s platelets after thrombin stimulation was 1.8 (range 0.4 – 3.3) for 
activated caspase-3 and similar to control (2.6, range 0.6 – 10.0). The fold increase in 
A23187-stimulated ITP patients’ platelets was 2.7 (0.8 – 5.7) for activated caspase-3 and 
significantly lower (p < 0.01) than in control (32.9, range 4.2 – 60.5). The fold increase in 
thrombin-stimulated platelets of ITP patients was 1.6 (range 0.1 – 5.5) for activated caspase-
9 and similar to control (2.4, range 0.1 – 13.7). The fold increase in A23187-stimulated ITP 
patients’ platelets was 2.1 (0.5 – 9.2) for activated caspase-9 and significantly lower (p < 
0.01) than in control (7.3, range 3.2 – 104.1). The fold increase in thrombin-stimulated 
platelets of ITP patients was 1.5 (range 0.4 – 3.8) for activated caspase-8 and similar to 
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control (1.5, range 0.8 – 9.2). The fold increase in A23187-stimulated platelets of ITP patients 
was 1.9 (0.5 – 4.9) for activated caspase-3 and significantly lower (p < 0.01) than in control 
(8.6, range 4.5 – 23.5). The acute ITP patients included in Table 3 is a subgroup of the ones 
included in the previous study of Chapter 2.  To summarize, activation of control platelets by 
A23187 is much higher than activation of acute ITP patient’s platelets shown by fold 
increases. Of these 10 patients we have complete data for activated caspase-3, -9 and -8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  ITP patients have a reduced endogenous thrombin generation potential (ETP). ETP 
was measured in platelet poor plasma (PPP) after addition of tissue factor according materials and 
methods. ETP of acute ITP patients before and after diagnosis was compared to healthy children, cTP 
children and children with a chronic ITP. Box plots represent the generated thrombin levels (nM). The 
upper and lower limits of the boxes represent the 75
th
 and 25
th
 percentiles, respectively; the horizontal 
bar across the box indicates the median and the ends of the vertical lines indicate the minimum and 
maximum data values  p < 0.01 - 0.05. n = 11 for ITP, n = 12 for IVIg, n = 16 for control, n = 7 for cTP 
and n= 13 for chronic where n indicates the number of patients. 
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 Table 3.  
Platelet activation in acute ITP patients compared to control as determined by activated 
caspases. Analysis of activated caspase-3, caspase-8 and caspase-9 in platelets of resting platelets, 
platelets stimulated with thrombin and platelets stimulated with A23187 in acute ITP patients at 
diagnosis (A) and in control (B) by FAM-DEVD-FMK, FAM-LETD-FMK or FAM-LEHD-FMK 
fluorescence. The fold increase of the proportions of platelets showing active caspases was analyzed 
by comparing thrombin- and A23187- stimulated platelets to resting platelets, respectively, in ITP 
patients (C) and in healthy control children (D). p < 0.01 for activated caspase-3, -9 and -8 between 
ITP and control in resting platelets. p < 0.01 for activated caspase-3, -9 and -8 between ITP and 
control in thrombin-stimulated platelets. p < 0.05 for activated caspase-9 and -8 between ITP and 
control in A23187-stimulated platelets. 
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Discussion 
 
In this study we investigated markers for platelet activation as well as the generation 
of the endogenous thrombin potential (ETP) in a clinically well-defined group of children with 
very low platelet counts that presented with bleeding symptoms including petechiae, large 
hematomas, mucosal bleeding and epistaxis all typical sings of primary ITP. We compared 
these results in ITP to those from healthy children and children with chemotherapy-related 
thrombocytopenia.  
We demonstrated that platelets of children with ITP have an increased CD62P as well 
as CD63 surface expression compared to both healthy and cTP children (Figure 1A & B). We 
further have shown that thrombin-induced activation in platelets of ITP patients is reduced 
similar to that in cTP (Figure 1A – C). The reduced thrombin-induced binding of PAC-1 might 
be responsible for the bleeding signs observed in ITP as binding of fibrinogen to activated 
GPIIb/IIIa is a final step in platelet aggregation. We also detected a reduced ETP in acute 
ITP patients as well as in chronic ITP patients but not in cTP patients (Figure 2). 
Furthermore, we indicated that in ITP patient’s platelets caspase-3 activation is increased by 
thrombin- as well as by A23187 (Table 3) while CD63 and CD62P activation in response to 
thrombin is impaired (Figure 1). Thus we assume that thrombin signaling in ITP patient’s 
platelets is functional.  
After IVIg treatment, the bleeding symptoms of ITP subsided and thrombin-induced 
platelet activation was ameliorated as well as ETP. Following IVIg treatment, plasma of ITP 
patients presented a similar ETP than healthy children even if the platelet count in ITP after 
treatment was not normalized (Figure 2). Although ETP correlated to the platelet count, the 
effect of IVIg on ETP can not be explained by a rise in platelet count alone. After IVIg 
treatment, ITP patients show less bleeding signs without presenting a normal platelet count 
as seen in controls. This is confirmed by the fact that patients suffering from a 
thrombocytopenia due to chemotherapy have a normal ETP despite their low platelet count. 
Thereby we confirm that platelets are not required for the generation of thrombin. Severe 
bleeding only occurs at a very low platelet count in acute patients and less in chronic 
patients. Treatment with IVIg ameliorated most abnormal signs observed in ITP patients at 
diagnosis as platelet activation, apoptosis and ETP. Thus we conclude that IVIg is an 
efficient treatment in ITP patients and its high cost is justified by its efficacy and by the 
patient’s safety. So far, next to the platelet count no other biological markers have been 
correlated to bleeding symptoms in ITP [21]. It will be necessary to include more subjects in 
the measurements of ETP to evaluate whether ETP is a potential biomarker for estimating 
the bleeding risk in thrombocytopenic patients.  
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In this study we also wanted to identify whether apoptosis correlates to platelet 
activation. It has been demonstrated that platelet activation and platelet apoptosis are 
different phenomena [22]. Here we show that platelet activation occurs in the same patients 
as are included in the study of platelet apoptosis in ITP [13]. We detected increased platelet 
activation in acute ITP in support with studies in chronic ITP [15] [16] [23]. We also show a 
reduced thrombin generation that might be responsible for reduced aggregation, thus 
bleeding. Another study demonstrated that sera from ITP patients either impair or enhance 
platelet aggregation [6]. Various other diseases have been associated with platelet 
dysfunction, activation or apoptosis as the Bernard-Soulier syndrome (BSS). BSS is an 
inherited platelet function disorder resulting in macro thrombocytopenia and bleeding. 
Patients present with low thrombin concentrations as well as increased CD62P and apoptotic 
events in platelets [24]. Despite the fact that ITP patients at diagnosis present increased 
CD62P and CD63 expression we did not detect a correlation of these activation markers to 
caspase activation. These data agree with the finding that PS exposure or microparticles are 
responsible for platelet activation and not expressed CD63 and CD62P. Furthermore, 
expression of CD63 and CD62P is crucial for an interaction of platelets with binding partners 
of the endothelial surface.  
In Table 3 we demonstrated that activated caspase-3 in resting platelets of ITP 
patients can be activated by thrombin similar to resting control platelets. In contrast, CD63 
and CD62P stimulation by thrombin was impaired. This finding indicates that thrombin 
stimulation is not entirely impaired in platelets of ITP patients. In contrast to caspase 
activation by thrombin, caspase activation by A23187 is significantly decreased in ITP 
platelets compared to control. The observed reduced fold increase of A23187-stimulated ITP 
platelets might be a consequence of a disruption in the Ca2+ homeostasis and an increase in 
the intracellular Ca2+ level. However, why thrombin stimulation is impaired in ITP platelets 
regarding CD63 and CD62P expression remains to be elucidated. We hypothesize that 
interfering autoantibodies on the platelet surface might be involved in the impaired activation 
of platelet surface proteins and are responsible for the observed increase in caspases.  
Furthermore, we observed that caspase-8 is activated by thrombin as well as by 
A23187 in control or ITP platelets (Table 3). Caspase-8 is also activated in resting ITP 
platelets as we already have demonstrated earlier in the study of Chapter 2. These data 
confirm that the intrinsic and extrinsic apoptotic signaling pathway lead to an activation of 
caspases in platelets of ITP at diagnosis and also in the stimulation of platelets by agonists. 
However, a stimulation of platelets by A23187 should only result in an increase of caspase-3 
and -9 activation as a disruption in the Ca2+ homeostasis initiates the intrinsic pathway via 
loss of the mitochondrial membrane potential. We therefore suggest that a positive feedback 
signaling is responsible for activation of caspase-8 in response to activated caspase-3. In 
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future studies, we aim to determine changes in the intracellular Ca2+ level in platelets of ITP 
patients by the fluorescent Ca2+ indicator Fura-2. We also want to determine whether 
caspase-8 is inhibited by the inhibitor of apoptosis cIAP-1. We consider inhibiting cIAP-1 by 
an artificial compound in a similar way as antagonizing XIAP with its inhibitor embelin as 
described in the study of Chapter 4. Furthermore, preliminary data indicate that platelets of 
chronic ITP patients have less activated caspases than of acute ITP underlying the 
assumption that etiology in chronic ITP is different from acute ITP. However, more chronic 
patients need to be investigated before defining a conclusion. 
 
To conclude, our results show that platelets of ITP patients at diagnosis are pre-
activated and that the capacity for further activation of these platelets on thrombin stimulation 
is impaired. However, GPIIb/IIIa was not activated in ITP platelets at diagnosis indicating that 
ITP platelets are not fully pre-activated. Besides, ITP patients have a low ETP. Treatment 
with IVIg ameliorates both thrombin activation and ETP in pediatric ITP patients. However, 
pre-activation of CD62P and CD63 are not significantly ameliorated by IVIg but a tendency is 
observed.  
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Summary 
 
Although platelets possess the hallmarks for apoptosis as activation of caspases, 
cytochrome c release and depolarization of the mitochondrial transmembrane potential 
(M), their apoptotic signaling pathway is not entirely understood. In this study expression 
as well as inhibition of Omi/HtrA2 by Ucf-101 and of XIAP by embelin were investigated by 
Western blot and flow cytometry in human platelets with and without apoptotic stimuli. We 
found that platelets contain the pro-apoptotic protease Omi/HtrA2, the pro-apoptotic protein 
Smac/Diablo and the X-linked inhibitor of apoptosis XIAP. Omi/HtrA2 and Smac/Diablo were 
released from mitochondria into the cytosol together with cytochrome c after induction of 
apoptosis by the Ca2+ ionophore A23187 or the BH3 mimetic ABT-737. Exposure of platelets 
to Ucf-101 did neither abolish loss of M nor impair activation of caspase-8, however, Ucf-
101 prevented apoptosis observed by a decrease in activated caspase-3 and caspase-9. In 
contrast, embelin promoted apoptotic events such as caspase-3 and -9 activation. These 
results verify that platelets have a complete intrinsic apoptotic signaling pathway including 
the pro-apoptotic protease Omi/HtrA2 and its target protein XIAP suggesting that platelet 
survival might be regulated by these proteins in addition to Bcl-family members. 
 
 
Keywords: apoptosis, caspase-3, platelets, Omi/HtrA2, XIAP 
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Introduction 
 
Apoptosis in nucleated cells is a well-known process regulating cell life span and the 
elimination of damaged or infected nucleated cells. Two different pathways of apoptosis have 
been described: the extrinsic pathway, initiated by death receptors; and the intrinsic pathway, 
initiated by stress signals e.g. DNA damage or disruption in the Ca2+ homeostasis. In 
addition, the extrinsic and intrinsic pathway can be connected by the BH3-interacting domain 
death agonist Bid that, once cleaved by caspase-8, translocates to the mitochondria and 
initiates oligomerization of Bax leading to mitochondrial outer membrane permeabilization 
(MOMP) [1] [2, 3]. Disruption of the Ca2+ homeostasis can also lead to MOMP, resulting in 
release of cytochrome c, Smac/Diablo, and the serine protease Omi/HtrA2 from their 
mitochondrial intermembrane space (IMS). Cytochrome c, together with Apaf-1 and dATP, 
forms the apoptosome, which then activates the initiator caspase-9. This initiator caspase 
then activates the effector caspases, caspase-3 and caspase-7 [1].  
Additionally, caspases are negatively regulated by inhibitors of apoptosis (IAP) such 
as cIAP or XIAP. XIAP is known to bind and inhibit caspase-3, -7 and -9 [4-6]. This is 
achieved via the characteristic protein domains of IAPs, the so-called baculovirus inhibitor of 
apoptosis protein repeats, or BIR motifs [7, 8]. The mitochondrial BIR3-binding protein, Omi 
(also known as HtrA2), that is released from the IMS into the cytosol upon MOMP, was 
identified as a caspase activator [6, 9, 10]. In addition, Omi/HtrA2 was shown to induce 
apoptosis in human cells in a caspase-independent manner through its protease activity, and 
in a caspase-dependent manner via its ability to disrupt caspase-IAP interaction [9]. 
Knockdown of Omi/HtrA2 increases the resistance of multiple cell lines to apoptotic stimuli, 
such as staurosporine, cisplatin, UV irradiation, anti-Fas and TRAIL [5, 9, 11, 12]. Moreover, 
the synthetic Omi/HtrA2 inhibitor Ucf-101 [13], partially protects from cell death induced by 
cisplatin, [14] or TNF- [15]. Similar to Omi/HtrA2, Smac/Diablo promotes caspase activation 
and apoptosis by binding to the BIR3 and BIR2 domains of XIAP and disrupting their 
interaction with caspase-9 and the effector caspases-3 and -7 [10, 16, 17].  
Although platelets are anucleate, they undergo apoptotic-like events, including MOMP 
with collapse of the mitochondrial inner membrane potential (ΔΨm) and  release of 
cytochrome c into the cytoplasm [18]. After platelet stimulation with thrombin, Lopez et al. 
reported truncation and translocation of Bid, a pro-apoptotic Bcl-2 protein, to mitochondria, 
inducing Bak and Bax oligomerization followed by cytochrome c release [19]. It is well 
accepted that the anti-apoptotic Bcl-XL counteracts Bax and protects mitochondria in 
platelets [20, 21]. Once Bcl-XL becomes inhibited, Bax oligomerizes and forms pores in the 
outer mitochondrial membrane releasing cytochrome c from the IMS [22, 23]. However, it is 
not yet known whether, in platelets, Omi/HtrA2 and Smac/Diablo are released from 
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mitochondria. However, in platelets, release of cytochrome c [24] and activated Caspase-3 
[23, 25] have been observed. In addition to these signs of apoptosis, increased microparticle 
formation [26], increased phosphatidylserine (PS) exposure, but also decreased life span of 
platelets leading to thrombocytopenia [20, 21] have been reported. Thus, these apoptotic 
events observed in platelets appear to be relevant in thrombocytopenia [27, 28]. Additionally, 
apoptotic events have been reported to occur during platelet storage [29] or after treatment 
with chemotherapeutic agents [20, 21, 23, 30]. 
 There is a growing body of evidence that apoptotic events in platelets are controlled 
both by anti- and pro-apoptotic proteins [18, 21, 23]. Thus, we were interested in determining 
whether platelets, in addition to cytochrome c, might also release the mitochondrial proteins 
Omi/HtrA2 and Smac/Diablo from the IMS into the cytosol, activating caspases by 
antagonizing IAPs. We showed that Omi/HtrA2, Smac/Diablo and XIAP are expressed in 
human platelets. Using Ucf-101, an Omi/HtrA2-inhibitor previously studied in cell lines [13], 
and embelin, a XIAP inhibitor [31, 32], we demonstrated that inhibition of Omi/HtrA2 prevents 
apoptosis in human platelets, whereas inhibition of XIAP by embelin promotes platelet 
apoptosis. 
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Materials and methods  
 
Materials 
Collagen (200 μg/mL) was obtained from HART Biologicals (Hartlepool, England); 
thrombin, A23187, PGE1, PGI2, GPRP, digitonin, BSA and embelin were from Sigma-Aldrich 
(Buchs, Switzerland); PPACK and the protease inhibitor 5-[5-(2-nitrophenyl) furfuryliodine]-
1,3-diphenyl-2-thiobarbituric acid (Ucf-101) were from Merck Chemicals (Zug, Switzerland); 
and ABT-737 was from Active Biochemicals (Maplewood, NJ, USA). All other chemicals and 
reagents were purchased from Sigma-Aldrich (Buchs, Switzerland). 
For Western blotting, anti-human caspase-3 mouse monoclonal antibody (mAb) 
(clone 3G2), anti-human caspase-7 mouse mAb (clone C7), anti-human caspase-9 rabbit 
polyclonal antibody (pAb), anti-human Omi/HtrA2 rabbit pAb, anti-human rabbit gelsolin pAb 
and anti-human -actin mouse mAb (clone AC-74) were from Cell Signaling Technology 
(Boston, MA, USA) and anti-human rabbit mAb cleaved caspase-3 (clone 269518), anti-
human Apaf-1 mouse mAb (clone 94408), anti-human cytochrome c mouse pAb (clone 
7H8.2C12), anti-human Smac/Diablo rabbit pAb and anti-human XIAP mouse mAb (clone 
117320) were from R&D Systems (Minneapolis, MN, USA). The caspase-3 antibody was 
used to detect the pro-caspase-3 (full length of 30kDa) and the cleaved caspase-3 antibody 
was used to detect the cleaved, active 17kDa fragment. 
 For flow cytometry, PerCP-conjugated anti-CD42a (glycoprotein (GP) IX; clone 
BEB1), APC-conjugated anti-CD62P (clone AK-4), PE-conjugated anti-CD63 (clone H5C6), 
as well as APC-labelled annexin A5 (that binds to cell-surface exposed phosphatidylserine 
(PS)) were used. Labelled mAbs and annexin A5 were purchased from Becton and 
Dickinson (Rotkreuz, Switzerland); fluorochrome inhibitors of caspases (FLICA) FAM-DEVD-
FMK specific for active caspase-3, FAM-LETD-FMK specific for active caspase-8 and FAM-
LEHD-FMK specific for active caspase-9 were from Millipore (Zug, Switzerland); the voltage-
dependent, membrane intercalating dye tetramethylrhodamine-ethyl-ester (TMRE), used to 
analyze the mitochondrial inner membrane potential (∆Ψm), was purchased from Invitrogen 
(Basel, Switzerland). 0.9 m polystyrene latex marker beads used to discriminate platelets 
from platelet-derived microparticles were purchased from BioCytex (Marseille, France). 
 
Blood sampling, preparation of washed platelets and platelet activation  
This study was approved by the local ethics committee and written informed consent 
was obtained from the blood donors. Venous blood samples from healthy donors who had 
not ingested any anti-platelet medications for at least two weeks were collected into citrate 
anticoagulant (final concentration, 10.5 mM).  Preparation of suspensions of washed 
platelets and platelet activation were carried out as described previously [33]. Briefly, 
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platelet-rich plasma (PRP) was obtained by centrifugation at 140g for 10 min at 22°C without 
braking, was removed to another tube and was supplemented with ACD (85 mM trisodium 
citrate, 78 mM citric acid, 110 mM glucose). PRP was centrifuged at 1200g for 12 min. The 
resulting platelet pellet was resuspended in Ca2+-free Tyrode-Hepes buffer (137 mM NaCl, 
2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1 mM MgCl2, 5.5 mM glucose and 5 mM 
HEPES) containing 0.02% EGTA and 0.35% albumin, pH 6.5. After each resuspension step, 
platelets were left at 22°C for 10 min and complemented with 72 μl ACD per mL of wash 
solution before centrifugation at 800g. The second washing medium was Ca2+-free Tyrode-
Hepes buffer without EGTA and the final resuspension medium was Tyrode-Hepes solution 
(137 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1 mM MgCl2, 2 mM 
CaCl2, 5.5 mM glucose, and 5 mM HEPES, pH 7.4) supplemented with 0.35 % BSA (TAH), 
0.05 U/mL apyrase and 2.5 mM GPRP. The platelet count was adjusted to 1 x 109/mL. 
Platelets were activated with either 10 g/mL collagen in combination with 1 U/mL thrombin 
for 5 min or with 3 M Ca2+ ionophore A23187 for 10 min. Platelet apoptosis was induced by 
3 M ABT-737 for 2 hr at 37°C. PGE1 as well as PPACK were used to stop the activation of 
collagen and thrombin stimulated platelets as previously described [33].  
To investigate the effect of blocking Omi/HtrA2, platelets were pretreated with 10 M Ucf-101 
for 2 hr as described in mouse fibroblasts [14] at 37°C before addition of agonist(s) or ABT-
737. To investigate the effect of blocking XIAP, platelets were pretreated with 20 M embelin 
for 2, 22 hr or 48 hr as described in prostate cancer or leukemic cells [32] at 37°C 
 
Western blotting 
 For preparation of cell lysates, a platelet pellet obtained by centrifugation of washed 
platelets incubated with 0.5 mM PGI2 at 500g for 10 min was lysed in lysis buffer (50 mM 
TrisHCl, 150 mM NaCl, 1% Tween, 1 mM EDTA, pH 7.4). The platelet lysates were cleared 
by centrifugation at 4°C and protein concentrations were determined. Alternatively, the 
release of mitochondrial proteins into the cytoplasm of platelets was assessed by lysis of 
platelet pellets in mitochondrial isolation buffer (250 mM sucrose, 20 mM Hepes pH 7.4, 5 
mM MgCl2, 10 mM KCl, 0.05% digitonin) following differential centrifugation as described by 
Vogler et al [23]. At this concentration, digitonin mainly permeabilizes the platelet plasma 
membrane. Thus, after centrifugation, the supernatant (SN) contains soluble cytosolic 
proteins and also any proteins released from mitochondria while the platelet pellet contains 
heavy protein complexes and membranes (HM) including mitochondria and the platelet 
cytoskeleton. Equal amounts of protein were electrophoretically separated on 4-12% BisTris 
NuPage gels (Invitrogen, Basel, Switzerland), and transferred to nitrocellulose membranes 
(Bio-Rad Laboratories AG, Reinach, Switzerland) that were blocked with 5% non-fat dried 
milk in Tris-buffered saline (20 mM Tris, 150 mM NaCl, pH 7.4) with 0.1% Tween-20. 
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Membranes were then incubated with primary antibodies followed by HRP-conjugated 
secondary antibodies (Jackson Immunology, Newmarket, UK) and developed with ECL 
reagent (GE Healthcare, Glattbrugg, Switzerland) or Visualizer Western Blot detection kit 
(Millipore, Zug, Switzerland) and autoradiography. Membranes were stripped (1% SDS, 25 
mM glycine, 2 mM dithiothreitol, pH 2) once or twice for reprobing. 
 
Flow cytometry  
Flow cytometric analyses were done using washed platelets. To analyze markers of 
platelet activation, washed platelets were diluted 50-fold with Tyrode-Hepes solution (137 
mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 
5.5 mM glucose, and 5 mM HEPES, pH 7.4) supplemented with 0.35 % BSA (TAH) , 
containing anti-CD42a-PerCP (used as the platelet marker), anti-CD63-PE and anti-CD62P-
APC (used as markers for platelet activation). To analyze markers of platelet apoptosis, 
washed platelets were incubated under the same conditions with either anti-CD42a-PerCP 
(used as the platelet marker), annexin A5-APC (to detect PS exposure) and FAM-DEVD-
FMK-FITC (to determine caspase-3); anti-CD42a-PerCP (used as the platelet marker) and 
FAM-LETD-FMK-FITC (to determine caspase-8); or anti-CD42a-PerCP (used as the platelet 
marker) and FAM-LEHD-FMK-FITC (to determine caspase-9). For the measurement of 
∆Ψm, platelets were incubated with the platelet marker anti-CD42a-PerCP and 100 nM 
TMRE. After 1 hr incubation at 22°C, samples were diluted further 10-fold with Tyrode-Hepes 
lacking BSA (TH). For each sample, 10’000 platelets, identified as CD42a-positive events, 
were acquired using a FACSCalibur flow cytometer (Becton Dickinson, Rotkreuz, 
Switzerland). Results are expressed as the percentage of platelets binding FAM-DEVD-FMK, 
FAM-LETD-FMK, FAM-LEHD-FMK, annexin A5, or anti-CD62P and anti-CD63 antibodies. 
For ∆Ψm analysis, the geometric mean fluorescence intensity (MFI) was quantified. The 
percentage of platelet-derived microparticles was defined as the proportion of CD42a-
positive events < 0.9 µm determined using calibrated beads as described [34]. Data were 
analyzed using FCS Express (De Novo Software, Los Angeles, CA, USA). 
 
Statistical analysis 
 All data are expressed as mean ± SEM, where n = the number of independent 
experiments performed with different blood donors. Statistical analysis was done using 
Kruskal-Wallis one-way ANOVA, followed by the Mann Whitney test (Figure 3 & 5) and 
paired t-test (Figure 4 & 6). p < 0.05 was considered statistically significant. Analysis was 
done using SPSS (Dynelytics, Zurich, Switzerland). 
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Results 
 
We first systematically investigated the expression of pro- and anti-apoptotic proteins 
of the intrinsic pathway in human platelets; by Western blot analysis, we detected the pro-
apoptotic proteins Omi/HtrA2, Smac/Diablo, cytochrome c, Apaf-1, caspase-9, caspase-3 
and caspase-7 and the anti-apoptotic protein XIAP in washed platelets (Figure 1). Caspase-3 
presented as a double band in some donors. We also detected the pro-apoptotic proteins 
Bid, Bax and Bad as well as the anti-apoptotic protein Bcl-XL (data not shown). These data 
confirm the presence of Bid, Bax, Bad, Bcl-XL, cytochrome c, Smac/Diablo and Apaf-1 that 
have been reported previously in platelets [24, 35]; however to our knowledge neither the 
pro-apoptotic Omi/HtrA2 nor its target anti-apoptotic protein XIAP have been reported to be 
expressed in human platelets.  
 
 
Increases in platelet cytosolic Ca2+ induced by Ca2+ ionophore A23187 and platelet 
apoptosis induced by ABT-737 lead to Omi/HtrA2, Smac/Diablo and cytochrome c 
release from mitochondria into the cytosol. 
 
To elucidate whether during apoptotic signaling in platelets Omi/HtrA2 and 
Smac/Diablo, in addition to cytochrome c [21], are released from mitochondria into the 
cytosol, washed platelets were treated with the combination of the physiological stimuli 
collagen and thrombin (C+T), the Ca2+ ionophore A23187, or the BH3-only mimetic ABT-737. 
In contrast to C+T, both A23187 and ABT-737 induced release of Omi/HtrA2, Smac/Diablo 
and cytochrome c from mitochondria (Figure 2A). In addition, we detected the activated 
forms of caspase-7 and caspase-3 in platelets stimulated with A23187 as well as with ABT-
737 confirming that these stimuli induced apoptotic events (Figure 2B). The active forms of 
caspase-3 and -7 were also detected in C+T stimulated platelets (Figure 2B). As described in 
nucleated cells, the data in Figure 1 and Figure 2A & B demonstrate that anucleated platelets 
also contain a complete intrinsic apoptosis-signaling pathway including Smac/Diablo and 
Omi/HtrA2 that can be released from mitochondrial IMS into the platelet cytosol, as well as 
the cytosolic anti-apoptotic XIAP.   
 
 - 94 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Platelets express the necessary components for a fully functional intrinsic apoptosis 
pathway. Western blot analysis of pro- and anti-apoptotic proteins of the intrinsic apoptosis pathway 
in washed platelets from 5 different donors. -actin was included as loading control (representative of 
3 experiments). Molecular weights are as indicated. 
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Figure 2.  Release of mitochondrial intermembrane space (IMS) proteins from mitochondria 
into the cytoplasm after induction of apoptosis in control platelets (A) as well as in Ucf-101 
treated platelets (C). Washed platelets (10
9
/mL in Tyrodes-Hepes buffer) were stimulated with 
collagen (10 µg/mL) and thrombin (1 U/mL) (C + T) for 5 min, or Ca
2+
 ionophore A23187 (3 µM) for 10 
min, or ABT-737 (3 µM) for 2 hr at 37°C. Release of mitochondrial IMS Omi/HtrA2, Smac/Diablo and 
cytochrome c was assessed by Western blot analysis of the supernatant (SN) containing soluble 
proteins that contain any proteins released from mitochondria and of the HM pellet containing heavy 
protein complexes and membranes including intact mitochondria and platelet cytoskeleton, isolated as 
described in Materials and Methods. Active caspase-3 and caspase-7 were analyzed in the HM (B 
and D). Representative Western blots of 3 different donors for C+T and A23187 and of 2 different 
donors for control and ABT-737. 
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Inhibition of the pro-apoptotic protease Omi/HtrA2 with Ucf-101 diminishes activation 
of caspase-3 and -9 
 
To investigate the role of Omi/HtrA2 during apoptotic signaling in platelets, we first 
characterized the impact of the Omi/HtrA2 inhibitor Ucf-101 on platelet function as 
determined by expression of platelet activation markers. Washed human platelets were 
incubated with increasing Ucf-101 concentrations (5 – 40 μM); up to a concentration of 40 
µM, Ucf-101 pretreatment alone did not induce surface expression of CD62P (Figure 3A) or 
CD63 (Figure 3B). As well, pretreatment of platelets with Ucf-101 up to 10 μM did not affect 
expression of CD62P and CD63 in C+T-stimulated platelets (Figure 3A & B). Ucf-101 started 
to significantly inhibit platelet activation by C+T at 30 µM in regard to CD62P expression and 
at 20 µM in regard to CD63 expression. Furthermore, platelet aggregation in citrated-PRP in 
response to 2 mM arachidonic acid, 5 or 10 µM ADP or 10 µg/mL collagen was not impaired 
by 10 µM Ucf-101 (data not shown). Therefore, in further experiments, 10 µM Ucf-101 was 
used to examine the effects of this inhibitor on platelet apoptosis. To investigate whether Ucf-
101 interferes with Omi/HtrA2-release from the mitochondrial IMS into the cytosol, washed 
human platelets were pretreated with Ucf-101 and stimulated with C+T or A23187 or with the 
apoptosis inducer ABT-737, and were analyzed for the release of mitochondrial IMS proteins 
into the cytosol. As in the absence of Ucf-101, pretreatment with 10 μM Ucf-10 induced a 
release of the IMS proteins Omi/HtrA2, Smac/Diablo and cytochrome c in A23187- and ABT-
737 stimulated platelets into the cytosol (Figure 2C). We also detected the activated forms of 
caspase-7 and caspase-3 in platelets pretreated with Ucf-101 stimulated with A23187 as well 
as with ABT-737 confirming that these stimuli induced apoptotic events not only in untreated 
but also Ucf-101 treated platelets (Figure 2D). These data confirm that any inhibitory effect of 
Ucf-101 does not occur at the level of Omi/HtrA2 release into the cytosol from the IMS.  
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Figure 3.  Effect of increasing Ucf-101 concentrations on platelet activation as determined by 
flow cytometry. Washed platelets (10
9
/mL in Tyrode-Hepes buffer) were treated with 5 - 40 μM Ucf-
101 for 2 hr at 37 °C and then stimulated with the combination of collagen (10 g/mL) and thrombin (1 
U/mL) (C + T) for 5 min at 37°C. The percentage of platelets expressing P-selectin, by APC-
conjugated CD62P (A) and of platelets expressing CD63, by PE-conjugated CD63 (B). Data are 
shown as mean ± SEM of at least 3 independent experiments (individual donors). Black squares: 
resting platelets treated with Ucf-101 alone; grey triangles: platelets pretreated with Ucf-101 and 
stimulated with C+T. * p < 0.05, ** p< 0.01 compared to C+T stimulated platelets pretreated with 
vehicle only (0 M Ucf-101).  
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 Next, washed human platelets were treated with C+T, the Ca2+ ionophore A23187 or 
the BH3 mimetic ABT-737 to induce apoptotic events in platelets: as determined by flow 
cytometry, C+T, A23187 and ABT-737 all induced statistically significant activation of 
caspase-3, caspase-8 and caspase-9 (p < 0.01 between ctrl and C+T and between ctrl and 
A23187; p > 0.05 between ctrl and ABT-737) (Figure 4 A-C). (Note that to determine whether 
only the intrinsic apoptotic pathway is activated or also the extrinsic, we investigated 
activation of caspase-8.) Furthermore, C+T, A23187 and ABT-737 induced formation of 
microparticles (Figure 4D), PS exposure (Figure 4E) and loss of the m (Figure 4F). 
However, after pre-treatment with 10 μM Ucf-101, the proportion of platelets with activated 
caspase-3 decreased significantly (C+T: 3.7 ± 0.9%; A23187: 7.3 ± 1.1%; ABT-737: 9.7 ± 
2%) (Figure 4A) compared to platelets not pretreated with Ucf-101 (C+T: 8.6 ± 1.2%; 
A23187: 19.8 ± 2.4%; ABT-737: 16.6 ± 2.5%) (p < 0.5 - 0.1). Ucf-101 pretreatment also 
decreased activation of caspase-9 (C+T: 2.5 ± 0.7%; A23187: 6.2 ± 1.9%; ABT-737: 11.8 ± 
3.5%) compared to platelets in the absence of Ucf-101 (C+T: 6.9 ± 2.8%; A23187: 16.6 ± 
4.7%; ABT-737: 17.9 ± 2.6%) (Figure 4B). In contrast, Ucf-101 pretreatment did not prevent 
caspase-8 activation or production of platelet-derived microparticles (Figure 4C & D). PS 
exposure was decreased in ABT-737 stimulated platelets pre-treated with Ucf-101 (77.2 ± 
4.0%) compared to control (89.0 ± 1.1%) (p < 0.05) and loss of m was decreased in Ucf-
101 pretreated platelets for C+T (MFI: 33.3 ± 5.1) compared to control (41.4 ± 4.0) as well as 
for A23187 (13.6 ± 3.5) compared to control (20.3 ± 7.4 ) (Figure 4E & F). Also, the inhibition 
of platelet activation by ABT-737 was not prevented by Ucf-101 (Figure 4G & H). Taken 
together, these data indicate that the Omi/HtrA2 inhibitor Ucf-101 inhibits activation of 
caspase-3 and caspase-9 in platelets.  
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Figure 4.  Decreased caspase-3 and caspase-9 activation in platelets treated with the Omi/HrA2 
inhibitor Ucf-101, as analyzed by flow cytometry. Washed platelets (10
9
/mL in Tyrode-Hepes 
buffer) were stimulated with 10 µg/ml collagen and 1 U/ml thrombin (C + T), 3 µM A23187 or 3 µM 
ABT-737 and compared to stimulated platelets that have been pretreated with 10 µM Ucf-101 for 2 hr 
at 37°C. The percentage of platelets with activated caspase-3 was determined by FAM-DEVD-FMK 
fluorescence (A), of platelets with caspase-9 by FAM-LEHD-FMK fluorescence (B) and of platelets 
with activated caspase-8 by FAM-LETD-FMK (C). The percentage of platelet-derived microparticles 
was determined as the proportion of CD42a-positive events <0.9 μm (D). The percentage of platelets 
exposing PS was determined by annexin A5 binding (E) and m by mean fluorescence intensity 
(MFI) of TMRE (F). P-selectin expression was assessed by APC-conjugated anti-CD62P antibody (G) 
and CD63 expression, by PE-conjugated anti-CD63 antibody (H). Black bars: platelets in the absence 
of Ucf-101; grey bars: platelets pretreated with Ucf-101. Data are shown as mean ± SEM of 5 
experiments (individual donors), except for ABT-737 where 4 experiments were performed and p < 
0.05 was considered as statistically significant. 
 
 
Inhibition of platelet XIAP increases caspase activity 
 
In nucleated cells, XIAP is an anti-apoptotic protein that inhibits active caspase-3 and 
caspase-9. The pro-apoptotic protein Omi/HtrA2 targets and inhibits XIAP. We continued our 
investigation examining caspase activation after the inhibition of XIAP by its inhibitor embelin 
that has previously been used in PC-3 prostate cancer cells or HL60 leukemic cells [31, 32, 
36]. The pro-apoptotic effect of embelin is only observed after a long time course as 
described in leukemic cells [32] . Platelets incubated with 20 µM embelin for 22 hr did not 
present platelet activation as surface expression of CD62P (Figure 5A) or CD63 (Figure 5B), 
also after 48 hr, CD62P and CD63 expression were not statistically significantly elevated. To 
conclude, 20 M embelin did not affect platelet activation. However, there was a tendency for 
increased CD63 expression after an incubation of 10 - 30 µM Ucf-101 for 48 hr and also for 
an increased CD62P expression even at 10 µM after 22 hr and after 48 hr. Incubation of 
platelets with 20 µM embelin led to an increase of activated caspase-3 and caspase-9 in up 
to 35% of platelets (Figure 6A & B). After incubation with embelin for 22 hr, the proportion of 
platelets with active caspase-3 was 4.1 ± 1.6% and of active caspase-9, 12.9 ± 7.2%, 
compared to a 2 hr embelin incubation with 0.3 ± 0.1% for active caspase-3 and 0.5 ± 0.2% 
for active caspase-9 that are similar to control levels at 22 hr (caspase-3: 0.7 ± 0.1%; 
caspase-9: 1.4 ± 0.8%). After a 48 hr incubation with embelin, values increased to 11.7 ± 2.9 
% for active caspase-3 and to 19 ± 18.4% for active caspase-9 compared to control at 48 hr, 
in the absence of embelin (caspase-3: 1.0± 0.3%; caspase-9: 1.4 ± 0.4%). Caspase-8 levels 
were less increased (3.0 ± 2.4% after 22 hr and 9.9 ± 5.5% after 48 hr) (Figure 6C) 
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compared to caspase-3 and -9. Furthermore, a significant increase in the proportion of 
platelet-derived microparticles (Figure 6D) was observed. After an embelin incubation of 22 
hr, microparticles increased to 10.4 ± 1.4% compared to control (6.2 ± 0.7%) and after 48 hr, 
values increased to 18.2 ± 1.7% compared to control (7.5 ± 0.8%). Platelets also presented 
significantly enhanced PS exposure with embelin incubation: 54.6 ± 10.4% after 22 hr 
compared to control 2.9 ± 0.8%, and 79 ± 18.2% after 48 hr compared to control 5.7 ± 18.2% 
(Figure 6E). Furthermore, treatment of platelets with embelin led to a loss of m (Figure 
6F), as reported by Hu et al. in leukemic cells [32]. After 22 hr platelets incubated with 
embelin presented a significantly decreased m of 17.3 ± 2.0 compared to untreated 
platelets (51.4 ± 0.3) and after 48 hr of 15.8 ± 2.5 compared to untreated platelets (42.5 ± 
0.2). The activation markers CD62P (Figure 6G) and CD63 (Figure 6H) were not significantly 
altered.  
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Figure 5.  Effect of increasing embelin concentrations on platelet activation, as determined by 
flow cytometry. Washed platelets (10
9
/mL in RPMI medium) were treated with embelin (5 – 30 μM) 
for 2, 22 and 48 hr at 37 °C under cell culture conditions. The percentage of platelets expressing P-
selectin, by APC-conjugated CD62P (A), and of platelets expressing CD63, by PE-conjugated CD63 
(B). Data are shown as mean ± SEM of at least 3 independent experiments (individual donors). Black 
diamonds: platelets treated with embelin for 2 hr; open triangles: platelets treated with embelin for 22 
hr and grey squares: platelets treated with embelin for 48 hr.  
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Figure 6.  Increased caspase-3 and caspase-9 activation in platelets treated with the XIAP 
inhibitor embelin, as analyzed by flow cytometry. Washed platelets (10
9
/mL in RPMI medium) 
were incubated with 20 µM embelin for 2, 22 or 48 hr at 37°C under cell culture conditions. The 
percentage of platelets with activated caspase-3 was determined by FAM-DEVD-FMK fluorescence 
(A), of platelets with caspase-9 by FAM-LEHD-FMK fluorescence (B) and of platelets with activated 
caspase-8 by FAM-LETD-FMK (C). The percentage of platelet-derived microparticles was determined 
as the proportion of CD42a-positive events <0.9 μm (D). The percentage of platelets exposing PS was 
determined by annexin A5 binding (E) and the m by mean fluorescence intensity (MFI) of TMRE 
(F). P-selectin expression was assessed by APC-conjugated anti-CD62P antibody (G) and CD63 
expression, by PE-conjugated anti-CD63 antibody (H). Black bars: platelets in the absence of embelin; 
grey bars: platelets treated with embelin. Data are shown as mean ± SEM of 3 experiments (individual 
donors), and p < 0.05 was considered as statistically significant. 
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Discussion 
 
In the present study, we identified the pro-apoptotic protease Omi/HtrA2 and its 
target, the X-linked inhibitor of apoptosis (XIAP) as important components and regulators of 
apoptotic signaling pathways in platelets. Initially, we showed that the pro-apoptotic protease 
Omi/HtrA2 and the mitochondrial protein Smac/Diablo, as well as XIAP are expressed in 
platelets (Figure 1 & 2). Both Omi/HtrA2 and Smac/Diablo are released from mitochondria 
into the cytosol in parallel with cytochrome c after induction of apoptosis by disruption of 
platelet calcium homeostasis (with A23187 or ABT-737), leading to caspase-3 and -7 
activation. By specifically inhibiting the pro-apoptotic protein Omi/HtrA2, the proportion of 
platelets showing active caspase-3/7 and -9 was diminished; however the proportion of 
platelets showing caspase-8 activation was not statistically decreased. This result supports 
our initial finding that platelets express inhibitor of apoptosis proteins such as XIAP that 
inhibits caspases-3/7 and -9. Additionally, direct inhibition of XIAP led to activation of 
caspase-3/7 also without disruption of calcium homeostasis by A23187 or targeting Bcl-XL 
and Bcl-2 by ABT-737. Of note is the fact that the physiological stimuli C+T did not induce 
release of Omi/HtrA2, Smac/Diablo and cytochrome c from mitochondria or only at the 
detection limit of Western blotting, thus caspase activation was only slightly increased.  
Our findings support a number of previous reports: The expression of Apaf-1 and 
Smac/Diablo have previously been shown by Wolf et al. and Plenchette et al., respectively, in 
platelets [24, 35], and cytochrome c release and activation of caspase-9 and -3/7 after 
inhibition of Bcl-2 and Bcl-XL in platelets are well established to occur [22, 23, 25]. These 
platelet apoptotic events, especially caspase activation, appears to also play a role in 
settings of disease such as thrombocytopenia [28, 37], Omi/HtrA2 not only has XIAP as its 
substrate. Omi/HtrA2 was shown to degrade several proteins, preferentially cytoskeleton 
components [38]. This finding might explain the caspase independent effects of ABT-737 that 
were reported [23].  
However, all stimuli that were used induced PS exposure and microparticle 
generation. On the basis of these results, we speculate that in resting platelets and in 
physiologically activated platelets, caspase activation is maintained at low levels by XIAP. 
Only if the mitochondrial integrity is disrupted, e.g. by ABT-737, A23187 or very likely by 
radical oxygen species as shown by Lopez et al. [22], cytochrome c, Omi/HtrA2 and 
Smac/Diablo are released from the mitochondrial IMS, leading to the formation of the 
apoptosome by Apaf-1, dATP and cytochrome c; and also to the degradation of XIAP by 
Omi/HtrA2 and Smac/Diablo, all culminating in the activation of caspase-9 and caspase-3/7. 
Activation of effector caspases leads to cleavage of target proteins such as PARP, gelsolin 
or -fodrin [23, 25] including transmembrane proteins [39], therefore we can not exclude that 
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platelet glycoproteins are also targets for caspase-3/7 which might eventually explain the 
decrease in platelet activation after thrombin stimulation. However another likely cause for 
this observation might be the opsonization of the platelets by autoantibodies. Unfortunately 
so far we were not able study whether human anti human-platelet proteins lead to decreased 
platelet activability or even increased caspase activity. 
We confirm that ABT-737 and the Ca2+ ionophore A23187, but less the combination 
of thrombin and collagen, can trigger platelet apoptosis [26, 40] leading to a depolarization of 
the mitochondrial transmembrane potential, phosphatidylserine exposure and activation of 
caspase-9, 3, -7, and -8 (Figure 4). We further show that Omi/HtrA2, Smac/Diablo and 
cytochrome c are released from mitochondria upon induction of apoptosis (Figure 2A) as 
previously indicated for cytochrome c [23], all in analogy to cytoplasmic apoptosis-events in 
nucleated cells [1]. Cilenti et al. showed that Ucf-101 functions as an Omi/HtrA2 inhibitor in 
mouse fibroblasts [13]. We demonstrate now that Ucf-101 inhibits apoptosis by reducing the 
activation of caspase-3 and caspase-9 but not of caspase-8 (Figure 4) suggesting that Ucf-
101 binds the pro-apoptotic protein serine protease Omi/HtrA2. We then show that 
Omi/HtrA2 is released from the mitochondria in apoptotic platelets pre-treated with Ucf-101 
(Figure 2C). This result indicates that the interaction of Omi/HtrA2 with Ucf-101 occurs in the 
cytosol and is a downstream effect of the MOMP. This finding is also confirmed by the fact 
that Ucf-101 does not abolish loss of the mitochondrial inner transmembrane potential in 
apoptotic platelets. It further confirms that Omi/HtrA2 is acting upstream of caspase-9 and 
caspase-3 and downstream of caspase-8. PS exposure however, has been reported to be a 
downstream manifestation of the intrinsic apoptotic pathway [41] but was not abolished by 
Ucf-101 in our study (Figure 4E). The proportion of platelet-derived microparticles was not 
decreased by Ucf-101 either in apoptotic platelets (Figure 4D). These data strongly suggest 
that in apoptotic platelets, Ucf-101 binds to Omi/HtrA2 neutralizing its inhibitory function 
towards XIAP. Consequently, XIAP is free to bind to active caspase-3 and active caspase-9 
thus preventing apoptosis. Induction of other apoptotic markers as caspase-8 activation, PS 
exposure and formation of microparticles do not or not exclusively involve the intrinsic 
pathway via Omi/HtrA2. Also, we observed a stronger decrease of activated caspase-3 than 
of activated caspase-9 since caspase-3 is acting at the very end of the apoptotic signaling 
cascade amplifying apoptotic events. Taken together, these findings demonstrate that Ucf-
101 inhibits apoptosis in platelets and prove that platelets have a functional intrinsic apoptotic 
signaling pathway. 
 
With the present study we demonstrate that platelets contain and release Omi/HtrA2 
and Smac/Diablo from the IMS upon apoptotic stimuli. Importantly we were able to show that 
in platelets, as previously well studied in nucleated cells, Omi/HtrA2 inhibits the caspase 
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antagonist XIAP. This new insight in platelet physiology might be of importance for the 
understanding of the pathophysiology of ITP, as we have shown previously activated 
caspases in this disease [28] but also for the development of new anti-cancer agents that 
target anti-apoptotic proteins such as Smac mimetics or BH3 mimetics as ABT-737 and ABT-
263 [23, 42]. 
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Apoptotic proteins in platelets and their interaction  
 
In this study we demonstrated that platelets contain Omi/HtrA2 and XIAP, two 
proteins of the intrinsic apoptotic signaling pathway. To identify also other proteins involved 
in the intrinsic as well as extrinsic apoptotic-signaling pathway in platelets, we systemically 
investigated pro- and anti-apoptotic by Western blot and immunoprecipitation. To analyze 
apoptotic proteins in human platelets, we first determined the relative levels of apoptosis-
related proteins in platelets on a Human Apoptosis Array (Figure 1A). Analysis of dot blots 
showed strong presence of procaspase-3, clusterin, cytochrome c and Smac/Diablo in 
human platelets, as well as an average presence of Bad, Bax, Bcl-2, Bcl-X, HiF1, Hsp27, 
Hsp60, Hsp70, Omi/HtrA2 and an indication for cIAP1, Fas and XIAP (Figure 1B). We did not 
detect a positive signal for TRAIL, TNFR1, livin nor survivin. Based on these results we 
analyzed the expression of the previously mentioned apoptotic proteins as well as additional 
ones in human PRP (Figure 2) as well as in washed platelets (Figure 3) by Western blot. We 
found that human platelets express the death domain FADD and the BH3 interacting domain 
Bid (Figure 3A). FADD is a mediator of the extrinsic apoptotic-signaling pathway that 
transmits apoptotic signals from death receptors such as TRAIL-R1 (TNF-related apoptosis-
inducing ligand receptor) or CD95 (Fas receptor) to procaspase-8 recruiting caspase-8 [1]. 
Bid is processed to a truncated form by active caspase-8 and localizes to the mitochondria 
thus connecting the extrinsic to the intrinsic pathway. Death receptors as well as their death 
ligands were not detected on the protein level apart from the decoy receptor DcR2 [2] and 
FADD has not been analyzed. We were unable to detect the death receptors DR3, DR5 and 
TNFR1 as well as the Fas ligand in human platelets. We confirmed also the presence of Bcl-
X, Bax and Bad that are well characterized in platelets and identified the inhibitor of 
apoptosis, cIAP-1 (Figure 2A & C). Furthermore, we found that platelets contain the heat 
shock proteins Hsp27, Hsp60 and Hsp70 (Figure 2B) as well as PON2 and clusterin (Figure 
2C). PON2 is an anti oxidative protein that in nucleated cells was shown to have a protective 
thus anti-apoptotic effect in endoplasmic reticulum (ER) stress-induced apoptosis but only 
when the Ca2+ homeostasis is maintained [3]. The anti-apoptotic effect of the heat shock 
proteins Hsp27, Hsp60 and Hsp70 were studied in human cell lines. Hsp27 was shown to 
inhibit cytochrome c mediated activation of caspases by binding to released cytochrome c 
which prevents formation of the apoptosome [4]. In another study, Hsp27 decreased 
apoptosis by inhibiting Bax oligomerization and translocation [5]. Also Hsp60 was considered 
to have a similar anti-apoptotic role by preventing Bax from oligomerization [6]. Another study 
demonstrated that mitochondrial procaspase-3 is present in a complex of the chaperones 
Hsp60 and Hsp10 while induction of apoptosis dissociated procaspase-3 from both heat 
shock proteins [7]. Hsp70 on the other hand was shown to interact with the recruitment 
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domain (CARD) of Apaf-1 [8] [9]. This interaction inhibits the apoptosome formation and 
activation of procaspase-9 [8] [9]. Another protein considered to be involved in apoptosis is 
clusterin [10]. Clusterin exists as a secreted form that may be pro-apoptotic [10] and as a 
nuclear form that has an anti-apoptotic role by interfering with Bax [11]. Additionally, to depict 
all pro- and anti-apoptotic proteins that we have so far found in platelets, included in Figure 
2A & 3A are those apoptotic proteins that we already mentioned previously (Chapter 4, 
Figure 2): Omi/HtrA2, Smac/Diablo, cytochrome c, Apaf-1, caspase-3, caspase-7 and XIAP. 
Analysis of a Human Apoptosis Array containing control PRP and aged PRP 
indicated that aged platelets have a higher expression of Bad, cleaved caspase-3 as well as 
less FADD, Bcl-X, Hsp27 and cIAP (Figure 1B). In contrast to resting platelets, aged platelets 
expressed the death receptor TRAIL R1/DR4 (Figure 1B). 
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Figure 1.  Platelets contain apoptotic proteins of the intrinsic and extrinsic signaling pathway. 
Platelets isolated from fresh (A) and aged PRP were analyzed on a Human Apoptosis Antibody Array 
for the presence of apoptotic proteins. Aged platelets were from the same donor as resting platelets 
and were stored for 7 days in capped tubes at RT. The integrated densities of the dot blot assays were 
calculated according to Dot blot analysis (ImageJ) and were adjusted to the positive control 
(representing 100%) (B). Representative data of two different donors. 
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Figure 2.  Platelets express the necessary components for a functional intrinsic apoptosis 
pathway. Western blot analysis of PRP using antibodies as indicated and described in materials and 
methods. Lysates from K562 or HEL cells were used as a positive control and lysates from K562 cells 
treated with Glivec as a control for apoptosis. Apoptotic platelet proteins of the extrinsic and intrinsic 
signaling pathway (A). Heat shock proteins in platelets (B). Further apoptosis-related proteins (C). A 
representative -actin was included as loading control.  
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 To elucidate whether in activated platelets an increased or decreased expression of 
apoptotic proteins is observed we investigated their expression in platelets stimulated with 
C+T as well as with A23187 by Western blot (Figure 3). To have a control for apoptosis, 
K562 cells were treated with the cancer drug Glivec that induces cell death. Glivec-treated 
K562 cells presented less protein expression of Bid, Bcl-X, procaspase-3, XIAP and Hsp27. 
In most stimulated platelets we were not able to confirm any differences in the expression of 
apoptotic proteins apart from Bcl-X, caspase-9, caspase-7 and Hsp27. The cleaved fragment 
of caspase-9 was detected in platelets stimulated with C+T as well as with A23187 and the 
level of procaspase-7 decreased after stimulation of platelets with A23187. Bcl-XL was not 
present in platelets stimulated with A23187 consistent with the fact that Bcl-XL is degraded 
during platelet apoptosis [12]. For washed platelets, we detected two Bcl-X bands; the 30kDa 
band corresponding to Bcl-XL and a smaller band probably corresponding to the 15kDa pro-
apoptotic Bcl-XS. Also in PRP, we were able to detect the smaller fragment of Bcl-X. In 
A23187-stimulated platelets, not only the anti-apoptotic Bcl-XL was decreased but also the 
pro-apoptotic fragment Bcl-XS. In A23187-stimulated platelets, we observed a decreased 
protein expression of FADD (3 independent experiments), as well as of Bax (2 independent 
experiments) (Figure 3A). Also Glivec-treated K562 cells had less FADD protein (Figure 3A). 
Interestingly, ABT-737-stimulated platelets showed also less FADD but more than A23187-
stimulated platelets (Figure 3C). In nucleated cells, it has not been reported that neither 
FADD nor Bax are degraded during apoptosis. In activated platelets Hsp27 is no longer 
present similarly to apoptosis-induced K562 cells (Figure 3B). However, in washed platelets 
we detected a smaller fragment (15kDa) of Hsp27 than the expected 27kDa. A23187-
stimulated platelets presented decreased expression of Hsp27 (4 independent experiments) 
compared to ABT-737 (two independent experiments). To compare platelet apoptosis with 
platelet aging, Western blot analysis was also performed of aged platelets. We detected less 
Hsp27 (27kDa) and less FADD (Figure 3C) as well as less Bcl-X and the active form of 
caspase-3 (data not shown) in aged platelets. However, aged platelets analyzed by Human 
Apoptosis Array presented less FADD than freshly isolated platelets (Figure 1B).  
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Figure 3.  Activated platelets only show minimal changes in the expression of apoptotic 
proteins. Western blot analysis of washed platelets using antibodies as indicated and described in 
materials and methods. Washed platelets (10
9
/mL in Tyrodes-Hepes buffer) were either stimulated 
with collagen (10 g/mL) and thrombin (1 U/mL) for 5 min, Ca
2+
 ionophore A23187 for 10 min (3 M), 
or ABT-737 (3 M) for 2 hr. For aging platelets, PRP was left in capped tubes for 7 days at RT. 
Lysates from K562 or HELA cells were used as a positive control and lysates from K562 cells treated 
with Glivec as a control for apoptosis. Expression of apoptotic proteins in platelets stimulated with C+T 
as well as A23187 or ABT-737 (A-C). A representative -actin was included as loading control.  
 
 
To get a better understanding of the apoptotic signaling pathway in platelets, as well 
as the interaction of apoptotic proteins, we performed immunoprecipitations of several 
apoptotic proteins in human platelets. Apaf-1 co-immunoprecipitated with cytochrome c as 
well as with the anti-apoptotic protein Bcl-X (Figure 4A). Moreover, Bcl-X interacted with the 
two pro-apoptotic proteins Bax and Bad (Figure 4B). We also precipitated caspase-3 but 
were not able to detect any binding partners such as XIAP or cIAP-1 (Figure 4C). To 
compare the interactions of apoptotic proteins in resting platelets with those of activated 
platelets, we performed immunoprecipitations of platelets stimulated with C+T as well as with 
A23187. IPs of Bcl-X showed less Bcl-X protein in C+T-stimulated platelets and no Bcl-X 
protein in A23187-stimulated platelets consistent the protein amounts of the inputs and with 
the fact that Bcl-X is degraded during apoptosis [12] (Figure 4D). In nucleated cells, 
immunoprecipitation verified an association of Bad with Bcl-XL [13]. Furthermore, Apaf-1 co-
immunoprecipitated with Bcl-XL and caspase-9 [14] and XIAP associated with the cleaved 
fragment of caspase-3 as well as caspase-7 [15]. The inhibitory effect of Omi/HtrA2 towards 
XIAP was shown by a direct association of Omi/HtrA2 with XIAP [16]. Moreover, an 
interaction of Apaf-1 with Hsp70 was demonstrated by IP [9]. 
 
 To conclude, platelets express all necessary apoptotic proteins of the intrinsic 
apoptotic pathway to have a functional apoptotic-signaling. Besides, there is indication of an 
extrinsic apoptotic signaling pathway shown by the presence of FADD. Co-
immunoprecipitation of Bcl-X with Bax and Bad in resting platelets verifies that Bcl-X inhibits 
the pro-apoptotic factors Bax and Bad when there is no onset of apoptosis. Furthermore, 
platelets contain the heat shock proteins Hsp27, Hsp60 and Hsp70 that in nucleated cells 
have been shown to interact with apoptotic proteins.  
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Figure 4.  In platelets, Apaf-1 interacts with cytochrome c and caspase-9; Bcl-X complexes with 
Bad and Bax. Immunoprecipitations of apoptotic proteins in platelet concentrates were performed 
according to the IP protocol followed by their detection by Western blot. IP of Apaf-1 probed for 
associated proteins (A). IP of Bcl-X probed for associated proteins (B). IP of caspase-3 (C). IP of Bcl-
X in platelets stimulated with C+T as well as with A23187 compared to the corresponding inputs (D). 
As a control, the relevant non-specific mouse, goat or rabbit immunogobulins G or A (IgG, IgA) were 
used. 
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Materials and methods 
 
Materials 
ABT-737 was from Active Biochemicals (Maplewood, USA). Glivec was provided by 
Dr Jeroen Goede, University hospital Zürich. 
For Western blot, in addition to the antibodies described in the beginning of Chapter 
4, anti-human Bax rabbit pAb from Cell Signaling Technology (Boston, MA, USA); anti-
human Bcl-X rabbit pAb, anti-human Bid rabbit pAb, anti-human Bad rabbit pAb, anti-human 
FADD goat pAb, anti human Hsp27 rabbit pAb, anti-human Hsp60 mouse pAb, anti-human 
Hsp70 mouse mAb (clone 242707), anti-human cIAP1 goat pAb, anti-human PON2 goat pAb 
from R&D Systems (Minneapolis, MN USA) were used. For immunoprecipitations, anti-
human caspase-3 goat pAb (clone CPP32), anti-human Bcl-X rabbit pAb and anti-human 
Apaf-1 mouse mAb (clone 94408) from R&D Systems (Minneapolis, MN USA) were used. 
 
Human Apoptosis Array  
 To simultaneously detect the relative expression of 35 apoptosis-related proteins in a 
single sample, a Human Apoptosis Antibody Proteome Profiler™ Array (R&D Systems, 
Minneapolis, MN USA) was used according to its manual. The array contained capture 
antibodies spotted in duplicates on a nitrocellulose membrane. As a lysed cellular extract we 
used platelets from freshly isolated PRP and from 7 days aged PRP (stored at RT) of the 
same donor. Diluted cellular extracts were incubated over night on the Human Apoptosis 
Array. The array was washed to remove unbound proteins, followed by incubation with a 
cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent 
detection reagents were applied and a signal was produced at each capture spot 
corresponding to the amount of protein bound. Dot blots were scanned with a brother MFC-
8880DN printer using a resolution of 600 dpi. To analyze, we determined the pixel density of 
each spot (ImageJ, Dot blot analysis). 
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Immunoprecipitation (IP) 
Preparation of platelet lysates: 15 mL PRP from platelet concentrates were 
supplemented with 5 mM EDTA and centrifuged for 20 min at 500g without breaking. The 
pellet was snap frozen in liquid nitrogen. For lysis, the pellet was thawed on ice and 3 
volumes of polysome lysis buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.5% 
Igepal, 20 mg/mL Heparin, protease inhibitors) were added. The extract was pipetted several 
times and centrifuged at 14’000g for 10 min at 4°C. The supernatant was removed, 
transferred to a new tube and centrifuged again twice to remove the lipid layer on top of the 
supernatant. Protein concentration was determined by Bradford and 20 mg protein cell 
extract aliquots were prepared. 
Preparation of antibody coating bead mix: For each IP 50 l of drained protein G 
(for mAbs) or A (for pAbs) Sepharose beads (GE Healthcare, Glattbrugg, Switzerland) were 
used. The ethanol was removed by centrifuging at 10’000 rpm for 3 min at 4°C. Beads were 
washed once in 8 volumes of NT2 buffer (50 mM Tris HCl pH 7.5, 300 mM NaCl, 5mM 
MgCl2, 0.05% Igepal, protease inhibitors) and twice with NT2-Ab buffer (NT2 buffer 
supplemented with 50mg/ml BSA, 20 mg/mL Heparin). Beads were resuspended in 8 
volumes of NT2-Ab. 20 g of the immunoprecipitating antibody was added and incubated 
over night on a rotating device at 4°C. 
Immunoprecipitation: The beads were washed 4 times with 1 mL NT2 buffer per 
assay by centrifuging at 10000 rpm for 3 min at 4°C and kept on ice. The lysate was thawed 
on ice for 10 min and centrifuged at 14’000g for 10 min at 4°C. The antibody-coated beads 
were resuspended in 10 mL NT2-RIP buffer (NT2 buffer supplemented with 2mM DTT, 1 g/L 
sodium azide and 20 mg/mL Heparin) - the volume of resuspended beads in NT2 buffer 
corresponds to 10 times the volume of the lysate – and the pellet lysate was added. The IP 
reaction was tumbled on a rotation device for 6 hr at 4°C. After incubation beads were 
centrifuged at 2000 rpm for 2 min at 4°C. 1 mL ice-cold NT2 buffer was added and the 
washing step was repeated 3 times. The washed beads were resuspended in 500 l SDS-
EDTA solution (50 mM Tris HCl pH 8, 10 mM EDTA, 1% SDS, 100 mM NaCl) and incubated 
at 65°C, 900 rpm, for 10 min. The beads were centrifuged at 10’000 rpm for 3 min at RT and 
the supernatant was saved for Western blot analysis. 
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Summary 
 
To evaluate the role of cytokines in pediatric immune thrombocytopenia, we investigated 
plasma of 10 pediatric patients with acute immune thrombocytopenia (ITP), before and after 
IVIg treatment. Healthy children with platelet counts in the normal range were enrolled as 
controls and children with a non-immune thrombocytopenia as a control for the low platelet 
count. All ITP patients presented with platelet counts < 25 x 109/L and bleeding symptoms. 
Plasma concentrations of 42 cytokines/chemokines were analyzed by Luminex technology 
measurements of all four groups. ITP patients had significantly increased levels of the Th1 
cell commitment cytokines TNF-, IFN- and IL-2 as well as of the Th2 cytokines IL-6, IL-10 
and IL-13 that are involved in the B cell differentiation. After IVIg treatment, platelet counts 
increased to > 20 x 109/L in all patients; the observed elevated plasma cytokine levels 
decreased after therapy but the differences were not statistically significant. In conclusion, in 
acute pediatric ITP, increased plasma cytokine levels are observed that are modulated by 
IVIg.  
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Introduction 
 
Primary immune thrombocytopenia (ITP) is an autoimmune disease, mainly caused 
by autoantibodies against platelet surface receptors leading to an enhanced clearance of 
platelets. ITP patients are treated with intravenous immunoglobulins (IVIg) or other 
medications such as corticosteroids, anti-D antibodies or CD20 antibodies that ameliorate 
thrombocytopenia after 24-48 h of administration. Apart from auto reactive B cells [1] also 
CD4+ T-helper (Th) cells as well as their cytokines have been associated with ITP, especially 
with chronic ITP [2] [3]. Th cells are essential players in immune responses and inflammatory 
diseases that after stimulation by antigen presenting cells differentiate into distinct lineages 
as Th1, Th2 or Th17 cells. Cytokines and chemokines function as cell signaling molecules in 
inflammation, immunity as well as in the hemostatic balance and are produced by different 
cell types such as T cells, macrophages or monocytes. In ITP, increased plasma levels of IL-
2, IFN- and/or IL-10 were reported to be associated with chronic ITP [4] [5]. In contrast, 
Semple et al. did not detect increased plasma concentrations of IL-2, IFN-y and IL-10 in 
acute ITP patients [4] and other groups mainly analyzed cytokines in chronic ITP patients. A 
recent study showed that chronic ITP patients have reduced serum expression levels of the 
transforming growth factor -1 (TGF-1) [6]. Additionally, higher IL-17 and IFN- plasma 
levels were found and a positive correlation of IL-17 with IFN- [6]. Th17 cells have been 
found to be more potent than Th1 cells in inducing autoimmune diseases [7]. TGF-1 
induces IL-17 helper cells, and is considered to be an inhibitor of B cell proliferation and 
autoantibody production as well as of megakaryocytes maturation [8]. It was suggested that 
increased plasma concentrations of IL-17 and  IFN- may be responsible for a dysregulation 
of cellular immunity in chronic ITP [6]. Furthermore, the negative correlation of TGF-1 with 
platelet counts indicated that TGF-1 might be one of the factors observed in chronic ITP [6]. 
Also in another study increased plasma cytokine levels of IL-17 were determined in chronic 
ITP [9]. Besides, increased levels of IL-1, IL-6 and IL-23, cytokines involved in Th17 cell 
activation and maintenance, were detected [9]. Furthermore, chronic ITP patients presented 
with elevated plasma cytokine levels of IFN-, IL-2, TNF-, IL-12p-70 and IL-10 but no with 
TGF- nor IL-4 [9]. Additionally, acute ITP patients as well as thrombocytopenic patients in 
general presented increased granulocyte-macrophage colony-stimulating factor (GM-CSF) 
plasma levels but not elevated IL-3 and IL-6 [10]. GM-CSF, as IL-3, is involved in the 
formation of megakaryocyte colonies while IL-6 is a late factor in megakaryocytes 
differentiation [11]. The B cell activating factor (BAFF) belongs to the TNF ligand family and 
is crucial for the maintenance of B cell development [12]. In a study of chronic ITP, higher 
levels of BAFF were measured in patients suffering from a chronic active ITP [13] [14] . 
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However, in ITP, the data on polarization of the immune system towards Th1, Th2 or 
Th17 cells are contradictory and results are not consistent. In an earlier study of chronic ITP 
patients, no difference in the levels of IL-17, TGF-, IL-6 nor IFN- were found compared to 
controls [15] while others reported only an involvement of the Th1 cell commitment and not of 
the Th2 commitment [5]. To extend these previous observations in acute ITP patients, we 
characterized the cytokine panel in ITP patients and studied whether increased cytokine 
levels occur in plasma of pediatric patients with primary ITP, whether their plasma levels 
change by treatment with IVIg. In this study we demonstrated that acute ITP patients at 
diagnosis have increased plasma levels of Th1 cytokines IFN-, TNF- and IL-2 as well as of 
the Th2 cytokines IL-6, IL-10 and IL-13. In conclusion, we confirmed that in ITP patients 
macrophages as well as B and T cells are activated.  
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Materials and methods  
 
Patients 
In this prospective study, approved by the local ethics committee, 10 children (4 
females and 6 males) with newly diagnosed ITP were investigated after obtaining written 
informed parental consent (Table 1 and 2). Patients were recruited in the Children’s Hospital 
Zurich within four years and followed during one year. All patients fulfilled the criteria for 
primary ITP [16]. The median age at diagnosis was 3.4 years (range: 1.6 – 6.5 years). 3 
patients had signs of a respiratory tract infection without fever at the date of diagnosis, one of 
them presented with urtikaria. One further patient was still under antibiotic treatment because 
of streptococcal angina. In 2 patients, ITP was preceded by 2–4 weeks by a viral 
gastroenteritis. In 4 patients, there was no history of infection. All patients had a very low 
platelet count median 3 x 109/L (range <1 to 22 x 109 /L) at diagnosis. The severity of 
bleeding symptoms at diagnosis was graded with a standardized bleeding score according to 
Buchanan and Adix [17] and Bolton-Maggs and Moon [18], which was modestly adapted. 
Bleeding scores were 2 to 3 with most patients showing large hematoma and multiple 
petechiae. Three patients presented with mucosal bleeding, one of them with severe 
epistaxis and hematemesis, in a second patient a tongue lesion was bleeding persistently 
and a third patient had bloody stools. 10 patients were treated with IVIg at a dose of 0.8 g/kg 
body weight and one patient received a second dose of IVIg. 
 9 healthy control children, 4 females and 5 males, median age of 15.9 years (range: 
0.8 – 18.1 years), with no history of autoimmune disease, coagulopathy, transfusion of blood 
products, or of ongoing medication, were recruited from the outpatient clinic after obtaining 
written informed parental consent. To control effects due to the thrombocytopenia itself, in 
addition, 9 children, 7 females and 2 males, median age 10.3 years (range: 4.2 – 15.3 years), 
1 patient with a thrombocytopenia due to aplastic anemia and 8 with a chemotherapy-related 
thrombocytopenia (cTP), were recruited after obtaining written informed parental consent. 
Their median platelet count was 12 x 109/L (range: 3 – 53 x 109L). 
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Table 1. 
Clinical and laboratory characteristics of children with primary ITP: bleeding scores and platelet count 
results before and after IVIg treatment are presented for each individual patient as well as platelet 
count at diagnosis and after treatment, infection prior or at time of diagnosis as well as patient’s 
history. Patients who recovered from ITP are defined as in remission; patients who had a low platelet 
count after 3 months were defined as persistent ITP and who suffered from ITP for longer than 6-12 
months as chronic ITP. 
 
 
 
 
 
 
 Table 2.  
Plasma cytokine levels of IL-6, IL-10, IL13, TNF-, IFN-, IL-1ra, GM-CSF and MIP-1 as well as 
proportions of platelets with activated caspase-3 (aCASP3), caspase-8 (aCASP8) and caspase-9 
(aCASP9) in pediatric ITP patients at diagnosis.   
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Blood sampling and routine testing  
 Venous blood samples for flow cytometric analyses were taken from ITP patients at 
the time of diagnosis prior to treatment and 12 to 24 hr after the last treatment with IVIg (prior 
to discharge from the hospital). Blood samples were taken from healthy controls when 
inserting a venous line and from children with cTP prior to transfusion of a platelet 
concentrate. Samples were collected into citrate anticoagulant (final concentration, 10.5 
mM). The total volumes of the blood samples taken did not exceed 1% of the total blood 
volume of the patients or the controls. Blood indices including platelet counts were measured 
using an automated blood counter, Sysmex XE-2100 (Sysmex Digitana, Horgen, 
Switzerland). Plasma samples were immediately frozen at -80°C. 
 
Luminex analysis 
Detection of 42 human cytokines/chemokines was done by Luminex® xMAP® 
Technology using MILLIPLEX® MAG multiplex immunoassays (Millipore, Rotkreuz, 
Switzerland). Preparation of plasma samples and measurements were performed according 
to the manual of Millipore. In short, plasma samples were assayed in duplicates and 
incubated in a 96-well solid plate with premixed magnetic beads, covalently coupled to a 
specific capture antibody, for 2 hr at RT. The plate was washed twice using a hand-held 
magnet. After incubation, biotinylated detection antibodies cocktail was added and reactions 
were incubated with shaking for 1 hr at RT. Subsequently, streptavidin-phycoerythrin solution 
was added and the reaction was incubated with shaking for 30 min at RT. The plate was 
washed twice and samples were resuspended in 150 μL sheath fluid. The fluorescent signal 
of the beads was read by a Bio-Plex 200 System with Bioplex Manager Software version 5.0. 
(Biorad, Reinach, Switzerland). The median fluorescent intensity data was analyzed using a 
5-parameter logistic curve-fitting method and the cytokine/chemokine concentrations of the 
samples were calculated (in picogram per milliliter, pg/mL). Final analysis of the raw data 
was done by Milliplex Analyst Software (Millipore, Rotkreuz, Switzerland). The 42 
cytokines/chemokines included in the multiplex immunoassay were: EGF, Eotaxin, FGF-2, 
Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, 
MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-
α, TNF-α, TNF-β, VEGF, sCD40L, sIL-2Ra. Whisker blots of statistically significant cytokines 
of the Th1 cell commitment, Th2 cell commitment and of chemokines were generated. 
 
Measurement of BAFF plasma levels 
 BAFF levels were measured using specific enzyme-linked immune assay (ELISA) 
according to the manufacturer’s recommendations (Hoelzel Diagnostica, Köln, Deutschland). 
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Serum BAFF levels were calculated from a standard curve generated from recombinant 
human BAFF.  
 
Statistical analyses  
Statistical analysis between the 4 groups (ITP, ITP after IVIg, healthy controls, cTP) 
was done using Kruskal-Wallis one-way ANOVA, followed by Wilcoxon signed-rank test 
between pairs of medians. Correlation was assessed by the Spearman correlation 
coefficient. Medians were considered statistically significantly different for p<0.05. Analysis 
was done using SPSS (SPSS, Zurich, Switzerland). 
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Results 
 
We recently found that ITP patients at diagnosis have increased proportions of 
platelets with activated caspase-3, -8 and -9 [19]. In this study we analyzed plasma cytokine 
levels in a subgroup of the previously included ITP patients. 
To investigate the role of cytokines in children with acute ITP, we evaluated the 
plasma concentration of 42 cytokines in ITP patients at diagnosis and after IVIg compared to 
healthy controls and children with a non-immune thrombocytopenia (cTP). At diagnosis ITP 
patients had a platelet count of 3 x 109/L. All patients showed a rise in platelet count above 
20 x 109/L in the next 24 to 48 hr after IVIg treatment, accompanied by declining bleeding 
symptoms (Table 1). From 10 patients blood was investigated at diagnosis of ITP and 24-48 
hr after treatment with IVIg. After 6 months 5 patients were in remission with stable 
normalized platelet counts without further treatment while one patient achieved remission 
one year after diagnosis. 2 patients had persistent ITP defined as a low platelet count for 
longer than 3 months and were followed less than 1 year. 2 patients suffered from chronic 
ITP with two of them receiving treatment intermittently.  
Due to the low platelet count (3 x 109/L) at diagnosis, ITP patients showed decreased 
levels of plasma cytokines that are produced by platelets such as RANTES and soluble 
CD40 ligand (sCD40L) (Figure 1A). After treatment of ITP patients, a significant increase in 
RANTES as well as sCD40L was detected. Furthermore, ITP patients at diagnosis presented 
decreased plasma levels of growth factors produced by platelets as the platelet derived 
growth factor PDGF-AA and PDGF-AB/BB as well as the growth regulated oncogene (GRO) 
(Figure 1B). After therapy, there was a significant increase in PDGF-AA and PDGF-AB/BB 
and a non significant increase in GRO. Also patients suffering from a thrombocytopenia due 
to chemotherapy had decreased plasma levels of RANTES, sCD40L, PDGF-AA and PDGF-
AB/BB. Of this group, one patient suffered from aplastic anemia and therefore did not receive 
chemotherapy but presented thrombocytopenia; however, this patient had normal plasma 
levels of RANTES and sCD40L. As expected, RANTES, sCD40L, PDGFAB/BB and GRO 
correlated positively with the platelet count.  
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Figure 1.  Platelet cytokines: ITP patients show clearly decreased levels of platelet-derived 
cytokines. Box plots representing the plasma levels of RANTES and SCD40L (A), PDGF-AA, PDGF-
AB/BB and GRO (B) in patients with acute ITP (n=10) at diagnosis and after therapy compared to 
controls (n=9) as well as cTP patients (n=9). The upper and lower limits of the boxes represent the 
75
th
 and 25
th
 percentiles, respectively; the horizontal bar across the box indicates the median and the 
ends of the vertical lines indicate the minimum and maximum data values * p < 0.05 and ** p < 0.01 
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 ITP patients at diagnosis had significantly increased Th1 cytokine plasma levels as 
TNF-, IFN- and IL-2 (Figure 2A) and elevated plasma levels of the Th2 cytokines IL-6, IL-
10 and IL-13 (Figure 2B) compared to controls. Furthermore, ITP patients at diagnosis had 
significantly increased plasma levels of GM-CSF and of the IL-12 subunit IL-12p 40 
compared to controls while the increase in the bioactive IL-12p 70 subunit was not significant 
(Figure 2C). 7 patients presented increased GM-CSF (> 12 pg/ml) plasma levels at diagnosis 
(Table 2) whereas after therapy only 3 patients had still elevated GM-CSF levels. Also cTP 
patients presented increased GM-CSF plasma levels, however, not statistically significant. 
IL-8 that is produced by macrophages was significantly increased in ITP patients. There was 
a tendency of an increase in the Th17 cytokine IL-17 as well as of IL-7, a cytokine involved in 
T cell expansion (Figure 2D). After treatment of ITP patients, the elevated plasma median 
concentrations of IL-2, IL6, IL-13, IFN-, IL-12 40P/70P, IL-8 and IL-17 decreased; however, 
medians were not statistically significant.  
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Figure 2.  Increased plasma levels of Th1, Th2 and Th17 cytokines in ITP patients: Box plots 
representing the plasma levels of Th1 cytokines (A) and Th2 cytokines (B), cytokines produced by 
macrophages (C) as well as of IL-8, IL-17 and IL-7 (D) in patients with acute ITP (n=11) at diagnosis 
and after therapy compared to controls (n=9) as well as cTP patients (n=9). The upper and lower limits 
of the boxes represent the 75
th
 and 25
th
 percentiles, respectively; the horizontal bar across the box 
indicates the median and the ends of the vertical lines indicate the minimum and maximum data 
values * p < 0.05 and ** p < 0.01 
 
 
 
Additionally, ITP patients at diagnosis also presented increased plasma levels of IL-1 
as well as of its receptor antagonist IL-1ra and the soluble IL-2ra, the receptor agonist of IL-2 
(Figure 3A). Besides, we detected increased plasma levels of chemokines: the interferon- 
induced protein 10 (IP-10) that is secreted in response to IFN-, the macrophage 
inflammatory proteins MIP-1 and MIP-1, the macrophage-derived chemokine (MCD) and 
the monocyte chemoattractant protein-1 (MCP-1) that recruits monocytes to sites of 
infections (Figure 3B). All plasma levels of cytokines and chemokines described in Figure 3 
did not present a significantly decreased median after treatment with IVIg apart from MIP-1 
levels that were statistically increased after treatment.  
We did not find a correlation between elevated levels of cytokines and chemokines 
and an ongoing or preceding infection at initial presentation of ITP nor revealed a connection 
to the patient’s history (Table 1), suggesting that infections were not responsible for the 
increased plasma expression levels of the described cytokines/chemokines. In Table 2 we 
show the proportions of platelets with activated caspase-3, -8 and -9 together with the 
plasma cytokines levels of IL-6, IL-10, IL-13, IFN-, IL1ra, GM-CSF and MIP-1. Patients 
with low plasma cytokine levels presented either high or low activated caspases.   
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Figure 3.  ITP patients have altered plasma levels of receptor agonist cytokines as well as of 
chemokines. Box plots representing the plasma levels of IL-1ra, IL1a, sIL-2Ra (A). Box plots 
representing IP-10, MIP-1, MIP-1, MDC and MCP-1 (B) in patients with acute ITP (n=10) at 
diagnosis and after therapy compared to controls (n=9) as well as cTP patients (n=9). The upper and 
lower limits of the boxes represent the 75
th
 and 25
th
 percentiles, respectively; the horizontal bar across 
the box indicates the median and the ends of the vertical lines indicate the minimum and maximum 
data values * p < 0.05 and ** p < 0.01 
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Apart from cytokines in Figure 1, cTP patients showed significantly increased plasma 
levels of the cytokines EGF, FGF-2, G-CSF, Flt-3 Ligand, IL-8, MCP-1 and VEGF compared 
to controls (data not shown) while MDC plasma level was statistically lower in cTP than in 
control (Figure 2 & 3). IL-8 and MCP-1 were increased in cTP as well as in ITP patients 
compared to healthy children. Cytokines statistically increased in ITP but not in cTP were 
TNF-, IL-10, IL-13, IL-12p40, IL-1ra, IL-1, MIP-1 and MIP-1. 
In our study population, acute ITP patients did not present increased levels of BAFF 
as described elsewhere [13] [20] [14] (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  BAFF levels in ITP patients compared to control: ITP patients did not present 
statistically significant increased or decreased levels of B cell activating factor (BAFF) at diagnosis and 
after treatment compared to control. BAFF concentrations were measured in plasma by ELISA. n = 10 
for ITP, IVIg as well as control 
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Discussion 
 
In this study, we investigated cytokines/chemokines in a clinically well-defined group 
of children with ITP that have been investigated previously for platelet apoptotic 
manifestations [19]. All patients presented with bleeding symptoms including petechiae, large 
hematomas, mucosal bleeding and epistaxis - typical signs of primary ITP and had very low 
platelet counts. Additionally, we compared these results in ITP to those from healthy children 
and children with cTP. 
In plasma from primary ITP patients we demonstrated the presence of elevated 
cytokines/chemokines of the Th1 as well as Th2 commitment (Figure 2) that is illustrated in a 
model in Figure 5. We showed that patients with acute ITP have increased levels of GM-CSF 
suggesting that GM-CSF is upregulated in ITP by macrophages in response to the low 
platelet count. These findings were in support with the report by Abboud et al. [10] (Figure 
2C) who discussed that GM-CSF stimulates the proliferation of megakaryocytes and might 
be a regulator of platelet production [10]. Additionally, we demonstrated that patients with 
acute ITP have increased plasma levels of the Th1 cell cytokines IFN-, TNF- and IL-2 
(Figure 2A) as well as of the Th2 cytokines IL-6, IL-10 and IL-13 that differentiate B cells into 
plasma cells (Figure 2B). Here we show that macrophages are activated in ITP patients as 
we observed increased levels of IFN- and IL-6. Also T cells are activated in ITP patients as 
indicated by increased levels of IL-10, IL-13, IL-6 and TNF- Higher concentrations of IL-6 
well as of IFN- and TNF- were already detected in earlier studies in chronic ITP.  
In this study, we demonstrated that ITP patients have increased plasma levels of IFN-
. It is known that cytotoxic T cells produce IFN- and thereby induce an activation of 
macrophages. Thus we assume that an increase in IFN- is responsible for the in ITP 
patients observed activation of macrophages. Olsson et al. reported that ITP is associated 
with a T cell mediated cytotoxicity towards platelets [21]. They observed increased cytotoxic 
genes such as Apo-1/Fas, granzymes and perforin as well as the Th1 response cytokines 
IFN- and IL-2 in CD3+ cells from active ITP patients [21]. We suggest that this observed 
cytotoxicity leads to caspase activation in the ITP patient’s platelets that we have observed 
in a recent study [19]. However, as shown in Table 2 we were not able to find any 
association of elevated plasma cytokine levels to an increased proportion of platelets with 
activated caspases in ITP patients. We therefore can not conclude that an increase in 
cytokines leads to an activation of caspases and cytotoxic T cells as well as granzymes and 
perforin have to be investigated in acute ITP patients.  
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In contrast to our previous study where platelet apoptotic events were ameliorated by 
IVIg treatment [19], we did not find a significant decrease of plasma cytokine levels after IVIg 
treatment although cytokines have a short half-life. This finding assumes that IVIg does not 
act on cytokine receptors. In this study we demonstrated that ITP patients at diagnosis have 
increased levels of TNF-. In mice, TNF- has been reported to induce thrombocytopenia 
and activation of caspase-3 [25]. However, while activation of caspase-3 was decreased 
after treatment with IVIg, TNF- levels were not. We speculate that IVIg might block the 
cytokine receptors but not the cytokine production itself so that we observe a reduction in 
activated caspase-3 but not in cytokine levels. As TNF- did not correlate to caspase 
activation we suggest that TNF- is not responsible for triggering apoptosis in ITP patients. 
Furthermore, we did not observe increased levels of BAFF in acute ITP patients (Figure 4). 
In an earlier study of chronic ITP, platelet apoptosis was shown to correlate with increased 
BAFF concentrations [20]. In vitro assays presented that recombinant human BAFF 
increased platelet apoptosis and levels of IFN- [20]. However, while we detected increased 
IFN- in our study in plasma of acute ITP patients we did not detect significant altered BAFF 
concentrations and might consider including more subjects.  
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Figure 5.  Increased plasma levels of cytokines involved in patients with acute ITP. ITP patients 
at diagnosis show increased plasma levels of cytokines that are involved in lineage development. The 
Th2 cytokines IL-6, IL10 and IL-13 as well as IL17 differentiate B cells into plasma cells. IL-12 
differentiates Th cells into Th1 cells via activated macrophages. Th1 cells induce a production of TNF 
and IFN-. Furthermore, activated macrophages also produce IL-6 and GM-CSF, cytokines that are 
also increased in ITP patients as well as the chemokines MIP-1 and MIP-1. ITP patients at 
diagnosis further presented increased levels of the chemokines MCP-1 and IP-10. We also detected 
elevated plasma levels of IL-1 and the agonists IL-1ra and sIL-2Ra in ITP patients.  
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Furthermore, in plasma of ITP patients we detected increased levels of the receptor 
agonists IL-1ra and sIL-2Ra that function as scavengers (Figure 3A). IL-1ra acts in response 
to IL-1 and sIL-2Ra in response to IL-2. We also found elevated plasma levels of IL-1 (Figure 
3A) as well as of IL-2 (Figure 2A). We also detected increased plasma levels of IP-10 (Figure 
3B) confirming that IP-10 is secreted in response to elevated IFN-levels (Figure 2A). We 
also detected increased levels of the chemokines MIP-1, MIP-1 as well as MCP-1 in 
plasma of ITP patients. This finding confirms that in ITP patients macrophages and 
monocytes are activated. 
 
We found that acute ITP patients have increased plasma levels of Th17, however, 
they were not statistically significant from control (Figure 2D). IL-17 mediates B cell 
differentiation as do IL-6, IL-10 and IL-13 (Figure 5) [9]. Th17 have been shown to be 
involved in autoimmune diseases [7] [22] and recently to have a role in chronic ITP [6] [9]. 
Recently it was also reported that patients with untreated active ITP have increased levels of 
IL-27, a cytokine of the IL-6/IL-12 family [23]. IL-27 can regulate T cell differentiation and in 
ITP IL-27 might be responsible for induction of Th1 cells and pro-inflammatory cytokines as 
TNF- and IFN- [23]. IL-27 was not included in our measurements, but as IL-27 has a 
similar function as IL-6 or IL-12 that are increased in our study population its concentration in 
acute ITP might also be higher. Furthermore, TNF- and IL-6 have been shown to induce an 
upregulation of the tissue factor that mediates the initiation of the coagulation process [24]. 
This might be a negative feedback in response due to the hemostatic abnormality, low 
platelet and bleeding in ITP patients. Unfortunately, TGF-, that has also been associated 
with chronic ITP in several studies, was neither included in our cytokine panel. 
Plasma concentrations of IL-8 and MCP-1 were increased in both cTP and in ITP 
patients compared to the control group suggesting that the increase occurs in response to 
the thrombocytopenia. Cytokine levels statistically increased in ITP but not in cTP were 
TNF, IL-10, IL-13, IPL-12 p40, IL-1ra, IL-1a, MIP-1 and MIP-1 as well as MDC indicating 
that they might be induced by a thrombocytopenia but rather by an autoimmune disease. In 
contrast to ITP, in a thrombocytopenia due to chemotherapy, proliferation of cells is probably 
impaired. Chemotherapy interferes with growth and proliferation of cells and megakaryocytes 
die due to cytotoxicity of the chemotherapy. Due to a defective megakaryopoiesis in the bone 
marrow, platelets are not produced anymore resulting in a low platelet count. In cTP we did 
not observe any activated caspases (described in the study of Chapter 2) because no new 
platelets are produced in response to chemotherapy. Here we detected that cTP patients 
have increased plasma levels of hematopoietic growth factors such as G-CSF, Flt-3 ligand, 
EGF or FGF-2 as well as the vascular endothelial growth factor VEGF, molecules that are 
involved in the progression of tumors. 
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As most studies concerning cytokines included chronic ITP patients and as we 
received different results, we conclude that alterations of concentrations of specific cytokines 
may be involved in the chronic history. In agreement with previous observations in chronic 
ITP [4] [5] [9], we also observed an upregulation of the Th1 lineage in acute ITP. We were 
not able to correlate the observed increase in plasma cytokine levels to infections prior or at 
diagnosis as patients with no infection also presented increased cytokine levels (Table 2). 
However, we cannot exclude that chronic ongoing inflammation processes are responsible 
for the induction of cytokines in ITP patients. 
 
To summarize, our study demonstrated that acute ITP patients have increased 
plasma cytokine levels of TNF-, IFN-, IL-6, IL-10 and IL-13 at initial presentation 
suggesting that these cytokines contribute to the pathogenesis of the disease. Therefore, 
these cytokines might be promising targets for new therapy approaches. According to our 
findings we conclude that ITP patients at diagnosis have activated macrophages, B cells and 
T cells (Figure 5) consistent with the ITP model where macrophages induce the stimulation 
of B and T cells and remove platelets from the system by binding to the anti-platelet 
autoantibodies [1]. 
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General discussion 
 
Despite the finding that anuclear platelets possess pro- and anti-apoptotic proteins and 
undergo apoptotic events [1], their apoptotic signaling pathway is not entirely understood. 
Proteins as Omi/HtrA2 or XIAP of the intrinsic pathway have not been investigated yet in 
platelets. In recent findings, apoptotic changes were discussed in a mouse model of the 
platelet disorder immune thrombocytopenia (ITP) [2] [3].  
 
Pediatric ITP is a common and benign platelet autoimmune disorder that presents as a 
sudden onset of petechiae and a very low platelet count in formerly healthy children, usually 
after a 1 to 3 weeks preceding viral infection. Although ITP is well characterized, the 
pathophysiology leading to the platelet consumption is not entirely understood [4] [5] nor why 
most patients recover from ITP within months and others develop into a chronic ITP. The 
current working model of ITP suggests that autoantibodies targeting platelet surface 
glycoproteins are responsible for an enhanced Fc receptor mediated platelet clearance.  
 
One goal of the present work was to characterize platelets in ITP in regard to platelet 
apoptosis and platelet function. Another aim was to identify apoptotic proteins in health and 
understand the possible apoptotic signaling pathways. A further aim was to identify a 
possible trigger for apoptosis in ITP patients. 
  
In a prognostic pediatric ITP study, described in Chapter 2, we demonstrated that ITP 
patients at diagnosis have increased apoptotic events in platelets as activated caspases, 
increased PS exposure and microparticles [6]. These apoptotic manifestations in platelets 
were ameliorated by IVIg treatment. We also found that platelets of ITP patients have a 
reduced m. However, the reduced m was not ameliorated by IVIg suggesting that IVIg, 
as observed in the ITP mouse model, only inhibits downstream apoptotic events in platelets 
[2]. We also detected a slight increase in caspase activation in platelets of chronic ITP 
(Chapter 3). However, this observed increase was much lower than in acute ITP and is 
based on preliminary data, but suggests that in chronic ITP the pathophysiology eventually 
could be mediated by different factors than in acute ITP.  
 
In the study described in Chapter 3 we found that platelets of ITP patients at diagnosis have 
increased pre-activation and reduced thrombin activation. We detected an increased surface 
expression of CD63 and CD62P compared to control, confirming the secretion of lysosomal 
or granule proteins in acute ITP patients, an early step in platelet activation [7]. In contrast, 
 - 155 - 
we did not observe an increased PAC-1 binding indicating that there was no conformational 
change in GPIIb/IIIa and therefore the fibrinogen binding site was not exposed [8]. As there 
was no active GPIIb/IIIa detected we conclude that platelets are probably not fully pre-
activated in ITP patients. We speculate that in response to the low platelet count and due to 
the expressed CD62P, ITP platelets increase their adhesiveness. Although CD63 and 
CD62P surface expression in circulating ITP platelets was higher, the capacity for further 
activation of these platelets by thrombin stimulation was impaired. Thrombin-induced 
stimulation was also lower in cTP patients but in contrast to ITP, CD63 and CD62P surface 
expression was not increased in cTP patients. Furthermore, in the study of Chapter 3 we 
described that ITP patients have a reduced endogenous thrombin potential. IVIg improved 
both ETP and thrombin activation of ITP platelets as well as the bleeding symptoms. The low 
ETP observed in ITP patients at diagnosis as well as in chronic ITP might be responsible for 
the bleeding observed in ITP. ETP correlated to the platelet count thus might be a biological 
marker for estimating the bleeding risk in ITP patients. However, cTP patients also presented 
a reduced platelet count but had an ETP comparable to healthy controls. Furthermore, it was 
assessed that the bleeding severity can not be predicted by thrombin generation [9] [10]. 
ETP did not correlate with CD63 and CD62P expression verifying that an increased 
expression of these proteins is not responsible for the low ETP.  
 
We also found that ITP patients at diagnosis have increased reticulated platelets that are 
defined as the young circulating platelets as well as an increased platelet size (Chapter 2). 
With these data we speculate that CD62P expression differs in younger, larger circulating 
platelets from normal-sized platelets.  
 
We did not find a correlation of CD63 and CD62P expression with activation of caspase-3 
indicating that pre-activated platelets (Chapter 2 and 3) are not responsible for an induction 
of caspase-3. This confirms the finding that platelet activation and platelet apoptosis are 
different events that occur sequentially [11] [12] [13]. The increase in PS exposure as well as 
microparticles might contribute to expression of CD63 and CD62P that we observed in 
platelets of ITP patients leading to an enhanced coagulation. However, increased PS 
exposure as well as elevated microparticles are also considered as apoptotic manifestations. 
A small proportion of platelets presented PS exposure as well as caspase activation 
indicating that this proportion was clearly involved in platelet apoptosis [6] (Chapter 2). 
Thrombin- as well as A23187- stimulation of resting platelets lead to an increase in caspase 
activation in contrast to the thrombin-reduced activation of CD63 and CD62P (Chapter 3). 
This suggests that the action of thrombin on platelets is not totally impaired in ITP. 
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It is not established what initiates apoptosis in ITP, whether the intrinsic pathway is triggered 
due to a disruption of the Ca2+ homeostasis or by the extrinsic pathway via a death receptor. 
At diagnosis of ITP, we observe signs of the intrinsic apoptotic pathway: a decrease in m, 
an activation of caspase-9 as well as of its effector caspase-3 in the patient’s platelets 
(Chapter 2). However, it remains to be elucidated whether cytochrome c is released in 
platelets of ITP patients. We also found an activation of caspase-8 in platelets of ITP patients 
that in nucleated cells is part of the extrinsic apoptotic pathway. We speculate that also Bid 
signaling might be involved in platelet apoptosis of pediatric ITP. In nucleated cells, Bid 
connects the extrinsic to the intrinsic pathway while activated caspase-8 processes Bid into 
truncated Bid that gets localized to the mitochondria [14]. Cleavage of procaspase-8 is 
mediated by death receptor signaling. However, in platelets apart from DcR2 no death 
receptors were identified so far [15]. We were unable to detect any receptors in platelets as 
TRAIL, DR3 or DR5. However, we found the death domain FADD that links death receptors 
to caspase-8 activation (Supplement of Chapter 4). We also confirmed the expression of Bid 
in platelets (Supplement of Chapter 4). The presence of FADD and Bid, and the finding that 
caspase-8 is activated by physiological and artificial compounds in platelets of healthy 
subjects as well as of ITP, indicate that platelets contain the extrinsic apoptotic pathway.  
 
Platelets have most important players of the apoptotic signaling pathway such as caspases, 
Apaf-1, cytochrome c, the anti-apoptotic protein Bcl-XL or the pro-apoptotic protein Bax [1] 
[12] [16] [17] [15]. However, the entire signaling pathway has not been described yet, 
especially proteins as XIAP or Omi/HtrA2 have not been analyzed. We identified two factors 
of the intrinsic apoptotic signaling pathway in human platelets- the pro-apoptotic factor 
Omi/HtrA2 as well as its target inhibitor XIAP, an anti-apoptotic protein (Chapter 4). We 
demonstrated that platelets release Omi/HtrA2 from mitochondria into the cytosol upon onset 
of apoptosis. We also confirmed that Smac/Diablo and cytochrome c are released from 
mitochondria into the cytosol as was shown previously [15] [13]. By using an inhibitor of 
Omi/HtrA2, Ucf-101 [18], we showed that apoptotic events were reduced and by using an 
inhibitor of XIAP, embelin [19], we demonstrated that apoptotic events were increased. Thus, 
we verified that as in nucleated cells Omi/HtrA2 is a pro-apoptotic protein and that caspase-3 
and 9 are inhibited by XIAP. We further indicated that the inhibition of Omi/HtrA2 by Ucf-101 
occurs in the cytosol, therefore after m depolarization.  
 
In mice, TNF-, a ligand for the receptor TNFR1 or TNFR2 in nucleated cells, has been 
reported to induce thrombocytopenia and activation of caspase-3 in healthy platelets [20]. In 
pediatric ITP, it is discussed that apart from macrophages also B and T cells are involved in 
the pathophysiology [5]. Furthermore in ITP, activated cytotoxic T cells were found that 
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induced platelet lysis and elevated expression of FasL and TNF- in these cytotoxic T cells 
was shown to be present [21] [22]. To investigate whether an extrinsic trigger as a ligand for 
death receptors such as TNF- may be responsible for induction of apoptosis in platelets of 
children with ITP, we studied cytokines in plasma of ITP patients (Chapter 5). We found that 
ITP patients at diagnosis have increased plasma levels of the Th1 cell cytokines IFN-, TNF-
 and IL-2 as well as of the Th2 cytokines IL-6, IL-10 and IL13 and increased GM-SCF 
(Chapter 4). However, while activation of caspase-3 was decreased after treatment with IVIg, 
TNF-levels were not. Neither did we found a correlation of caspase activation with TNF- 
nor with other cytokines that showed increased levels at diagnosis. Thus, it is unlikely that an 
increased TNF- concentration is responsible for triggering apoptosis. However, other 
cytokines not included in this study, might still be candidates for inducing apoptosis. Or, 
elevated cytokines might be involved in chronic ITP. We consider analyzing cytokines in 
chronic ITP patients also as cytokines are involved in immune-mediated inflammations. In 
platelets of patients with chronic ITP we detected less activated caspases suggesting that 
other factors are involved in the pathophysiology of chronic ITP than of acute ITP.  
 
The present work generated findings of activated caspases in platelets in acute pediatric ITP 
patients. We found that in ITP patients, after an increase in platelet counts by IVIg, platelet 
apoptotic and activation events as well as the low endogenous thrombin potential were 
ameliorated. We therefore prove the efficacy of the IVIg treatment in ITP patients. However, 
we do not know how IVIg decreases caspase activity in platelets of ITP. In a next step, we 
will administer anti-GPIIb antibodies as well as IVIg in healthy platelets in vitro in order to 
investigate whether anti-GPIIb antibodies induce caspase activity and whether IVIg reverses 
this activity. Of great note is to find out which apoptotic signaling is activated in ITP platelets 
and whether platelets have death receptors. For this, it would be important to detect more 
apoptotic changes in ITP platelets such as a release of cytochrome c or Omi/HtrA2. 
However, due to the low platelet count of ITP patients at diagnosis it is nearly impossible to 
detect proteins by Western blot and we might include other approaches in the future such as 
intracellular flow cytometry staining. At the moment we can not show that ETP or any other 
laboratory parameter correlates to bleeding signs. It will be our continued intention to 
estimate by a biological marker if a patient is at a high bleeding risk such as cerebral 
bleeding or not.  
 
To summarize, we showed that ITP patients at diagnosis have increased manifestations of 
platelet apoptosis, decreased thrombin-induced platelet stimulation as well as a reduced 
ETP. We proved that after IVIg treatment all apoptotic manifestations except m were 
normalized. Also as the decreased thrombin-induced platelet stimulation and the reduced 
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ETP were improved. Additionally we verified that platelets contain the important apoptotic 
proteins to have a functional apoptotic signaling. We assume that an apoptotic-like signaling 
is present in ITP platelets at initial presentation. 
 
The significance of this study is to gain an increase in the understanding of the 
pathophysiology of ITP by analyses of apoptotic signaling and thrombin generation in 
platelets of ITP patients. By extending our findings to a larger study it might be possible to 
find a clear correlation between clinical parameters and laboratory data. In future studies, it 
will be important to distinguish which ITP patient develops into low risk or high risk of 
bleeding or into a chronic ITP. A clinical aim of this study is not to treat ITP children in 
Switzerland with low risk of bleeding and spontaneous remission with IVIg, an expensive and 
invasive treatment. 
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Abbreviations 
 
BAFF B cell activating factor 
BH3 Bcl-2 homology domain 3 
BIR Baculovirus inhibitor of apoptosis repeats 
BSS Bernard-Soulier syndrome 
CAD Caspase-activated DNase 
Ca2+ Calcium  
CaM Calmodulin 
CARD Caspase recruitment domain 
CsA Cyclosporin A 
C+T Collagen and thrombin 
cTP Chronic ITP 
CypD Cyclophilin D 
DTS Dense tubular system 
m Mitochondrial membrane potential  
ER Endoplasmatic Reticulum 
ETP Endogenous thrombin potential 
Fc receptor Fragment crystallizable receptor 
FLICA Fluorochrome inhibitors of caspases 
GM-CSF granulocyte-macrophage colony-stimulating factor  
GP Glycoprotein 
Hsp Heat shock protein 
IAP Inhibitor of apoptotic proteins 
IL Interleukin 
IMS Mitochondrial intermembrane space  
IP Immunoprecipitation 
ITP Immune thrombocytopenia 
IVIg Intravenous immunoglobuline 
MFI Geometric mean fluorescence intensity 
MOMP Mitochondrial outer membrane permeabilization 
MPs Platelet-derived microparticles 
MPTP  Mitochondrial permeability transition pore 
PCs Platelet concentrates  
RES Reticuloendothelial system 
PKC Protein kinase C  
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PPP Platelet poor plasma 
PRP Platelet rich plasma 
PRT Pathogen reduction technology  
PS Phosphatidylserine 
RT Room temperature 
TAH Tyrodes Hepes buffer with albumin 
TF Tissue factor 
TGF-1 Transforming growth factor -1 
Th T helper cells 
TH Tyrodes Hepes buffer 
TNF Tumor necrosis factor 
TMEM Transmembrane protein 
TMRE Tetramethylrhodamine-ethyl-ester  
TPO Thrombopoietin   
vWF von Willebrand Factor 
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